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Chapter 1
The human body is composed of eleven different organ systems which are interconnected 
and dependent on each other, including the respiratory, digestive, nervous and cardiovascular 
system. Through a closed network of blood vessels, the cardiovascular system transports 
blood through the body with every heartbeat. With the help of the constant blood flow, 
nutrients, oxygen, and waste products can be transported from the circulation across the 
vessel wall to and from all organs and tissues.
The inner surface of the vasculature is lined by a single layer of endothelial cells (EC), 
supported by smooth muscle cells and connective tissues in the middle and outer layer of 
the vessel wall (Figure 1). The ECs, also referred to as the endothelium, form a tight barrier 
through cell-cell junctions to control extravasation of fluid, macromolecules and cells in 
order to maintain homeostasis [1]. While passive transport over the endothelial barrier is 
limited by the cell-cell junctions, active transport through the cell body (transcellular) and 
in between cells (paracellular) is subject to tight regulation (Figure 1). Besides its function 
as a physical barrier between blood and underlying tissues, the endothelium orchestrates 
many physiological processes including regulation of smooth muscle cell contraction and 
vascular tone, inflammation, angiogenesis, and wound healing [2-4]. Aberrant EC functioning 
therefore underlies cardiovascular diseases including atherosclerosis, vascular leakage, and 
tissue edema, as well as cancer metastasis [5].
Figure 1 - Cross-section of the arterial wall. Endothelial cells form a monolayer on the inside of blood 
vessels with layers of smooth muscle cells underneath. The endothelium is therefore the first contact with 
blood-borne components and circulating cells. Through trans- and paracellular transport, exchange of cells 




The endothelium forms a barrier through several intercellular adhesive structures called 
Adherens Junctions (AJ) and Tight Junctions (TJ) [6]. These intercellular junctions are formed 
between the plasma membranes of two cells, with one part of the junctional protein residing 
inside the cell and the other part protruding outside of the cell to meet its specific partner 
on the adjacent cell [6]. Both AJs and TJs are important for the regulation of paracellular 
transport of solutes and leukocytes, and AJs induce contact inhibition between endothelial 
cells to prevent overgrowth. Although TJs are not extensively researched in endothelial 
cells, they are thought to be important for cell polarity. Depending on the vascular bed ECs 
reside in, they can express over 40 different types of junctional proteins, some of which are 
also expressed by other cell types (e.g. epithelial cells). The junctional protein expressed 
exclusively by ECs is Vascular Endothelial (VE)-cadherin, a marker for AJs. VE-cadherin is a 
type I transmembrane protein that binds homotypically through its extracellular domain to a 
VE-cadherin protein on the neighboring cell [6-8]. Deletion of VE-cadherin in several stages 
of development in mice showed that VE-cadherin regulates both assembly and maintenance 
of the vasculature [9, 10]. The cytosolic tail of VE-cadherin recruits adapter proteins, namely 
α, β, γ, and p120 catenin, which build a molecular bridge between VE-cadherin and the actin 
cytoskeleton [11] (Figure 2).
Figure 2 - VE-cadherin forms the link between EC, and associates to the actin cytoskeleton. A close-up 
of two cellular membranes is depicted showing the VE-cadherin containing AJs, and the catenins forming the 




In a stable barrier, a cortical actin ring, which lies parallel to the cell membrane, supports 
the VE-cadherin junctions [12, 13]. In response to several stimuli, such as a disturbance in 
blood flow or pro-inflammatory molecules and activated leukocytes, contractile F-actin 
filaments (‘stress fibers’) can be formed perpendicular to the junctions. Pulling forces from 
these stress fibers on the intercellular junctions may lead to gaps in the endothelial barrier 
and consequent interstitial leakage [14]. The F-actin cytoskeleton is therefore an important 
element in the endothelial barrier, and determines the strength of the endothelial junctions. 
Through rapid actin polymerization and disassembly, ECs can adapt their shape to the needs 
of the endothelial monolayer. This intricate dynamics of the cytoskeleton are regulated by 
members of the family of Rho GTPases [15, 16].
Endothelial barrier integrity: regulation on a molecular level by Rho GTPases
Rho GTPases belong to the Ras superfamily of small GTPases, which act as molecular ‘on’ 
and ‘off’ switches in cellular signal transduction [17]. The protein family of Rho GTPases 
contains approximately 22 members, of which RhoA/B/C, Rac1 and Cdc42 have been most 
extensively investigated [18]. In their inactive form, Rho GTPases bind a GDP molecule. 
Through the action of a Guanine Nucleotide Exchange Factor (GEF), the GDP can be 
exchanged to a GTP which alters the conformation of the Rho GTPase to allow interaction 
with downstream effector proteins. The hydrolysis of GTP to GDP is catalyzed by GTPase 
activating proteins (GAP), returning the Rho GTPase to its inactive state [19]. In GDP-bound 
state, the Rho GTPase is bound by a guanine nucleotide dissociation inhibitor (GDI). The GDI 
orchestrates the interaction of Rho GTPases with GEFS, but also protects the Rho GTPases 
from degradation [20] (Figure 3). Interestingly, the GTPase RhoB is an exception since it does 
not bind to the ubiquitously expressed RhoGDI. As GTP levels in cells are higher than those 
of GDP, newly synthesized RhoB rapidly becomes GTP-bound and active, initiating signaling 
prior to its GAP-mediated inactivation or degradation [21, 22].
Although Rho GTPases are very homologous in amino acid sequence and structure, signaling 
by each Rho GTPase has distinctively different effects on the actin cytoskeleton of cells. 
Especially the Rho/Rac counterbalance is well-documented (Figure 4) [23-25]. RhoA and 
Rac1 play counteracting roles in endothelial barrier function, not only through their opposing 
regulation of the actin cytoskeleton but also by affecting each other’s activity. [13, 26, 27]. 
Rac1 and Cdc42 activity induces cell spreading and migration through the formation of 
actin protrusions named lamellipodia and filopodia, respectively [28, 29]. Additionally, Rac1 
supports the formation of cortical actin to stabilize VE-cadherin junctions and strengthen 
the endothelial barrier, and inhibits RhoA activity by activating p190-RhoGAP [30, 31]. In 
barrier disruption, signaling from RhoA, and RhoB, induces stress fiber formation and cell 
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contraction through activation of Rho kinase (ROCK), which in turn phosphorylates myosin 
light chain (MLC) [32]. MLC phosphorylation induces actin-myosin mediated contraction, 
followed by membrane retraction in ECs [33, 34]. Additionally, RhoB was found to further 
ameliorate loss of endothelial junctions by directly interfering with Rac1 localization, hereby 
inhibiting Rac1-mediated cortical actin formation [35].
Figure 3 - Rho GTPase cycling between GDP- and GTP-bound states. Rho GTPases are bound by the GDI 
in their GDP-bound state. When the Rho GTPase is released, GDP can be exchanged to GTP by a GEF, induc-
ing a conformational change in the GTPase allowing downstream signaling. The hydrolysis of GTP to GDP to 
inactivate the Rho GTPase is catalyzed by a GAP, after which the Rho GTPase can be bound by the GDI again.
RhoB, like RhoA, induces cell contraction but the time scale of signal transduction elapses 
differently. RhoA-mediated signaling relies on the rapid GDP to GTP exchange in response 
to an external stimulus, transformed into an internal signal through G-protein coupled 
receptors (e.g. thrombin receptor) [36]. In contrast, the RhoB-mediated cellular response 
relies on increased transcription of RhoB, which is typically induced in inflammatory 
situations and can be stimulated by bacterial LPS and by cytokines such as TNF-α, TGF-β 
and IL-1β [37-39].
As highlighted earlier, dysfunction of the endothelium can worsen or even underlie many 
diseases. Both over- and underactivation of Rho GTPases has been implicated in EC 
dysregulation [40]. Activity of Rho GTPases was found necessary to keep Ras isoforms 
in check and prevent malignant transformation of cells [41-43]. In many types of cancer 
however, increased levels of Rho GTPase proteins were found. Although not much data 
exists on genetic mutations in Rho GTPases leading to cardiovascular malformations, there is 
a treatment window for modulation of these small regulatory proteins. Dysregulation of Rho 
GTPases has especially been implicated in diseases and syndromes where cardiovascular 




Figure 4 - Regulation of endothelial junction integrity by RhoA/RhoB and Rac1. In a stable endothelial 
barrier, Rac1 signaling induces cortical actin formation, which stabilizes VE-cadherin junctions. Rac1 also 
inhibits RhoA through activation of p190 RhoGAP. In the case of barrier disruption, RhoA and RhoB signal 
via Rho kinase (ROCK) to induce stress fiber formation. These actin cables are formed perpendicular to the 
VE-cadherin junctions and by the actomyosin-based contractile force (indicated by the arrows), the junctions 
are pulled apart.
Post-translational modifications in Rho GTPase regulation
Alterations of the genomic DNA, as well as external stimuli (e.g. inflammation or hypoxia) can 
alter the transcription- and translation rate of proteins. DNA-damaging agents were found to 
increase RhoB and RhoC transcription, whereas RhoA levels remain unaffected. Additionally, 
elevated RhoB transcription is induced by growth factors (e.g. transforming growth factor 
β), inflammatory agents (e.g. TNF-α and bacterial LPS) and other stressors such as sudden 
changes in flow or hypoxia [38, 46, 47]. For RhoB especially, increased transcription rates 
play an important role in its regulation since RhoB has a short (30 minutes) half-life in cells, 
in contrast to RhoA, RhoC, Rac1 and Cdc42 which are relatively stable (all between 15 and 
30 hours) [48-50]. Besides the regulation of Rho GTPases at the transcriptional level to 
increase their abundance in cells, post-translational modifications (PTM) add another level of 
regulation. PTMs that are found to influence Rho GTPase signaling include phosphorylation, 
prenylation, palmitoylation, methylation, acetylation, SUMOylation and ubiquitination [51, 




Prenylation is the covalent attachment of a lipid containing three (farnesyl) or four 
(geranylgeranyl) isoprenoid units to the side chain of the cysteine amino acid at the 
C-terminal CAAX box of a protein [53, 54]. These farnesyl and geranylgeranyl isoprenoids 
are formed as intermediate products of the cholesterol synthesis pathway and are attached 
to proteins by farnesyl transferase and geranylgeranyl transferase, respectively (Figure 5). 
Prenylation of Rho GTPases occurs in the ER and Golgi after protein synthesis, and allows the 
interaction of the Rho GTPase with RhoGDI and with endosomal- and plasma membranes 
(Figure 6). When the C-terminal cysteine is mutated to a non-prenylatable amino acid, Rho 
GTPases fail to interact with the GDI and cellular membranes, distorting their localization 
and signaling capacity. [55, 56]. RhoB can be both farnesylated and geranylgeranylated, 
while Rac1 and RhoA are only geranylgeranylated [57].
Figure 5 - Scheme of the cholesterol synthesis pathway and Rho GTPase prenylation. In the cascade 
of cholesterol synthesis from Acetyl-CoA, the intermediate products farnesyl-PP and geranylgeranyl-pp can 
be attached to Rho GTPases by farnesyl transferase (FTase) and geranylgeranyl transferase (GGTase). RhoA 
and Rac1 can only be geranylgeranylated, whereas RhoB can be both farnesylated and geranylgeranylated.
Another important aspect in regulation and termination of Rho GTPase signaling is 
ubiquitination. We have written a detailed review of the role of ubiquitination on Rho GTPase 
function in endothelial cells in chapter 2. Ubiquitin is a small, 76 amino acid long protein that 
can influence the localization and trafficking of the protein it is attached to. Furthermore, 
ubiquitination affects protein recognition by signaling- or regulatory complexes, and 
regulates proteasomal or lysosomal degradation [58, 59]. When inactive, Rho GTPases are 
bound to the GDI where they are shielded from ubiquitination and degradation. Upon 
release from the GDI, Rho GTPases can be activated and become prone to ubiquitination 




protein, by the subsequent action of E1, E2 and E3 ubiquitin ligases, with each step increasing 
in specificity of the enzymes for the target protein. It is in these ligases that therapeutic 
targets lie; by identifying and targeting the machinery for Rho GTPase ubiquitination, specific 
cellular processes can be either enhanced or disrupted. The work presented in this thesis 
aims to provide further insights in these regulatory mechanisms and their potential for 
targeting in the context of endothelial monolayer integrity.
Figure 6 - Different levels of Rho GTPase regulation. Rho GTPases are regulated on transcriptional, 
translational and post-translational level. PTMs regulate Rho GTPase at different steps in their activation/
deactivation cycle. Among others, prenylation at the C-terminus of Rho GTPases is required for their binding 
to the GDI. In the proximity of the plasma membrane, GDI binding is replaced by membrane binding and the 
Rho GTPase is activated by a GEF. Rho GTPases can be de-activated by GAPs, or the active Rho GTPase can 
be ubiquitinated and degraded.
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OUTLINE OF THE THESIS
In the following chapters, we describe the role of the post-translational modifications of 
Rho GTPases, specifically ubiquitination and prenylation, in endothelial cells. To investigate 
the effect of these modifications on Rho GTPase signaling, we used a variety of inhibitors, 
knockdowns of specific proteins and site-directed mutagenesis of selected amino acid 
residues in the GTPases RhoB and Rac1 which are modified by PTMs.
Chapter 2 reviews the role of ubiquitination in endothelial barrier maintenance, summarizing 
published research on ubiquitination in the regulation of Rho GTPases and endothelial cell-
cell contact.
In chapter 3 we describe the regulation of RhoB ubiquitination by E3 Cullin RING ligase, 
using chemical inhibition and knockdown of the E3 ligase(s) and their associated adaptor 
proteins. We established that the Cullin-3-Rbx1-KCTD10 complex induces K63-ubiquitination 
of RhoB to induce its lysosomal degradation.
Since Cullin inhibition disrupts the endothelial barrier, we investigated the effect of Cullin 
activation on endothelial integrity in chapter 4 using the Cullin E3 ligase activator CSN5i-3. 
Unexpectedly, we found that treatment of endothelial cells with CSN5i-3 also disrupted the 
endothelial barrier, albeit not through signaling by Cullin-3, but through a Cullin-1-mediated 
increase in transcription of NFkB-induced genes including RhoB.
Chapter 5 describes the role of the Cullin-1 substrate receptor FBXW7 in RhoB stability 
and endothelial barrier regulation. Our research showed that FBXW7 is a positive regulator 
of endothelial barrier integrity. Rather than inducing RhoB ubiquitination, we found that 
FBXW7 affects RhoB prenylation and its subcellular localization.
In chapter 6, we investigated the relationship between GDI binding, activity and 
ubiquitination of Rac1 using single amino acid mutations. By using a spectrum of differentially 
activated and ubiquitinated Rac1 proteins, we found a significant correlation between Rac1 
activity and ubiquitination, but no significant regulation of its ubiquitination by GDI binding.
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Endothelial cell–cell contacts are essential for vascular integrity and physiology, protecting 
tissues and organs from edema and uncontrolled invasion of inflammatory cells. The 
vascular endothelial barrier is dynamic, but its integrity is preserved through a tight control 
at different levels. Inflammatory cytokines and G-protein-coupled receptor agonists, such 
as histamine, reduce endothelial integrity and increase vascular leakage. This is due to 
elevated myosin-based contractility, in conjunction with phosphorylation of proteins at 
cell–cell contacts. Conversely, reducing contractility stabilizes or even increases endothelial 
junctional integrity. Rho GTPases are key regulators of such cytoskeletal dynamics and 
endothelial cell–cell contacts. In addition to signaling-induced regulation, the expression 
of junctional proteins, such as occludin, claudins and vascular endothelial cadherin, also 
controls endothelial barrier function. There is increasing evidence that, in addition to 
protein phosphorylation, ubiquitylation (also known as ubiquitination) is an important and 
dynamic post-translational modification that regulates Rho GTPases, junctional proteins 
and, consequently, endothelial barrier function. In this Review, we discuss the emerging 
role of ubiquitylation and deubiquitylation events in endothelial integrity and inflammation. 
The picture that emerges is one of increasing complexity, which is both fascinating and 
promising given the clinical relevance of vascular integrity in the control of inflammation, 
and of tissue and organ damage.
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INTRODUCTION
The inner lining of all blood and lymphatic vessels is formed by a monolayer of vascular 
endothelial cells (ECs), which preserves integrity through dynamic but well-controlled cell–
cell contacts. Loss of endothelial integrity, due to increased actomyosin-based contractility 
and reduced cell–cell contact, is among the first signs of inflammation and is associated with 
vascular pathology that accompanies chronic disorders, such as diabetes, atherosclerosis 
or rheumatoid arthritis [1-3]. Because of its clinical relevance, there is much interest in 
the mechanisms that govern endothelial integrity. This integrity is mainly determined by 
the adhesive function of vascular endothelial (VE)-cadherin, which acts in complex with 
F-actin-binding adapter proteins, such as β-catenin, α-catenin and vinculin. The adhesive 
function of this VE-cadherin (also known as CDH5) complex is mediated and controlled 
by actin dynamics and tyrosine (de)phosphorylation of VE-cadherin and β-catenin [4-9]. 
Recently, there has been growing interest in another post-translational modification that 
controls endothelial integrity, namely protein ubiquitylation (also known as ubiquitination).
Protein ubiquitylation is a three-step process, in which the 76-amino-acid peptide ubiquitin 
is transferred from an E1 to an E2 ligase, after which an associated E3 ligase catalyzes 
covalent linkage of the ubiquitin moiety to the substrate, in most cases on a lysine residue, 
or to lysine residues of a previously linked ubiquitin. This results in ubiquitin chain formation 
through, for example, K63 or K48 linkages (Figure 1) [10]. In addition to ubiquitin, cells also 
use ubiquitin-like proteins such as small ubiquitin-like modifier (SUMO) to modify target 
proteins [11, 12]. It is estimated that there might be up to 600 ubiquitin E3 ligases, which 
can be subdivided in several families [10]. Homologous to the E6AP C-terminus (HECT) 
ligases obtain the ubiquitin from the E2 ligase, prior to linkage to the substrate. In contrast, 
really interesting new gene (RING) ligases, multi-protein complexes comprised of scaffold, 
adapter and substrate recognition proteins, do not bind ubiquitin directly, but mediate its 
transfer from the E2 ligase to the substrate [12, 13]. The ring-between-ring (RBR) E3 ligases 
(for example PARKIN) are a relatively small subgroup (14 members in humans) that combines 
features of HECT and RING ligases in their mode of ubiquitin binding and transfer to their 
substrates [14, 15]. Finally, a new class of ubiquitin ligase was recently identified, designated 
RING-Cys-relay (RCR), which transfers ubiquitin to its substrate in a unique way, through 
esterification of a threonine, rather than a lysine, residue [16].
In addition to the variety in the types of ubiquitin ligase, there is also considerable complexity 
in the site-specific modifications with ubiquitin, including mono-, di- or poly-ubiquitylation, as 




linear ubiquitin chain assembly complex (LUBAC) has a preference for sites that are already 
modified by K63-linked ubiquitin chains. Its addition of linear, methionine-linked ubiquitin 
results in a K63-polyUb/M1-polyUb hybrid or mixed chains [18, 19].
There is increasing evidence that ubiquitylation not only serves to target the substrate for 
proteasomal degradation, but in fact controls cellular functions in many ways, including 
regulation of protein–protein interactions, vesicular trafficking, receptor internalization 
and subcellular localization of signaling proteins [10, 13]. Since ubiquitylation is reversible 
through the action of deubiquitylating enzymes (DUBs), it qualifies as a bona fide signal 
transduction event, similar to (de)phosphorylation or (de)acetylation [13, 20-25].
Increasing numbers of ubiquitin E3 ligases and DUBs have recently been linked to endothelial 
cell–cell contact and inflammation. There is evidence that ubiquitylation regulates proximal 
signaling induced by inflammatory cytokines, such as tumor necrosis factor (TNF), that 
increase endothelial permeability, leading to edema and, eventually, tissue damage [20, 22, 
26-28]. Here, we will first briefly address ubiquitin modifications that have been described 
in inflammatory cytokine signaling, before discussing the regulation of Rho GTPases by 
ubiquitylation. Rho GTPases act downstream of inflammatory and other activating agonists, 
and are considered master regulators of endothelial cell–cell contact and inflammation. 
Finally, we discuss ubiquitylation of junctional proteins and the relevance of ubiquitylation 
for vascular disease.
Ubiquitylation in cytokine-induced inflammation and vascular integrity
Inflammatory signaling in ECs serves to protect tissues from excessive damage by initiating, 
directly or indirectly, the removal of infectious or damaging agents. Uncontrolled or low-
grade chronic inflammation, however, leads to pathologies, such as rheumatoid arthritis or 
atherosclerosis. ECs are among the first cells to participate in an inflammatory response. In 
ECs, this response comprises the production of reactive oxygen species (ROS), upregulation 
of adhesion molecules that recruit activated leukocytes and lymphocytes, a disruption of 
the endothelial barrier and increased leukocyte diapedesis [29]. One of the key pathways 
that drives these effects downstream from the pro-inflammatory cytokine TNFα, the 
interleukins IL-1β and IL-17, or Toll-like receptor (TLR) ligands such as lipopolysaccharide 
(LPS), is the nuclear factor κB (NFκB) pathway [30, 31]. The NFκB pathway is complex, 
and its activation comprises a series of different components that are regulated by both 
phosphorylation and ubiquitylation [32]. The first level of ubiquitin-mediated regulation 
concerns the transmembrane receptors and associated adaptor proteins. These are typified 
by the E3 ligases cellular inhibitor of apoptosis protein (cIAP)1 and cIAP2 (also known as 
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BIRC2 and BIRC3, respectively), LUBAC and Itch, which have all been linked to the TNF-
induced ubiquitylation of receptor interacting protein 1 (RIP1, also known as RIPK1) [33-36]. 
Ubiquitylation by these ligases and regulated deubiquitylation by the DUBs cylindromatosis 
(CYLD), A20 (also known as TNFAIP3) and Otulin are crucial for steering the TNF pathway 
towards pro-survival NFκB-dependent signaling [26, 37-40]. Furthermore, polyubiquitin 
chains assembled by these E3 ligases are required for the activation of the IκB kinase 
(IKK)α–IKKβ complex and subsequent phosphorylation of IκBα, the inhibitory subunit of 
NFκB [41]. Phosphorylated IκBα is subsequently ubiquitylated by the E3 ligase SCF-βTRCP 
[the Skp, cullin, F-box-containing complex containing βTRCP (also known as BTRC) as the 
F-box protein] and degraded by the proteasome. This results in the release and nuclear 
translocation of NFκB, which then activates the transcription of genes required for cell 
survival and leukocyte-endothelial cell interactions [33, 41, 42].
In TNF-treated retinal ECs, NFκB-dependent loss of vascular integrity has been linked to 
reduced expression and altered subcellular localization of the tight junction proteins Zonula 
occludens 1 (ZO-1, also known as TJP1) and claudin-5 [43]. In lymphatic ECs, IL-1β and TNF 
have been found to decrease the expression of VE-cadherin and activate actomyosin-based 
contraction, partially through an endothelial nitric oxide synthase (eNOS, also known as 
NOS3)-dependent mechanism whose molecular details remain to be established [44]. Finally, 
in murine brain ECs, IL-17 induces ROS production and actomyosin contraction, resulting in 





Figure 1 - Protein ubiquitylation complexity. (A) The different steps in protein ubiquitylation through E1, 
E2 and E3 ligases are depicted. Ubiquitin (Ub) is transferred from the E1 to E2 and subsequently the HECT 
or RING E3 ligase. The E3 ligase interacts with the substrate for final ubiquitin transfer, either directly to the 
substrate acceptor site or to a lysine residue in already linked ubiquitin, resulting in chain formation. (B) A 
selection of different ubiquitin chain elongation and branching products are depicted with their associated 
cellular responses (e.g. proteasomal degradation or endocytosis) indicated. Importantly, the orientation of 
ubiquitin moieties is different in K48-linked chains compared to K63-linked chains. This allows different binding 
partners to associate to either of these poly-ubiquitin chains for signal transmission. Please note that additional 
linkage types are known, see also main text.
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Together, while ubiquitylation is an abundant post-translational modification (PTM) in 
cytokine-induced proximal signaling, its regulation of the associated reduced expression 
of junctional proteins and the loss of endothelial barrier function remains to be further 
investigated. In this context, the role of actomyosin-based contraction, which may weaken 
junctions mechanically and thereby indirectly induce junctional protein internalization and 
possibly degradation, also warrants more detailed analysis.
Rho GTPase ubiquitylation and endothelial integrity
The integrity of the endothelial barrier is dependent on the dynamic stability of cell–cell 
contacts in the monolayer. Each EC exerts pushing and pulling forces on its neighboring cells, 
and the net result of these forces determines junctional integrity and permeability. Changes 
in these forces, for instance due to vascular contraction or relaxation, will determine the 
response of ECs to maintain and restore the barrier. ECs control the strength of their cell–
cell contacts in part through the actin cytoskeleton, for instance by inducing actin (de)
polymerization or the formation and bundling of F-actin stress fibers. The key molecular 
players that control these actin dynamics are members of the family of Rho GTPases.
Rho GTPases switch between GTP-bound ‘on’ and GDP-bound ‘off’ states through the 
action of guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins 
(GAPs), respectively [46]. When GTP bound, Rho GTPases are typically located at the 
plasma membrane where they interact with their effectors, including protein kinases and 
actin-binding proteins. This way, they affect the local assembly or disassembly of F-actin 
and allow polarized regulation of cell motility [47-51]. In their GDP-bound state, most Rho 
GTPases are bound to a member of the cytosolic Rho GDP dissociation inhibitor (GDI) family, 
which prevent nucleotide dissociation and thus the activation of Rho GTPases. The GDI also 
protects the Rho GTPase from degradation [52, 53].
More than 20 members of the family of Rho GTPases have been described thus far [54]. 
The best characterized of these, and which are implicated in endothelial barrier function, 
are RhoA, RhoB, RhoC, Rac1 and Cdc42, each with distinct roles in cell adhesion [55, 56]. 
Typically, RhoA activity leads to stress fiber formation and actomyosin-based contraction, 
whereas activation of Rac1 and Cdc42 gives rise to actin polymerization and cell spreading 
due to the formation of lamellipodia and filopodia, respectively. The mechanical force 
exerted by contracting F-actin filaments on VE-cadherin complexes, and thereby on 
cell–cell contacts in an intact monolayer, can lead to barrier disruption. Consequently, 
tightly coordinated (in)activation of Rho GTPase signaling is essential for the stabilization, 




key to their activation and downstream signaling and is regulated by PTMs, including 
phosphorylation, isoprenylation, palmitoylation and, as identified more recently, sumoylation 
and ubiquitylation [57].
A clear role for ubiquitylation in the regulation of both Rho GTPase localization, as well 
as proteasomal degradation has been shown by us and others. Treatment of human 
umbilical vein endothelial cell (HUVEC) monolayers with the neddylation inhibitor MLN4924, 
an inhibitor of cullin RING ligase (CRL) activity, induces a rapid loss of endothelial barrier 
function [20, 58]. Neddylation is the covalent attachment of the ubiquitin-like Nedd8 protein 
to the cullin scaffold proteins, a modification that is required for their activity. MLN4942-
induced loss of barrier function is accompanied by an increase in the levels of RhoB, which 
results from a decrease in RhoB degradation [20]. This indicates that, in resting conditions, 
HUVECs constantly ubiquitylate and degrade RhoB through CRLs to preserve endothelial 
integrity. The de-neddylation inhibitor CSN5i-3 caused similar barrier-disruptive results, 
which were also accompanied by an increase in RhoB levels, although in this case, this was 
a result of increased IκB degradation, NFκB activation and a subsequent increase in RhoB 
transcription [20, 54, 59, 60]. Thus, CRLs play divergent roles in endothelial integrity, in 
part direct, by ubiquitylating key signaling molecules, such as RhoB, and indirect, through 
the activation of inflammatory signaling pathways. Since the role of ubiquitylation in the 
localization and activity of Rho GTPases has been previously reviewed [57, 61-63], here, we 
limit the discussion to their regulation of endothelial barrier function (Figure 2).
RhoA
In human embryonic kidney 233 (HEK293T) and mouse embryonic fibroblast (MEF) cells, 
RhoA is targeted for ubiquitylation and degradation at K5 and K6 by the HECT ligase Smurf1 
[64], an event localized at cellular protrusions [65]. Smurf1 acts in a complex formed by 
Cdc42, PAR6 and PKCζ, which induces the ubiquitylation and degradation of RhoA. This in 
turn stimulates the localized activation of Rac1 and Cdc42, thereby identifying ubiquitylation 
as part of the mechanism by which RhoA inhibits signaling by Rac1 and/or Cdc42 [66, 67]. In 
brain ECs, cerebral cavernous malformation protein 2 (CCM2) localizes Smurf1 to the plasma 
membrane, thereby targeting RhoA for degradation [68]. To counteract RhoA degradation, 
the actin-associated protein synaptopodin can directly bind to RhoA, which blocks Smurf1-
mediated ubiquitylation and degradation in podocytes [69]. Recently, it was reported that 
HUVECs express synaptopodin when they are under laminar shear stress, suggesting that 
similar signaling takes place in the vascular endothelium [70]
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Figure 2 - Ubiquitin E3 ligases and DUBs regulating Rho GTPases. Indicated here are the different ubiq-
uitin ligases as well as several identified DUBs that target the Rho GTPases. Barrier-protecting or -disrupting 
functions of the different Rho GTPases are highlighted, with RhoA and RhoB being disruptive, and Rac1 and 
Cdc42 protective. The Ras-like GTPase Rap1 is known for its barrier-stabilizing properties and is therefore 
included in the figure. See main text for further details. BACURD, BTB-containing adaptor for Cul3-mediated 
RhoA degradation.
RhoB
The regulation of RhoB is significantly different from that of RhoA and RhoC. This is mainly 
due to the difference in their hypervariable C-terminal regions. The hypervariable region 
of RhoB contains more polar amino acids than that of RhoA and RhoC, and additional 
isoprenylation modifications have been reported for RhoB [71-73]. Unlike RhoA and RhoC, 
RhoB does not bind the ubiquitously expressed RhoGDI1 (also known as ARHGDIA) and is 
therefore prone to ubiquitylation and degradation [74]. As a result, ECs typically express 
only low levels of RhoB in resting conditions [20, 75].
Mechanistically, we found that in HUVECs, knockdown of components of the RING E3 ligase, 
which comprises the scaffold protein Cullin3, the adapter protein Rbx1 and its RhoB-binding 
substrate receptor KCTD10, increases the protein level and activation of RhoB, resulting in 
cell contraction and barrier disruption [20]. We further identified the relevant ubiquitylation 
acceptor sites in RhoB as K162 and K181, following ectopic expression of RhoB loss-of-
ubiquitylation (K-R) mutants in HEK293T cells. In HUVECs, ubiquitylation of RhoB at these two 
lysine residues leads to its lysosomal targeting and degradation [20]. A recent study showed 
that KCTD10-mediated RhoB degradation in epithelial cells serves to allow Rac1 activation 
[76]. In HUVECs, Rac1 is a barrier-stabilizing Rho GTPase (see below). This suggests that 
KCTD10-mediated downregulation of RhoB not only limits contractility, but also promotes 
cell spreading and endothelial barrier stability. Conversely, RhoB has been shown to drive 
internalization of Rac1 in TNFα-treated HUVECs, which limits the capacity of Rac1 to stabilize 





Unlike what is seen for RhoB, the majority of Rac1 in resting ECs is localized in the cytosol, 
where it is bound to the chaperone RhoGDI and therefore inactive [52, 77]. Upon cell 
stimulation, Rac1 is released from the GDI to be activated at cellular membranes by a local 
GEF, followed by its interaction with nearby effectors [49]. These include p21-activated 
kinases (PAKs), which induce lamellipodia formation [78], partitioning defective (PAR)6, 
which is important for cell polarity [79] and IQGAPs, which increase cell–cell adhesion, 
proliferation and angiogenesis [80], as well as, specifically, Rac1-associated 1 (SRA1), WASP-
family verprolin-homologous (WAVE) proteins and p67phox, part of the NADPH oxidase 
complex that leads to ROS production [81]. To limit localized Rac1 signaling, active Rac1 
is ubiquitylated, which is accompanied by its internalization and leads to its proteasomal 
degradation [25, 82]
Inhibition of Rac1 degradation increases ROS production and disrupts the endothelial 
barrier; this occurs through various mechanisms, including disruption of the plasma 
and mitochondrial membrane through membrane lipid peroxidation, which reduces ATP 
generation and decreases metabolism and cell survival [83-86]. To inhibit ROS production, 
the HECT E3 ubiquitin ligase HACE1 targets active Rac1 for degradation by ubiquitylation 
at K147 [83, 87-89]. In contrast, Rac1-mediated ROS production is increased by the E3 
ligase TRAF6. TRAF6-mediated ubiquitylation of Rac1 occurs in response to H2O2 and 
IL-1β stimulation, and after ischemia-reperfusion injury, all of which also lead to a loss of 
endothelial barrier function [90, 91].
Several other ubiquitin ligases also target Rac1. K147 polyubiquitylation and Rac1 
degradation can be mediated by X-linked IAP (XIAP), cIAP1 and cIAP2 in HeLa and HEK293T 
cells [92]. In addition, the SCF-FBXL19 E3 ligase targets Rac1 K166 for ubiquitylation and 
degradation, an event which requires AKT-mediated phosphorylation of Rac1 at S71 [93]. 
Through this pathway, FBXL19 negatively regulates Rac1 signaling; this impairs cell migration 
and reduces endothelial barrier integrity [73].
Collectively, these studies illustrate that Rho GTPases are subject to ubiquitylation by HECT 
and RING E3 ligases, which, in most cases, alters their localization and limits their abundance 
and signaling capacities. This is not unique for Rho-like small GTPases, as the activation and 
output of Ras and Rab GTPases are also controlled through ubiquitylation [94, 95].
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Ubiquitin modifications at endothelial cell-cell junctions
Cell–cell contacts between ECs comprise different types of junctions (adherens, tight and 
gap junctions) with different cell adhesion molecules and regulators. A large, and growing, 
number of E3 ligases and some DUBs have been implicated in the control of intercellular 
contacts, both in epithelial and ECs (Table 1; Figure 3). A selection of these, i.e. those relevant 
for endothelial integrity, is discussed below.
Table 1. Ubiquitin ligases and DUBs implicated in the control of endothelial junctional proteins
Target Ubiquitin ligase Output Reference
ZO-1 Ubr1 Negative regulator of integrity [96]
VE-cadherin;
α-, β-, γ-catenin (indirect)





Negative regulator of integrity [28, 58, 97] 
VE-cadherin unidentified Bradykinin-induced permeability [7]
Occludin Itch VEGF-induced permeability [98, 99]
VEGFR2 β-Trcp1,
CHIP
VEFGR2 degradation; inhibition of 
angiogenesis
[100-102] 
VEGFR2 Cbl VEFGR2 degradation; inhibition of 
VEGF-induced eNOS
[103]
AMOTL-1 HECW2 Stabilization of junctions [104]
Claudin-5 HECTD1 Disruption of blood-brain barrier [105]
Junctional proteins 
(indirect, via FoxO)
March3 Negative regulator of integrity [106]




NOTCH USP10 Endothelial sprouting [108]
VE-cadherin A20 Protection of lung endothelial 
barrier function
[109]
Kowalczyk and colleagues provided the first indications that the expression levels of 
VE-cadherin and its localization at junctions are regulated by controlled, lysosomal 
degradation in primary microvascular dermal ECs [110]. Subsequently, it was shown that 
VE-cadherin is internalized in a clathrin-dependent fashion in ECs [111, 112] The notion 
that the clathrin-mediated internalization of VE-cadherin is the result of its ubiquitylation 
was proposed by Orsenigo et al. [7]. These authors demonstrated that bradykinin induces 




ubiquitylation, internalization and degradation. Although the responsible ligase was not 
identified in this study, VE-cadherin ubiquitylation was suggested to occur through K63-
linkage, in line with its lysosomal degradation [7]. Interestingly, VE-cadherin-associated p120 
catenin (also known as CTNND1) protects VE-cadherin from internalization [111, 112]; this is 
caused by the binding of p120 catenin to an endocytic motif in the intracellular part of VE-
cadherin, which limits both its internalization as well as ubiquitylation. In Kaposi sarcoma, 
which is caused by human herpesvirus 8, VE-cadherin is ubiquitylated by the virus-encoded, 
transmembrane MARCH-family ubiquitin ligase K5 [28, 97](see Box 1). This E3 ligase thus 
contributes to the sarcoma-associated vascular leakage and tumorigenesis though its effect 
on VE-cadherin ubiquitylation and degradation.
Box 1. Degradation of endothelial junction components in virus-induced 
vascular leakage
Viral infections with the highly pathogenic strains of the influenza A virus, or even 
more severely with hemorrhagic viruses (e.g. Hanta, Dengue or West Nile Virus) can 
induce disruption of the endothelial barrier, acute lung injury and shock. Viruses can 
both directly and indirectly disrupt the endothelial barrier [113, 114]. Accordingly, 
strengthening of the endothelial barrier by signaling through Tie2, the receptor for 
angiopoietin, or by Robo-4, the receptor for the chemorepellent SLIT1, improves 
lung injury and survival of mice in an influenza model [115]. Influenza A virus induces 
degradation of the tight junction component claudin-5 in primary microvascular ECs 
and of ZO-1 in primary HUVECs and in mice [113, 116]. Furthermore, the H1N1 influenza 
strain enhances hyper-phosphorylation of β-catenin and its proteasomal degradation 
in primary HUVECs [117]. In addition, the E3 ubiquitin ligase Itch was found to be 
necessary for uncoating of influenza A virus and its transport from endosomes to the 
nucleus [118]. In epithelial cells, Itch mediates degradation of occludin [119]; however, 
direct interaction partners for Itch that mediate virus-induced loss of endothelial 
cell–cell contact remain to be identified. Finally, infection of HUVECs or HMECs with 
dengue virus also causes disruption of adherens and tight junctions, changes in the 
actin cytoskeleton and reduced expression of several junctional proteins including 
PECAM-1/CD31 and VE-cadherin [120-122]. Although the molecular mechanisms of this 
downregulation are currently incompletely understood, examples of virus-encoded 
ubiquitin ligases do exist; an example is the MARCH-family ubiquitin ligase K5 from 
herpesvirus (see main text) [97].
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Ubiquitylation of the tight junction protein occludin in ECs has been implicated in junctional 
stability (see Box 1 and Table 1). PKCβ-mediated phosphorylation of occludin at S490 [99] and 
its subsequent ubiquitylation by the E3 ligase Itch have been linked to vascular endothelial 
growth factor (VEGF)-induced permeability in primary bovine retinal ECs [99]. Interestingly, 
these authors showed that a C-terminal occluding–ubiquitin chimera was internalized, 
bypassing the requirement for phosphorylation [98]. Thus, VEGF, through PKCβ-mediated 
phosphorylation, promotes Itch-mediated ubiquitylation of occludin, which is required for 
its internalization and degradation, thereby enhancing retinal endothelial permeability.
Figure 3 - Ubiquitylation in cell–cell contacts. Overview of the various ubiquitin E3 ligases (in red) and 
DUBs (in green) that regulate junctional proteins in endothelial cells. In tight junctions, occludin and claudin-5 
are regulated by the E3 ligases Itch and HECTD1, respectively, while ZO-1 is regulated by Ubr1. For adherens 
junctions, several other E3 ligases and their substrates, including both adhesion molecules and cell surface 
receptors, have been identified. The indicated ligases and DUBs that control endothelial integrity are discussed 




Furthermore, another study has shown that ischemia in the rat brain, induced by permanent 
middle cerebral artery occlusion, is associated with increased Itch-mediated ubiquitylation 
of occludin and loss of vascular integrity [123]. The ischemia also induced a downregulation 
of Notch1 and, in line with Notch regulation by γ-secretase, intraventricular treatment with 
the γ-secretase inhibitor DAPT prevented the ubiquitylation and degradation of occludin. 
This also reduced Evans Blue leakage of the brain vasculature, indicative of restored barrier 
function. The notion that Notch may stabilize junctions by limiting occludin ubiquitylation 
is intriguing, and is in line with the finding that DAPT-mediated inhibition of γ-secretase 
induces vascular barrier protecting properties [123]. Finally, the tight junction protein ZO-1, is 
targeted for ubiquitylation by the E3 ligase N-recognin-1 (Ubr1) [96]. This is initiated through 
the inflammatory cytokine IL-6, which, in turn, is produced following an infection of brain 
pericytes with Japanese encephalitis virus [96]. Thus, a growing number of ubiquitin ligases 
appears to be involved in regulation of junctional integrity. Some of these target junctional 
proteins directly, or control barrier function indirectly, by ubiquitylating regulatory proteins 
that, for example, control cytoskeletal dynamics.
Ubiquitin ligases and junctional regulation
A number of different E3 ligases have been linked to the control of endothelial junctional 
integrity (Table 1). For instance, ectopic expression of MARCH family of E3 ligases, MARCH2 
and MARCH4, whose mRNA is expressed in primary dermal microvascular ECs, impairs 
VE-cadherin localization to junctions [28]. However, this does not exclude a mechanism 
that involves ubiquitylation of VE-cadherin-associated proteins, which could regulate its 
internalization. The MARCH3 E3 ligase also negatively regulates endothelial integrity, but in 
an indirect manner. In human brain ECs in which MARCH3 was downregulated, histamine-
induced permeability was reduced [106]. In brain ECs transfected with siRNA targeting 
MARCH3, both the mRNA and protein levels of claudin-5 and occludin were increased, 
whereas the mRNA and protein levels of VE-cadherin were only increased slightly. Here, 
MARCH3 was found to act through the transcription repressor FoxO1 to reduce the mRNA 
expression levels of the tight junction proteins occludin and claudin-5. Thus, MARCH3-
mediated reduction of mRNAs that encode tight junction proteins impairs adherens junction 
stability and endothelial integrity [106]. This mechanism is thus clearly different from the 
ubiquitylation of claudin-5 in human brain microvascular ECs by the HECT domain E3 
ubiquitin protein ligase (HECTD)1 [105]. This pathway was identified following Streptococcus 
infection, which induced the ubiquitylation and degradation of claudin-5, which weakened 
the blood–brain barrier and promoted further infection with the pathogen [105].
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Furthermore, it has recently been shown that activation of CRLs by neddylation is required 
for endothelial integrity [58]. Here, pharmacological inhibition of CRL neddylation by 
MLN4924 induces a strong increase in the permeability of HUVECs that is associated with 
the loss of VE-cadherin protein, but not a decrease in its mRNA levels. The study further 
showed that the cullin 3 scaffold protein is required for the stabilization of VE-cadherin and 
endothelial integrity. However, it was not established whether the reduced VE-cadherin 
protein levels were an indirect result of the loss of integrity, or whether CRLs directly control 
VE-cadherin stability by ubiquitylation [58].
As discussed above, the cullin3 scaffold, in complex with the adapter protein Rbx1, and the 
substrate receptor KCTD10, stabilizes the integrity of endothelial monolayers by limiting 
RhoB levels and signaling output [20]. Intriguingly, KCTD10 also stimulates developmental 
angiogenesis in mouse embryos, as determined by knockout studies [107]. Here, KCTD10, 
in conjunction with cullin 3, was suggested to ubiquitylate Notch1, which reduces Notch 
signaling in the vasculature. Notch1 positively regulates endothelial integrity by activating a 
non-canonical VE-cadherin–Trio–Rac1 signaling pathway [124]. Thus, the role of the Cul3–
Rbx1–KCTD10 RING ligase in ECs is complex, as it not only negatively regulates Notch1, thus 
reducing barrier function, but also downregulates RhoB, which results in barrier stabilization.
Another E3 ligase that negatively regulates endothelial integrity is PDZ domain-containing 
ring finger 3 (PDZRN3) [125]. PDZRN3 acts downstream of the PAR3 polarity complex and 
targets the protein discs lost-multi-PDZ domain protein 1 (MUPP1, also known as MPDZ) 
for poly-ubiquitylation and degradation. This pathway was identified in infarcted mouse 
brain, thereby implicating PDZRN3 as an important mediator of a compromised blood–brain 
barrier and tissue damage in acute ischemic stroke [125].
In contrast to MARCH3 and PDZRN3, the endothelial E3 ligase HECW2 (also known as NEDL2), 
a member of the NEDD4 family of ligases that also includes Itch, stabilizes endothelial 
junctions [104]. Accordingly, siRNA-mediated loss of HECW2 reduces endothelial barrier 
function and promotes angiogenic sprouting. The authors suggest that this occurs through 
ubiquitylation-mediated stabilization, rather than destabilization, of the junctional protein 
AMOTL1 [104].
Although there is accumulating data on the role of ubiquitin ligases in endothelial integrity, 
only very little is known with regard to the role of DUBs in barrier regulation. For instance, the 
DUB Cezanne (also known as OTUD7B) has been shown to protect against hypoxia-induced 




of the E3 ligase TRAF6, which is part of the NFκB pathway [126]. Another example is the DUB 
USP40, which is particularly highly expressed in glomerular ECs, as well as in podocytes in 
rats and mice [127]. In in vivo experiments in zebrafish, USP40 morpholinos induced cardiac 
edema and loss of glomerular permeability. Although the USP40 targets were not identified, 
its association with the intermediate filament protein nestin suggests that it is an endothelial 
integrity-stabilizing DUB that acts on cell–cell junctions through intermediate filaments [127]
Ubiquitin-dependent modifications in vascular disease
It is not surprising, given the abundance and importance of protein ubiquitylation, 
that this process (and its deregulation) contributes to a range of disorders, including 
neurodegenerative and inflammatory diseases, as well as cancer [10, 128]. Consequently, 
proteasome inhibition has already been in use as a therapeutic intervention for more than 
two decades; however, such an approach obviously shows limited specificity, and the use of 
proteasome inhibitors is accompanied by (cardiovascular) side effects [129, 130].
Most, if not all, vascular disorders are accompanied by a loss of endothelial integrity, which 
causes edema and tissue damage owing to elevated interstitial pressure and increased influx 
of activated leukocytes [2, 29]. It is therefore imperative to understand in detail the different 
molecular mechanisms that control stable, as well as disrupted, endothelial barrier function. 
While the role of ubiquitylation in vascular pathologies is perhaps less well established 
compared to that in, for instance, cancer, some clear connections exist.
Probably the best-studied pathway involves the regulation of (tumor) angiogenesis through 
the degradation of hypoxia inducible (HIF) transcription factors by the von Hippel–Lindau 
(VHL) protein, a substrate receptor that is part of a Cul2–Rbx1-containing RING ubiquitin 
ligase [131]. Loss of VHL promotes VEGF expression and tumor vascularization as a result 
of HIF1 being stabilized [132]. Several other studies have implicated (de-)ubiquitylation in 
hypoxia and angiogenesis, either through ubiquitin-mediated interactions between VEGFR2 
and epsin1, which drives angiogenesis and wound healing [133], or through sumoylation of 
Notch1, which controls VEGF receptor (VEGFR) signaling and angiogenesis [134]. Interestingly, 
Notch1 ubiquitylation by the FBXW7 RING ligase is required for angiogenesis in vitro and in 
vivo [135]. In good agreement with this, loss of Usp10, the DUB for Notch1, promotes in 
vivo vessel sprouting [108]. Finally, VEGFR2 has been identified as a substrate for several 
ubiquitin ligases, including SCF-βTRCP, CHIP (also known as STUB1) and Cbl, which all 
regulate angiogenesis through directly targeting VEGFR2 [101-103].
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As discussed above, ubiquitin ligases and/or DUBs have been implicated in inflammatory 
vascular disorders, for example in the lung or the brain [10, 21, 136, 137]). Aberrations in the 
TNF signaling pathway underlie several human pathologies, as has been corroborated by 
functional studies in animal models. Mutations in TNFR1 or the LUBAC component HOIL-1 
(also known as RBCK1) cause inflammation in affected individuals [33, 138]. Furthermore, 
genetic depletion of the DUBs A20 or CYLD in mice rendered them more susceptible to 
inflammatory bowel disease [139, 140]. A20 was recently proposed to act as a DUB for 
VE-cadherin, thereby preserving endothelial barrier function, and its re-expression in 
A20-deficient mice was found to limit their lung permeability [109]. Conversely, the RBR 
E3 ligase Parkin, originally linked to Parkinson disease, was recently shown to mediate 
vascular permeability both in vitro and in vivo in a study showing that Parkin-deficient mice 
are protected from LPS-induced acute inflammation and leakage in the lung [141].
A deletion in the cullin 3 scaffold (cullin3Δ9, a deletion of 57 amino acids encoding exon 9) 
drives vessel wall stiffness and hypertension due to impaired turnover of RhoA, resulting in 
increased smooth muscle cell contractility [142]. Conversely, the cullin 3 substrate adapter 
RhoBTB1 protects from arterial stiffness and hypertension through its ubiquitylation and 
the consequent degradation of the phosphodiesterase PDE5. Lower amounts of PDE5 lead 
to increased cGMP levels, which in turn promotes smooth muscle cell relaxation [143]. This 
important role for cullin 3 in vascular smooth muscle cells is in good agreement with its 
degradation of RhoB in ECs, which also limits contraction and preserves endothelial integrity 
[20, 58]. Taken together, a growing number of ubiquitin ligases and DUBs has been implicated 
in vascular disorders. Targeting these individual ligases, based on detailed structural and 
mechanistic studies, is of key importance to selectively limit chronic inflammation, together 
with its associated loss of barrier function and tissue damage.
CONCLUDING REMARKS
The ubiquitous nature of protein regulation through controlled degradation makes it obvious 
that this process is important, and it is also important for endothelial permeability and 
associated vascular pathologies, such as tumor angiogenesis and inflammation. The above 
overview aims to highlight our growing knowledge on the role of protein ubiquitylation in 
endothelial integrity. Although several of these ubiquitin ligases have already been implicated 
in vascular permeability, many questions remain unanswered. For instance, what is the 
ubiquitin ligase for VE-cadherin? Do endothelial-specific ubiquitin ligases or DUBs exist for 
the control of cell–cell adhesion? If so, do these show vascular-bed-specific distribution and 




interesting aspect is that autophagy, which comprises lysosomal degradation and recycling 
of proteins, is vascular barrier-protective in both the brain and the lung [144, 145]. Since 
K48 ubiquitylation drives lysosomal degradation, this type of ubiquitin modification may 
directly link cellular homeostasis, controlled by autophagy, to endothelial integrity. This may 
also prove pivotal in the aging-related loss of autophagy, which correlates with an increase 
in cardiovascular disease [146].
The above overview also underscores how many different ubiquitin ligases are 
mechanistically, both directly and indirectly, linked to the control of endothelial integrity. This 
apparent excess of regulators is not unique and is similar to, for example, the large number 
of RhoGEFs and GAPs (in total over 150) that regulate only ~20 Rho GTPases [46]. It is likely 
that the relatively crude way in which ubiquitin ligases have been studied so far obscures 
differences in their specific localization or in the conditions during which one or the other 
ligase or DUB is most relevant. On top of this, cell-type-specific differences in expression, 
even between EC subtypes, is likely to play a role, in addition to divergent culture conditions 
or cellular stimulation. The development of specific antibodies for detection of individual 
E3 ligases or DUBs, as well as of the ubiquitin chains on specific substrates, use of super-
resolution imaging and careful definition of the cell type and conditions used, will increase 
our insight in this complex mode of cellular signaling. Clearly, protein ubiquitylation and 
its intersection with critical regulatory pathways predicts a busy, but also very interesting 
future for this field of research.
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RhoGTPases control endothelial cell (EC) migration, adhesion, and barrier formation. 
Whereas the relevance of RhoA for endothelial barrier function is widely accepted, the 
role of the RhoA homologue RhoB is poorly defined. RhoB and RhoA are 85% identical, but 
RhoB’s subcellular localization and half-life are uniquely different. Here, we studied the role 
of ubiquitination for the function and stability of RhoB in primary human ECs. We show that 
the K63 polyubiquitination at lysine 162 and 181 of RhoB targets the protein to lysosomes. 
Moreover, we identified the RING E3 ligase complex Cullin-3–Rbx1–KCTD10 as key modulator 
of endothelial barrier integrity via its regulation of the ubiquitination, localization, and activity 
of RhoB. In conclusion, our data show that ubiquitination controls the subcellular localization 
and lysosomal degradation of RhoB and thereby regulates the stability of the endothelial 
barrier through control of RhoB-mediated EC contraction.
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INTRODUCTION
Endothelial cells (ECs) are tightly connected cells that line the luminal side of blood and 
lymphatic vessels. Loss of endothelial barrier integrity is a hallmark of chronic inflammatory 
diseases and will lead to edema, tissue damage, and loss of organ function. Adherens 
junctions (AJs) are key structures in the regulation of endothelial barrier function [1]. AJ-
associated protein complexes form contacts between two neighboring ECs through Ca2+-
dependent, homotypic interaction of vascular endothelial (VE)–cadherin molecules. The 
interaction of the VE–cadherin complex with the actin cytoskeleton limits its endocytosis and 
stabilizes AJs [2]. Conversely, altered actin dynamics can induce junctional rearrangement 
and contractility-driven disassembly of AJs [3].
Morphology and dynamics of the actin cytoskeleton are regulated at the level of actin 
(de)polymerization as well as bundling and the interaction of polymerized actin with the 
cell adhesion machinery, processes regulated by Rho GTPases. For example, activation 
of Rac1 or Cdc42 induces actin polymerization and formation of membrane protrusions, 
which promote cell migration [4]. In contrast, activation of RhoA induces myosin activation, 
F-actin stress fiber formation, and cell contraction. In ECs, the latter pathway promotes 
force-induced disassembly of AJs and loss of endothelial integrity [5-8].
Given the pathophysiological relevance of endothelial integrity, it is crucial to uncover the 
molecular details of the mechanisms that drive RhoGTPase (in)activation. After initial studies 
[9, 10], analysis of regulation of Rho GTPases has led to the discovery of guanine nucleotide 
exchange factors, GTPase-activating proteins, and guanine nucleotide dissociation inhibitors 
that govern the activation, inactivation, and the stability of Rho GTPases, respectively [11].
Posttranslational modifications such as ubiquitination were also found to control the 
localization, activity, and stability of Rho GTPases, including RhoA and Rac1 [12-15]. 
Ubiquitination involves covalent attachment of an ubiquitin moiety to a lysine residue in 
the substrate [16]. Several inhibitors of the ubiquitination machinery are currently tested in 
clinical trials for treatment of solid tumors and leukemia (e.g., MLN4924 [17]).
Currently, the molecular mechanism that links ubiquitination to GTPase-regulated 
endothelial integrity is unknown. We therefore tested whether inhibition of ubiquitination 
using a targeted shRNA-mediated knockdown approach would affect endothelial barrier 
stability. Based on published information [11, 18-21], we selected ubiquitination-regulating 




found that depletion of members of Cullin–RING ligase (CRL) family of proteins, specifically 
Cullin-3, strongly impairs endothelial barrier function. Furthermore, we found that loss of 
Cullin-3 selectively impairs RhoB degradation and that CRL inhibition by MLN4924 increases 
RhoB levels and activation. In addition, we found that RhoB is primarily K63 polyubiquitinated 
and subsequently degraded in lysosomes. Using a focused siRNA screen, we identified the 
BTB protein KCTD10 as substrate receptor for RhoB in the Cullin-3–Rbx1 ligase complex. 
Finally, we identified at least two lysine residues of RhoB, K162 and K181, as acceptor residues 
for KCTD10-mediated ubiquitination.
Our results show that continuous, Cullin-3–Rbx1–KCTD10–mediated RhoB ubiquitination and 
degradation preserves endothelial barrier function, supporting the concept that controlled 
protein turnover in ECs is instrumental for the maintenance of blood vessel integrity.
RESULTS
Ubiquitination regulates the actin cytoskeleton and AJs in ECs
Activity of RhoGTPases is crucial for actin dynamics and endothelial barrier function [22, 
23]. Therefore, we hypothesized that interfering with ubiquitination of Rho GTPases would 
impact F-actin distribution and endothelial integrity. To test this, we used lentiviral shRNA-
mediated knockdown of 22 genes (Figure S1, A and B) comprising E3 ubiquitin ligases, CRL 
substrate recognition receptors, ubiquitin proteases, and other proteins and analyzed the 
consequences for the actin cytoskeleton and AJ morphology (Figure S1, B and C).
In line with published data, we found an increase of actin stress fibers when we depleted 
XIAP, BIRC2 (Rac1 ubiquitin ligases), or SMURF1 (a RhoA ubiquitin ligase [18, 19]; Fig. S1 
B). Interestingly, depletion of CRL complex proteins (Cullin-3, FBXW7, and FBXL19; Figure 
S1 B) strongly affected the actin cytoskeleton and VE–cadherin distribution (see following 
paragraph). Based on these initial and published observations [12], we focused on the role 
of Cullin-3 in cytoskeletal organization and endothelial barrier function.
Cullin-3 is crucial for maintenance of endothelial barrier integrity
Depletion of Cullin-3 led to increased formation of F-actin stress fibers in primary human 
umbilical vein endothelial cells (HUVECs; Figures 1 A and S1 D) and an ~20% decrease in 
transendothelial electrical resistance (Figure 1, B and C). Using multifrequency scanning 
and modeling software, we found that Cullin-3 knockdown decreased Rb (barrier resistance) 
~10-fold (Figure 1 D).
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Figure 1 - Knockdown of Cullin-3 impairs cell signaling involved in endothelial barrier maintenance. 
(A) HUVECs were transduced with the control shRNA or Cullin-3–targeting shRNA and stained for VE–cad-
herin and F-actin at 72 h after infection. Dashed boxes correspond to zoomed images. Bars, 15 µm. (B) ECIS 
measurement of HUVECs prepared as in A. 105 cells were seeded per well in an eight-well ECIS slide at 72 h 
after infection, and electrical resistance was measured at 4,000 Hz (n = 5). (C) Resistance values at 4,000 Hz 
were compared by analysis of 10 measurement points 16–17 h after seeding for the cells prepared as in A 




resistance of the endothelial monolayer was measured at 4,000 Hz using ECIS. Cells were stimulated with 1 U/
ml thrombin and, after recovery, with 500 nM S1P, and electrical wounding was performed at 100 kHZ, 6,500 
µA for 120 s. (F) Maximum response to thrombin response was calculated using GraphPad Prism (n = 5). (G) 
Recovery upon thrombin stimulation was measured at 1.5 h upon thrombin addition and normalized to the 
resistance values before thrombin addition (n = 5). (H and I) Analysis of S1P response in cells prepared as in 
A (n = 5). Areas under the curve of S1P response were calculated using GraphPad Prism. Error bars represent 
SD. **, P = 0.01–0.001; ****, P < 0.0001.
Thrombin-induced disruption of the endothelial barrier is used to define the role of GTPases, 
kinases, and phosphatases in vascular integrity [24, 25]. The modulation of endothelial 
integrity by Thrombin, histamine, or sphingosine-1-phoshate (S1P), occurs through 
G-protein–coupled receptors [26, 27]. This ensures rapid, but also transient responses, 
in contrast to the barrier loss induced by inflammatory cytokines such as TNFα or growth 
factors such as VEGF [28, 29]. The Thrombin-induced loss of endothelial resistance (Figure 1 
E) was not altered by Cullin-3 depletion (Figure 1, E and F). However, the subsequent recovery 
of endothelial barrier function was significantly impaired (Figure 1 G), suggesting that Cullin-3 
protects against Thrombin-induced, prolonged loss of integrity in ECs.
To test whether barrier-promoting signaling was affected in Cullin-3 knockdown cells, we 
treated ECs with S1P (Figure 1 E). We did not observe any significant change in the barrier-
protecting response to S1P upon loss of Cullin-3 measured at 4,000 Hz (Fig. 1 H). However, 
depletion of Cullin-3 caused a three- to fourfold increase in resistance when measured at 
32,000 Hz (Figure 1 I). These data suggest that loss of Cullin-3 promotes barrier function 
through increased cell–matrix interactions.
Cullin-3 depletion impairs FA dynamics in ECs
Adhesion of ECs to the extracellular matrix is mediated by integrins. We found that α5 
integrin– and activated-β1-integrin–positive adhesions were increased in size in S1P-
stimulated, Cullin-3 knockdown cells (Figure 2 A). Based on the immunofluorescence (Figures 
1 A and 2 A) and electrical cell-impedance sensing (ECIS) data (Figure 1, B–D), we concluded 
that the increased adhesion and integrin activation in Cullin-3 knockdown cells was caused 
by increased contractility. In line with this, we found that depletion of Cullin-3 increased 
the phosphorylation status of Erk1/2 5.2-fold (Figure 2, B and C) and of myosin light chain 
(MLC) 6.5-fold (Figure 2, B and D), but not that of PAK1/2/3 (Figure 2 B). As shown in Figure 
1 A, Cullin-3 depletion induces formation of actin stress fibers, anchored at focal adhesions 
(FAs). Staining for phospho Paxillin (pPaxillin) and vinculin, well-established FA markers, 
showed a shift in distribution of FA from the cell periphery in control cells to a more central 
distribution in Cullin-3 knockdown cells (Figure S2 A).
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Figure 2 - Cullin-3 knockdown and MLN4924 treatment impair FA dynamics in ECs. (A) Immunofluores-
cence staining of HUVECs transduced with the control- or Cullin-3 shRNA and stimulated with 500 nM S1P for 
15 min. Upon stimulation, cells were fixed and stained for α5- and activated β1-integrin. Bars, 10 µm. Higher 
magnifications of marked regions are in the right panels. (B) Immunoblots (IB) of duplicate lysates prepared 
from HUVECs transduced with the control shRNA or Cullin-3 shRNA. Membranes were probed with pErk Tyr204, 
pMLC Thr18/Ser19, and pPAK 1/2/3 Ser141 antibodies. Erk1/2 and vinculin were used as loading control. (C 
and D) Densitometric analysis of the pErk1/2 Tyr204 (C) and pMLC Thr18/Ser19 (D) immunoblots (n = 5). (E) 
Still images of movies (Videos 1 and 2) of control and CUL3 shRNA-transduced HUVECs, cotransfected with 




FAs at the earliest time points; red, FAs at the latest time points. (F and G) Assembly rate (F) and disassembly 
rate (G) were obtained from analysis of single adhesions via the FA analysis server (http://faas.bme.unc.edu/). 
(H) Confocal immunofluorescence of HUVECs treated with 500 nM MLN4924 for 4 h. After stimulation, cells 
were fixed and stained for pPaxillin and vinculin. Bars, 20 µm. (I and J) The number of FAs per cell (I) and the 
mean size of FAs ( J) were analyzed using ImageJ software and the particle analysis function. All adhesions in 
the range of 1–10 µm2 from 10 cells per condition were included in the analysis. Error bars represent SD. n.s., 
P ≥ 0.05; *, P = 0.01–0.05; **, P = 0.01–0.001; ***, P = 0.001–0.0001.
Subsequent live-cell microscopy (Figure 2 E and Videos 1 and 2) showed that depletion of 
Cullin-3 leads to an increased assembly rate of FAs (Figure 2 F), whereas FA disassembly 
was not affected (Figure 2 G). Thus, Cullin-3 attenuates both MLC phosphorylation and FA 
assembly rate in ECs.
Chemical inhibition of CRLs by MLN4924 causes loss of endothelial barrier 
integrity and induces FA formation
CRLs are activated by covalent attachment of the ubiquitin-like protein Nedd8 to the Cullin 
subunit. MLN4924 (Pevonedistat) inhibits the Nedd8-activating enzyme, blocking CRL 
activation [30]. In line with the findings described in the previous paragraph, we found that 
MLN4924 increased formation of FAs threefold (Fig. 2, H and I) with only a modest increase 
in FA size (Fig. 2, H and J). Additionally, we found that MLN4924 increased formation of stress 
fibers and cortical actin bundles (Fig. 3 A), accompanied by contraction and formation of 
intercellular gaps.
Disruption of endothelial integrity by MLN4924 was further confirmed by ECIS analysis (Fig. 
3 B). The gradual loss of endothelial resistance induced by MLN4924 surpassed the effect 
induced by the inflammatory cytokine TNF-α (Fig. 3 B), with no additive effect of combining 
TNF-α with MLN4924. MLN4924 also induced a loss of junctional VE–cadherin staining (Fig. S2 
B). These data show that CRL activity, specifically Cullin-3, is important for the maintenance of 
the endothelial barrier through the regulation of AJ stability and FA formation.
CRL inhibition disrupts endothelial barrier via stabilization and activation of RhoB
It was previously reported that MLN4924 inhibits degradation of RhoB in liver cancer and 
ECs [31]. Therefore, we tested whether the MLN4924-induced contraction and loss of barrier 
integrity (Fig. 3, A and B) was caused by its effects on RhoB. RhoB, but not Rac1 or RhoC, 
levels in HUVECs were increased 20-fold upon 4 h of MLN4924 treatment (Fig. 3 C and D). 
RhoA showed a modest, MLN4924-induced increase in expression (3.5-fold; Fig. 3, C and 
D). In cycloheximide-chase experiments, we found that the effects of MLN4924 on RhoB 
and RhoA were caused by increased protein stability (Fig. 3, E and F; and Fig. S2 C) and not 
increased de novo protein synthesis (Fig. 3 G).
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Figure 3 - MLN4924 treatment increases expression, and activation of RhoB and disrupts the en-
dothelial barrier. (A) The F-actin network in HUVECs treated with 500 nM MLN4924 for 4 and 20 h. Bars, 
20 µm. (B) ECIS measurement of a HUVEC monolayer treated with 500 nM MLN4924, 10 ng/ml human TNF-α, 
or both. Resistance at 4,000 Hz was measured, and the graph shows a representative experiment with tripli-
cate measurements per condition. (C) Immunoblot analysis of Rho GTPases in HUVECs treated with 500 nM 
MLN4924, 10 ng/ml human TNF-α, or both for 4 h. Lysates were probed with Rac1, RhoA, RhoB, and RhoC 
antibodies; Erk1/2 was included as loading control. Erk1/2 loading control is identical for Rac1 and RhoA im-
munoblots. (D) Densitometric analysis of Rac1, RhoA, RhoB, and RhoC immunoblots. Rac1, RhoA, RhoB, and 
RhoC expression was normalized to the loading control and in MLN4924-treated samples normalized to the 
corresponding untreated controls (n = 3–7). (E) Effect of MLN4924 on RhoB protein stability. HUVECs were 




for the indicated time points. Cells were lysed, and 20 µg of total proteins was analyzed by immunoblot with 
anti– RhoB antibody. (F) Densitometric analysis of E was performed using ImageJ software (n = 3). (G) RT-PCR 
analysis of RhoB mRNA expression in HUVECs treated with 500 nM MLN4924, 10 ng/ml human TNF-α, or 
both for indicated times. mRNA was isolated upon treatment and analyzed for RhoB transcripts using RT-PCR 
(n = 3). (H)HUVECs were transfected with siRNA targeting RhoA, RhoB, RhoC, or control siRNA. 72 h after 
transfection, cells were starved for 24 h and treated with 500 nM MLN4924, after which resistance was 
measured at 4,000 Hz and normalized to values before the addition of MLN4924. (I) Quantification of H at 5 h 
after addition of MLN4924 (n = 7). ( J) Quantification of the MLN4924 effect on the barrier function of HUVECs 
pretreated with Y-27632 or C3-transferase. Graph represents normalized resistance at 15 h after MLN4924 
addition (n = 3–8). (K) Rhotekin pull-downs were performed using lysates of HUVECs treated or not with 500 
nM MLN4924 or 10 ng/ml human TNF-α for 4 h or with 2.5 µM PR619 for 2 h. Input is equal to 2.5% of the lysate 
used for the pull-down. Vinculin was used as loading control (n = 3). Error bars represent SD. n.s., P ≥ 0.05; *, 
P = 0.01–0.05; **, P = 0.01–0.001; ***, P = 0.001–0.0001; ****, P < 0.0001.
TNF-α increased expression of RhoB as well ([32]; Fig. 3 C). Quantitative PCR analysis showed 
that TNF-α efficiently induced transcription of RhoB mRNA after 2 h (Fig. 3 G). In line with 
this, inhibition of protein synthesis with cycloheximide completely abrogated TNF-α–
induced RhoB expression (Fig. S2 D). We next depleted RhoA/B/C proteins individually or in 
combination (Fig. S4 A). We found that transendothelial resistance in control cells, treated 
with MLN4924, dropped to 60% after 5 h and that depletion of RhoB, but not RhoA or RhoC, 
rescued this loss of resistance (Fig. 3, H and I). The combined knockdown of RhoA and RhoB 
and of RhoA/B/C was very efficient in rescuing the effect induced by MLN4924 (Fig. S3, B and 
C). This was further confirmed using the cell-permeable C3 transferase, which inactivates 
all three Rho GTPases (Figs. 3 J and S3 D). Finally, inhibition of the Rho-effector kinases 
ROCK1/2 [28] with Y27632 before MLN4924 treatment prevented the loss of endothelial 
monolayer resistance (Figs. 3 J and S3 D). These results show that protection of endothelial 
monolayer integrity by CRL is largely mediated via ubiquitination and degradation of RhoB, 
which signals through ROCK to induce EC contraction.
Next, we tested whether the increased expression of RhoB in MLN4924- or TNF-α–treated 
HUVECs was accompanied by increased RhoB activity. Using a Rhotekin-RBD pull-down 
assay, we could show that MLN4924 caused a strong activation of RhoB and, to a lesser 
extent, RhoA (Fig. 3 K), but not Rac1 (Fig. S4 E), whereas a 4-h TNF-α stimulation induced 
only minor activation of RhoB.
In contrast to inhibition of CRL, the deubiquitination inhibitor PR619 did not alter RhoB 
activation and induced only a minor increase in RhoB expression (Fig. 3 K). However, PR619 
decreased the levels and activity of Rac1, in line with published data [33].
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Figure 4 - CRL-mediated ubiquitination targets RhoB for lysosomal degradation in ECs. (A) HUVECs 
were treated overnight with 300 nM MLN4924, 10 ng/ml human TNF-α, or a combination of both. Cells were 
fixed and stained for RhoB and VE–cadherin, F-actin, and nuclei. Bars, 20 µm. (B) Line scans of fluorescence 
intensity of RhoB and VE–cadherin were performed on images shown in A and analyzed using ImageJ. Yellow 
dashed lines in A mark the scanned area. (C) Colocalization of RhoB with Lysotracker in TNF-α–treated HUVECs. 
Cells were treated and stained as in A. Before fixation, cells were incubated with Lysotracker for 30 min. Bars, 
5 µm. (D) Quantification of Mander’s coefficient of colocalization of RhoB colocalization with Lysotracker was 
performed using ImageJ and JACoP plugin (Bolte and Cordelières, 2006; n = 17–19). (E) Immunoblot (IB) analysis 




MG132, 100 µM chloroquine, 30 mM NH4Cl, or 50 µM leupeptin. Vinculin was included as loading control. (F) 
Immunofluorescence staining of HUVECs treated overnight with 5 µM MG132 or 10 mM NH4Cl. After treatment, 
cells were fixed and stained with RhoB and LAMP-1 antibodies and phalloidin. Bars, 20 µM. (G) Samples for 
confocal microscopy were prepared as in F with MG132 treatment. Images were captured using a Leica TCS 
SP8 X (Leica Microsystems) microscope using a 100× 1.4 NA oil objective. Images were acquired at Nyquist rate 
using Nyquist Calculator (Scientific Volume Imaging) and subsequently deconvolved using Huygens Professional 
(Scientific Volume Imaging). Dashed box represents an enlarged lysosome, which is depicted in upper left 
corner of each panel. Bar, 5 µm. Error bars represent SD. n.s., P ≥ 0.05; ***, P = 0.001–0.0001.
Ubiquitination targets RhoB to lysosomes in ECs
We next tested whether RhoB ubiquitination regulates its localization. TNF-α–induced 
RhoB is primarily localized in the endosomal compartment (Fig. 4, A and B), in particular 
in lysosomes (Fig. 4, C and D). In marked contrast, MLN4924-induced RhoB was primarily 
localized at the cell membrane (Fig. 4, A and B). If MLN4924 was added together with TNF-α, 
we observed the same increase in RhoB expression as with TNF-α, but this pool of RhoB 
failed to localize to the endosomal compartment (Fig. 4, A–D).
Because of its localization in lysosomes, we hypothesized that RhoB is degraded via the 
lysosomal and proteasomal pathways. We found that inhibitors of lysosomal acidification 
(chloroquine and NH4Cl) or an inhibitor of lysosomal proteases (leupeptin) increased RhoB 
expression, similar to the proteasome inhibitors bortezomib or MG132 and MLN4924 
(Fig. 4, D and E; and Fig. S3 F). In addition, inhibition of the proteasome or, even more 
efficiently, lysosomal inhibition both led to accumulation of RhoB in lysosomes, specifically in 
LAMP-1–positive lysosomal membranes (Fig. 4, F and G). Although some of these inhibitors, 
such as chloroquine and NH4Cl, have limited specificity, these data suggest that RhoB 
ubiquitination promotes its localization to lysosomes and that RhoB degradation occurs 
through a lysosomal as well as a proteasomal pathway.
RhoB is polyubiquitinated via K63 linkage at lysines 162 and 181
Immunoprecipitation of endogenous RhoB from HUVECs confirmed that RhoB is 
polyubiquitinated under normal conditions and that this was completely prevented by 
MLN4924-mediated inhibition of CRLs (Fig. 5 A). Conversely, inhibition of deubiquitination 
by PR619 increased the levels of polyubiquitinated RhoB (Fig. 5 A). TNF-α did not reduce 
ubiquitination of endogenous (Fig. 5 A) or transfected RhoB (Fig. S4 A). Immunofluorescence 
analysis showed that RhoB colocalized with K63-polyubiquitin chains in endosomes in a 
CRL-dependent fashion (Fig. 5 B). These data suggest that RhoB might be K63 ubiquitinated 
followed by translocation to, and degradation in, lysosomes.
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Using an in vivo ubiquitination assay, we found that RhoB T19N is predominantly 
polyubiquitinated by K63-linked ubiquitin chains and that this was inhibited by MLN4924 
(Fig. 5 C). Based on published data, we hypothesized that the lysine acceptor site for RhoB 
ubiquitination is close to the C terminus [34, 35]. Therefore, we mutated lysines, the side 
chains of which are exposed on the surface of the RhoB structure (Fig. 5 D). Although 
mutation of lysine 135 did not interfere with K63 polyubiquitination of RhoB, mutation of 
either lysine 162 or 181 almost completely abolished K63 polyubiquitination of RhoB (Fig. 
5 E). In the next experiment, we transfected wild-type or the K162/181R double mutant 
of RhoB in ECs and analyzed the effects on cell size as a measure for contraction. Wild-
type RhoB decreased cell size by 50%, whereas the K161/181R double mutant of RhoB 
induced even stronger contraction and a 60% reduction in cell size (Fig. 5 F). Moreover, 
ECIS measurements showed that the K162/181R mutant of RhoB significantly decreased 
endothelial monolayer resistance (Fig. 5 G). Finally, we found that lysosomal inhibition 
increased wild-type, transfected RhoB by 40%, whereas expression of the K162/181R mutant 
was not increased (Fig. 5, H and I). Thus, we conclude that CRL-mediated polyubiquitination 
of RhoB is primarily K63 linked and occurs at two lysine residues (K162 and K181), which 
allows lysosomal degradation.
Cullin-3 is required for RhoB degradation in ECs
Knockdown of Cullin-3 in ECs induced robust expression of RhoB (Fig. 6, A and B). To test 
for a specific role of Cullin-3 in the degradation of RhoB, we knocked down Cullin-1, Cullin-2, 
and Cullin-3 in HUVECs and analyzed RhoB expression. As a positive control, we used Rbx1, 
a CRL adaptor protein, previously linked to degradation of RhoB in liver cancer cells [31]. We 
found that only knockdown of Rbx1 and of Cullin-3, but not Cullin-1 or Cullin-2, significantly 
increased RhoB expression (Fig. 6, A and B). Moreover, in Cullin-3 knockdown cells, RhoB 
is not in endosomes (Fig. 6 A) but rather at the plasma membrane, as in cells treated with 
MLN4924 (Fig. 4, A–C). In addition, Cullin-3 and Rbx1, but not Cullin-1 or Cullin-2, knockdown 
ECs displayed increased F-actin stress fiber formation and contractility (Fig. 6 A).
Subsequently, we found that only knockdown of Cullin-3, but not Cullin-1 or Cullin-2, impaired 
basal monolayer resistance (Fig. 6, C and D). Finally, in coimmunoprecipitation experiments, 
we detected Cullin-3 in complex with endogenous RhoB (Fig. 6 E). To confirm these results, 
we cotransfected HEK293T cells with mCherry-wtRhoB, dominant-negative mCherry-
T19NRhoB [36], and constitutively active mCherry-G14VRhoB [36], together with Cullin-3. 
We only found the dominant-negative T19N mutant of RhoB in complex with Cullin-3 (Fig. 6 




Figure 5 - RhoB is K63 polyubiquitinated by CRLs on lysines 162 and 181. (A) RhoB was immunopre-
cipitated (IP) from lysates of HUVECs treated with MLN4924, TNF-α, or PR619. Input is equal to 2.5% of the 
lysate used for immunoprecipitation. Ubiquitinated proteins were detected using ubiquitin (Ub; FK-2) anti-
body. Polyubiquitinated RhoB is indicated on the right. (B) Confocal immunofluorescence staining of RhoB 
in HUVECs treated overnight with 10 ng/ml TNF-α or 10 ng/ml TNF-α in combination with 300 nM MLN4924. 
Cells were stained for RhoB, polyubiquitin K63, and VE–cadherin. Zoomed areas (white boxes) are shown at 
the bottom. Bars, 10 µm. (C) Denaturing coimmunoprecipitation of ubiquitin and RhoB. HEK293T cells were 
cotransfected with HA-ubiquitin K48 only or HA-ubiquitin K63 only and mCherry-RhoB-T19N. Samples were 
analyzed by immunoblotting for presence of RhoB using RhoB antibody. Vinculin immunoblot was used as a 
control. (D) 3D structure of RhoB and indication of lysines 162 and 181. Ribbon structure of RhoB (aa 4–187) 
was obtained from the Protein Data Bank (2FV8). The figure was prepared using Pymol molecular visualization 
system (Schrödinger). Lysine residues 162 and 181 are shown in red. (E) Denaturing coimmunoprecipitation 
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of ubiquitinated T19N RhoB with introduced lysine mutations. The experiment was performed as in C with 
the indicated mutants of RhoB. Cells transfected with mCherry and HA-ubiquitin K63 only were used as neg-
ative control. (F) Quantification of the cell size of HUVECs microporated with mCherry, mCherry-wtRhoB, or 
mCherry-K162/181R RhoB. Transfected cells were imaged live with an Etaluma 720 lumascope microscope 
using a 10× dry objective, and cell size was measured cells using ImageJ software (n = 100). (G) HUVECs were 
microporated with the same constructs as in F. Quantification of endothelial resistance measured at 4,000 Hz 
and normalized to mCherry-transfected cells is shown. Values were obtained in two independent experiments 
(n = 5 per experiment). (H) Immunoblot analysis of the expression of microporated RhoB in HUVECs prepared 
as in F and treated with NH4Cl for 6 h. Vinculin was used as a loading control. (I) Densitometric analysis of 
RhoB immunoblots from H. Quantification was done using ImageJ software (n = 3). Error bars represent SD. 
n.s., P ≥ 0.05; ***, P = 0.001–0.0001; ****, P < 0.0001.
KCTD10 is the substrate receptor for RhoB degradation via Cullin-3 complex in ECs
The role of members of the Bacurd family of proteins KCTD13 and TNFAIP1 in the degradation 
of RhoA was noted previously [12]. Therefore, we tested whether knockdown of KCTD13, 
TNFAIP1, and KCTD10 would influence contractility and RhoB expression in ECs. Loss of 
KCTD10, but not KCTD13 of TNFAIP1, induced strong actin polymerization and contraction, 
similar to Cullin-3 knockdown (Fig. 7 A). Cullin-3 and KCTD10 depletion had only a mild effect 
on RhoA levels, but it induced a sixfold increase in expression of RhoB (Fig. 7, B and C). 
Knockdown of KCTD13 had no effect, and TNFAIP1 knockdown showed only a slight increase 
in RhoB expression level (Fig. 7, B and C). Although depletion of Cullin-3 or KCTD10 increased 
RhoA mRNA levels, it had the opposite effect on RhoB mRNA expression (Fig. S4 B).
Subsequent ECIS analysis showed that KCTD10-depleted ECs displayed a major loss of 
endothelial barrier function (Figs. 7 D and S4 C). This effect was transient and correlated 
with the expression levels of RhoB (Fig. 7, B and C). Quantification of endothelial barrier 
resistance at 72 h after transfection showed that knockdown of KCTD10 induced a 50% loss 
of resistance when compared with control or knockdown of other Bacurd family members 
(Figs. 7 E and S4 C). Under these conditions, TNF-α did not reduce barrier function any 
further (Fig. S5 A). More detailed analysis showed that cell–cell interaction in KCTD10-
depleted ECs was strongly decreased (Fig. 7 F). Furthermore, TNFAIP1 knockdown caused 
a small decrease in Rb parameter values in accordance with the slightly increased RhoB 




Figure 6 - Cullin-3 is required for degradation of RhoB in ECs. (A) HUVECs were transduced with control, 
Cullin-1, Cullin-2, Cullin-3, or RBX1 shRNA, and cells were fixed and stained at 72 h for RhoB (magenta) and 
F-actin (red). Bars, 15 µm. (B) Cells were treated as in A, and lysates were analyzed for RhoB, Cullin1, Cullin-2, 
Cullin-3, and Rac1. (C) HUVECs were treated as in A and seeded in ECIS eight-well arrays at 72 h after infection, 
and resistance was measured at 4,000 Hz. (n = 3). (D) Quantification of the measured resistance from C at 20 
h after seeding is shown. (E) RhoB was immunoprecipitated from lysates of HUVECs, and rabbit IgG antibody 
was used as a negative control. Input equals 2.5% of the lysate. Samples were analyzed for Cullin-3 and RhoB. 
(F) HEK293T cells were cotransfected with HA-tagged Cullin-3 and mCherry (control) or mCherry-wtRhoB, 
-T19N RhoB, or -G14V RhoB. 24 h after transfection, HA–Cullin-3 was immunoprecipitated using anti-HA aga-
rose. Input equals 5% of the lysate. Samples were analyzed for RhoB and HA and GAPDH was used as loading 
control. Error bars represent SD.
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Figure 7 - KCTD10 is a substrate receptor for RhoB in a Cullin-3 complex in ECs. (A) HUVECs transfected 
with CUL-3, KCTD13, TNFAIP1, and KCTD10 siRNA were stained for F-actin and nuclei and imaged at 24, 48, 
and 72 h after transfection. Bars, 20 µm. (B) HUVECs were transfected as in A. 15 µg protein was loaded and 
the membrane was probed for RhoA, RhoB, and GAPDH as loading control. (C) Quantification of the RhoA 
and RhoB immunoblots from B. n = 3. (D) ECIS measurement (4,000 Hz) of HUVECs transfected with siRNAs 
as in A. (E) Quantification of resistance at 72 h after transfection of HUVECs prepared as in A. (F) Analysis 
of the Rb parameter was performed as in F. Error bars represent SD. n.s., P ≥ 0.05; *, P = 0.01–0.05; ***, 
P = 0.001–0.0001; ****, P < 0.0001.
Furthermore, we tested whether ubiquitination of endogenous RhoB is affected by 
KCTD10 knockdown. Whereas loss of KCTD10 strongly induced expression of RhoB, its 
ubiquitination was reduced (Fig. 8 A). To analyze whether RhoB interacts with KCTD10, we 
transfected HEK293T cells with mCherry-tagged wild-type RhoB, RhoB T19N, or RhoB G14V 




all samples where RhoB was present (Fig. 8 B). This confirms that RhoB interacts with both 
Cullin-3 and KCTD10 in vivo. Subsequent rescue experiments showed that overexpression 
of a siRNA-resistant KCTD10 construct in KCTD10-depleted cells restored RhoB expression 
to basal levels (Fig. 8 C). In addition, cell contraction and F-actin accumulation induced by 
KCTD10 depletion were reverted by the siRNA-resistant KCTD10 construct (Fig. 8 D).
Figure 8 - Degradation of RhoB via Cullin-3–
KCTD10 complex is required for maintenance 
of endothelial barrier function. (A) Cells were 
transfected with KCTD13, TNFAIP1, KCTD10, or 
control siRNA. 72 h after transfection, cells were 
treated with 5 µM MG132 for 4 h, followed by 2.5 µM 
PR619 for 2 h. RhoB was immunoprecipitated, and samples were analyzed for ubiquitination with ubiquitin 
FK-2 antibody. (B) HEK293T cells were cotransfected with HA-tagged Cullin-3, KCTD10, and mCherry-wtRhoB, 
mCherry-RhoB-T19N, and mCherry-RhoB-G14V. 24 h after transfection, RhoB was immunoprecipitated using 
polyclonal RhoB antibody. Input equals 5% of the lysate used for immunoprecipitation. Samples were an-
alyzed using RhoB, Cullin-3, and KCTD10 antibodies. (C) Immunoblot (IB) analysis of the RhoB expression 
in the KCTD10-rescue experiment. KCTD10 constructs corresponding to LV-KCTD10 or empty vector were 
expressed in HUVECs using the Lentivirus gene expression system. Control siRNA or siRNA targeting the 3′ 
UTR of KCTD10 was transfected into the cells. GAPDH immunoblot is shown as loading control. (D) Cells were 
prepared as in C. After 72 h, cells were fixed and stained for F-actin (red) and nuclei (blue). Bars, 20 µm. (E) 
HUVECs were transfected with single siRNA or combinations of siRNAs as shown in the graph, and endothelial 
monolayer resistance was measured using ECIS at 72 h after transfection. Error bars represent SD. n.s., P ≥ 
0.05; ****, P < 0.0001.
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Moreover, we found that cotransfection of the RhoB targeting siRNA in combination with 
Cullin-3 or KCTD10 siRNA completely abolished the barrier disruptive effects induced by loss 
of Cullin-3 or KCTD10 (Fig. 8 E). Finally, we conclude that a Cullin-3–KCTD10 complex mediates 
degradation of RhoB and is required for the maintenance of endothelial barrier function.
DISCUSSION
Previously, the RhoGTPase RhoA was identified as a key negative regulator of endothelial 
barrier function via its stimulation of actomyosin contractility through ROCK1/2 activation 
and subsequent MLC phosphorylation [6, 37]. In contrast to RhoA, the function and 
regulation of RhoB in EC has not been studied extensively. Recently, it was shown that 
hypoxia induces RhoA and RhoB expression and activity in human microvascular lung ECs 
[38]. RhoB is a short-lived protein with a half-life of 1–2 h [34, 39], in marked contrast to 
the 24-h half-life of RhoA. Stability of RhoA in HeLa cells is regulated by CRL-mediated 
ubiquitination and proteasomal degradation of inactive RhoA [12]. In comparison, hypoxia, 
TNF-α, or TGF-β stimulation, application of genotoxic agents or inhibitors of isoprenylation 
all increase the expression of RhoB [32, 40, 41].
Based on these published data, we set out to identify the molecular components of the RhoB 
degradation machinery in ECs and to define their role in endothelial barrier maintenance 
(Fig. 9 [working model]). We found that depletion of Cullin-3 significantly reduced basal 
endothelial resistance and impaired both thrombin- and S1P signaling toward loss or gain, 
respectively, of endothelial integrity. Cells lacking Cullin-3 showed increased actin stress 
fiber formation accompanied by increased MLC phosphorylation. Phosphorylated MLC 
induces actomyosin contractility and formation of actin stress fibers that are structurally 
and functionally connected to FA complexes [28]. Our data suggest that Cullin-3 depletion 
enhances cell contractility and signaling pathways related to FA formation and turnover. 
In accordance with this, knockdown of Cullin-3 or inhibition of CRLs by MLN4924 induces 
actin stress fiber formation and increased FA numbers, most probably via increased FA 
assembly. Simultaneously, AJs are disrupted and endothelial integrity is gradually impaired. 
We recently found that long-term treatment of HUVECs with MLN4924 decreased protein 
expression of VE–cadherin, resulting in increased permeability [42]. In this study, we show 
that short term-treatment with the drug increased expression of RhoB, resulting in the 
same phenotype. Thus, the molecular basis underlying increased endothelial permeability 




Figure 9 - Model for CUL3/KCTD10-mediated ubiquitination of RhoB and its subsequent lysosomal 
degradation in maintenance of endothelial barrier function. RhoB is expressed at very low levels in 
quiescent endothelium (left side of the model) and is efficiently degraded via the proteasome and lysosomes 
because of CUL3/KCTD10-dependent K63 ubiquitination. As a result, the endothelial barrier remains intact. 
Inflammatory cytokines (e.g., TNF-α) enhance the expression of RhoB in ECs (right side of the model), and 
a fraction of RhoB escapes ubiquitination by CUL3/KCTD10 and subsequent lysosomal degradation. This 
remaining, active RhoB is associated with the plasma membrane and promotes formation of F-actin stress 
fibers, which results in disruption of endothelial barrier. Ribbon structure of RhoB (aa 4–187) was obtained 
from the Protein Data Bank (2FV8). GEF, guanine nucleotide exchange factor.
The effect of CRL inhibition on the endothelial barrier was dependent on Rho signaling via 
ROCK1/2. We show that RhoB plays a major role in this pathway, in conjunction with RhoA. 
Recently, Cullin-2 was identified as a key regulator of RhoB degradation [31]. In accordance 
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with this, we confirmed the role of another CRL component, Rbx1, but not of Cullin-2, in 
RhoB degradation in primary HUVECs. Cullin-3 appears the most important regulator 
of RhoB turnover and signaling output in ECs. These findings indicate that Cullins have 
specific functions, dependent on tissue-specific expression of Cullin isoforms and substrate 
receptors.
Cullin-3 interacted most efficiently with inactive RhoB, similar to what was previously 
described for RhoA [12]. CUL3-based ubiquitin E3 ligases ubiquitinate their substrates 
through the formation of a complex with BTB domain–containing proteins [43]. Chen et 
al. identified BACURD proteins (KCTD13 and TNFAIP1) as substrate receptors for RhoA 
degradation [12]. However, KCTD13 and TNFAIP1 did not mediate degradation of RhoB in 
ECs. We found KCTD10 to be most relevant as substrate receptor for the ubiquitination and 
degradation of RhoB. KCTD10 contains a BTB/POZ domain and regulates cardiovascular 
development in zebrafish and mouse [44-46]. Although different substrates were proposed 
to mediate the effects of loss of KCTD10 in these animal models, RhoGTPases were suggested 
as potential targets of KCTD10 in regulation of cardiovascular development. Our current 
findings corroborate this suggestion by underscoring the role of KCTD10 in regulating RhoB.
Deletion of RhoB in mice did not have detrimental effects on development and fertility, 
possibly because of a compensatory role of other RhoGTPase family members [47, 48]. 
However, these mice do display defects in vascular sprouting in the retina, impaired 
morphology of neurons, and thymus atrophy [49-51]. In contrast to these relatively mild 
effects, recent publications show that increased expression of RhoB correlates with human 
pathologies and can even cause fatal disease, such as capillary leak syndrome [41, 52-54].
RhoB expression is increased not only by CRL-mediated inhibition of RhoB degradation but 
also by TNF-α–induced transcription and translation (Fig. S5 B). The subcellular localization 
of RhoB under these conditions is different. Although in unstimulated cells, RhoB is in 
lysosomes, as it is in TNF-α–stimulated cells, inhibition of CRL-mediated RhoB degradation 
in resting cells induced its translocation to the cytoplasm and the plasma membrane. In 
our experiments, lysosomal localization of RhoB was almost completely abolished by the 
inhibition of CRLs, suggesting that the CRL-dependent ubiquitination of RhoB controls, in 
addition to proteasomal degradation, its lysosomal targeting and degradation. Furthermore, 
we could show that TNF-α induces colocalization of RhoB with K63-polyubiquitination–
positive endosomes, which was lost upon CRL inhibition. Importantly, TNF-α does not 
act by inhibiting CRL-mediated ubiquitination of RhoB. In contrast, TNF-α increases the 




is preferentially polyubiquitinated by K63-specific linkage, independent of TNF-α, which 
was largely inhibited by MLN4924. K63-linked polyubiquitination was described to target 
proteins toward the lysosomal degradation pathway via their interaction with the ESCRT 
machinery [55]. Although the CRLs are traditionally referred to as K48-linkage–specific E3 
ligases, different type of linkages mediated by this set of enzymes were described previously 
[56, 57]. To our knowledge, our study is the first one to describe CRL-dependent K63 
polyubiquitination of RhoGTPases in ECs.
Differential localization (endosomal vs. plasma membrane) of RhoB and differential 
functionality depending on its cellular locale was postulated previously[58-60]. We found 
that the increased expression and membrane association of RhoB caused by inhibition 
of CRLs indeed leads to a significant increase in its activity. These findings suggest that 
in resting ECs, RhoB is expressed at low levels and is localized, in nonubiquitinated form, 
outside of lysosomes, in part at the plasma membrane, where it exerts its activity (Fig. 9). 
Low levels of RhoB are maintained via constant CRL-dependent ubiquitination, subsequent 
targeting to lysosomes and degradation. This is supported by the increased formation of 
stress fibers upon CRL inhibition. CRL inhibition leads to RhoB up-regulation and activation, 
inducing contraction and impaired endothelial barrier stability. In contrast, TNF-α induces 
de novo synthesis of RhoB accompanied by limited RhoB activation (Figs. 9 and S5 B). In line 
with this, the negative effects of TNF-α on endothelial barrier function are also more limited 
than those induced by inhibition of CRL-mediated RhoB degradation.
The C terminus of RhoB encodes the signal that determines its localization and degradation 
[34, 35]. This fact and the apparent role of ubiquitination in the regulation of RhoB 
localization and degradation led us to hypothesize that the lysine acceptor site for RhoB 
ubiquitination is located at the C terminus. Furthermore, the increased turnover of RhoB 
could be caused by additional ubiquitin acceptor sites specific for RhoB. Because Lys181 
is only present in RhoB and not in RhoA or RhoC, we decided to mutate Lys181 and other 
lysines in the C-terminal half of RhoB, the side chains of which are exposed at the surface 
of the molecule (Lys135 and Lys162). We found that mutation of only Lys162 or Lys181 
significantly impairs the efficiency of RhoB K63-specific polyubiquitination, suggesting that 
the short half-life of RhoB protein is caused by efficient ubiquitination of RhoB at multiple 
lysine acceptor sites followed by lysosomal degradation.
Ubiquitination-dependent regulation of RhoGTPases was previously studied only in the 
context of proteasomal degradation [12, 18, 19]. We and others showed that ubiquitination 
might target Rac1 to an endosomal compartment[61, 62]. To our knowledge this study 
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is the first to report the K63-linkage–specific polyubiquitination and subsequent 
lysosomal degradation of a RhoGTPase. Novel, specific inhibitors targeting components 
of the ubiquitination machinery may provide new options for treatment of various human 
pathologies. A crucial goal in these efforts should be to identify determinants of specificity, 
especially in terms of substrate-binding receptors in ubiquitin ligase complexes such as 
CRLs. Here, we show that the specificity of the substrate recognition can be very strict, even 
among a highly conserved group of proteins such as the RhoA, RhoB, and RhoC GTPases.
MATERIALS AND METHODS
Cell culture
HUVECs were purchased from Lonza and cultured on fibronectin-coated dishes at 37°C 
in 5% CO2 atmosphere. EGM2 medium supplemented with SingleQuots (Lonza) was 
used for culturing HUVECs. Cells were used for experiments until passage 5. HEK293T 
cells were purchased from ATCC and cultured in Iscove’s modified Dulbecco’s medium 
(Lonza) supplemented with 10% FCS and l-glutamine. Cells were used until passage 35 for 
production of lentiviral particles, native coimmunoprecipitation and immunoprecipitation 
of ubiquitinated proteins under denaturing conditions.
Antibodies
The following primary antibodies were used in this study: mouse αVE–cadherin/CD144–Alexa 
Fluor 647 (BD), rabbit αErk1/2 (Santa Cruz), mouse αpErk1/2 (Santa Cruz), rabbit αpMyosin 
LC2 Thr18/Ser19 (Cell Signaling), rabbit αpPAK1/2/3 Ser141 (Invitrogen), rabbit αvinculin 
(Sigma), rabbit αGAPDH (Cell Signaling), mouse αHA (Sigma), rabbit αLAMP1 (Cell Signaling), 
rabbit αKCTD10 (Sigma), rabbit αPaxillin Tyr31 (Sigma), mouse αRac1 (BD), rabbit αRhoC (Cell 
Signaling), rabbit αRhoA (Cell Signaling), rabbit αRhoB (Santa Cruz), mouse αRhoB (Santa 
Cruz), mouse αUbiquitin (FK-2; Boston Biochem), rabbit αUbiquitin, Lys63-specific (Apu3; 
Millipore), rabbit αCullin-3 (Cell Signaling), mouse αCullin-2 (BD), mouse αCullin-1 (Santa Cruz), 
rabbit αKCTD10 (Sigma), rat αmouseCD29 (9eg7; BD), rabbit αIntegrin α-5 (Abcam), and rabbit 
p-NF-κB p65 (Ser536; Cell Signaling). Mouse anti–HA agarose was purchased from Sigma.
Lentiviral shRNA constructs
Lentiviral shRNA constructs were obtained from the TRC/Sigma Mission library (Sigma). 
All the constructs were cloned into pLKO.1 vector. The following clones were used in 
this study: BIRC2 TRCN00003780 and TRCN0000320867, XIAP TRCN00003785 and 
TRCN0000231578, FBXW7 TRCN0000355641, TRCN0000355643 and TRCN0000355644, 




TRCN0000307983, BTRC TRCN00006543 and TRCN00006545, USP8 TRCN0000284767 
and TRCN0000284769, CYLD TRCN0000230278, TRCN0000230279, TRCN0000230280 
and TRCN0000230281, TRIP12 TRCN0000273210 and TRCN0000273135, TNFAIP3 
TRCN000050961, OTULIN TRCN0000275410 and TRCN0000275411, FBXL19 TRCN000062336 
and TRCN0000359134, SMURF2 TRCN00003478 and TRCN0000272880, HACE1 
TRCN00003415, TRCN0000415313 and TRCN0000427070, RABGEF1 TRCN000047237, 
TRCN0000419718 and TRCN0000422664, SMURF1 TRCN00003471 and TRCN00003473, 
USP17L2 TRCN0000376547, CBL TRCN0000288695, KIA0317 TRCN0000280035, NEDD4L 
TRCN0000904, NEDD4 TRCN0000905 and TRCN00007550, and CAV1 TRCN00008002 and 
TRCN000011218. As a negative control, nontargeting shRNA TRCN0000SHC002 was used.
Lentivirus production
Lentiviral particles were produced by transfecting HEK293T cells with the third-generation 
HIV-1 packaging plasmids (Addgene) using Trans IT (Mirus). Cell culture medium containing 
virus particles was collected at 48 and 72 h after transfection, centrifuged, and filtered 
through 0.45-µm polyvinylidene fluoride filter (Millipore). Supernatant containing lentivirus 
was used to infect subconfluent HUVECs. Infected HUVECs were used for experiments at 72 
h after infection. All shRNA clones that were used in the study were verified by sequencing 
(45 clones targeting 22 proteins) and are shown in Fig. S1 B . The identity of 7 clones used 
in the screen could not be validated by sequencing and is therefore omitted from Fig. S1 B 
and the phenotype analysis. The efficiency of the knockdown in several cases was assessed 
by immunoblotting.
For KCTD10 lentiviral overexpression, KCTD10 cDNA was cloned into a CSII-CMV-MCS-
IRES2-Bsd vector and packed into lentivirus particles as described previously [63]. Lentiviral 
expression and packaging vectors were kindly provided by H. Miyoshi (RIKEN BioResource 
Center, Wako, Japan). Template cDNA (product ID FHC07641) was purchased from Kazusa 
DNA Research Institute.
Immunoblotting
Cell lysates for immunoblotting were collected by lysing cells in sample buffer (125 mM 
Tris, pH 6.8, 20% glycerol, 4% βmercapto-EtOH, and 0.001% bromophenol blue). Lysates 
were separated using SDS-PAGE on 7% or 12% polyacrylamide gels and transferred to 
the nitrocellulose membrane. Membranes were blocked in 5% BSA in TBST-T for 1 h and 
probed with primary antibodies diluted in the blocking buffer overnight at 4°C. Proteins 
were visualized using secondary anti–rabbit or anti–mouse antibodies coupled to the HRP 
and x-ray films. Densitometric analysis of the band intensities was performed using ImageJ.
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Endothelial barrier integrity measurement
Measurement of the integrity of endothelial barrier was performed using ECIS. For this 
assay, 100,000 HUVECs were seeded in fibronectin-coated eight-well ECIS slides (Applied 
Biophysics). Slides were mounted into the ECIS Zθ (theta) instrument, and the resistance of 
the electrodes was monitored at multiple frequencies at 37°C during next 48 h. At 16–18 
h, upon seeding, cells formed a stable monolayer, and resistance at 4,000 Hz was used to 
compare the barrier integrity among different samples. For thrombin stimulation, cells were 
treated with 1 U/ml thrombin (Sigma). S1P response was assessed by adding 500 nM S1P to 
the cells. As the last parameter, wounding recovery was measured. In this assay, the HUVEC 
monolayer was wounded electrically at 100,000 Hz and 6,500 µA for 2 min, and the recovery 
of the wounded area was monitored over the next 6 h. The Rb values were obtained by 
modeling from the multiple frequency scans using ECIS software from Applied Biophysics.
siRNA transfection and chemical inhibition of Rho signaling
For these experiments, HUVECs were freshly isolated from umbilical cords as previously described 
[64] and used for experiments at passage 2. siRNA SMART pools targeting RhoA (L-008555-
00-0005), RhoB (L-008395-00-0005), and RhoC (L-003860-00-0005) and ON-TARGETplus 
Non-targeting Pool control siRNA (D-001810-10-05) were purchased from Dharmacon. siRNAs 
targeting CUL3, KCTD13 (SASI_Hs01_00120957), TNFAIP1 (SASI_Hs01_00131786), KCTD10 
(custom-made, sense sequence: 5′-GUAACAACAAAUACUCAUATT-3′), siRNA sequence 
targeting the 3′ UTR of KCTD10 (sense sequence: 5′-GAAUGAGCGUCUAAAUCGUTT-3′), 
and control siRNA (SIC-001) were all purchased from Sigma. Additional siRNAs targeting 
KCTD10 (siRNA 1, HSS130450; siRNA 2, IHSS130452; and siRNA 3, HSS188856) and 
control siRNA L (12935-200) and siRNA M (12935-300) were all purchased from Invitrogen.
HUVECs were seeded on gelatin-coated eight-well ECIS slides (Applied Biophysics) at 60–70% 
confluency and transfected with final concentration of 25 nM siRNA using DharmaFECT 
(Dharmacon). ECIS measurement and MLN4924 treatment was performed 72 h after 
transfection. Because of the high concentration of serum (20%) in the medium, cells were 
starved in serum-free medium containing 1% human serum albumin for 24 h before the 
addition of 500 nM MLN4924.
For chemical inhibition of ROCK1/2 or RhoGTPases with 10 µM Y-27632 or 1 µg/ml C3-
transferase, respectively, HUVECs were seeded on gelatin-coated eight-well ECIS slides 
(Applied Biophysics) and grown to confluency. Before the addition of inhibitors, cells were 
starved for 1.5 h and then treated with Y-27632 or C3-transferase for 30 min, followed by 





For immunofluorescence analysis, HUVECs were seeded on fibronectin-coated 12-mm 
glass coverslips. Cells were treated with 300 nM MLN4924, 10 ng/ml TNF, or combination 
of both for 4 or 18 h For activated β1-integrin staining, cells were stimulated with 500 nM 
S1P for 15 min. Cells were briefly washed in PBS containing 1 mM CaCl2 and 0.5 mM MgCl2 
and fixed for 15 min with 4% PFA. Upon fixation, cells were permeabilized with 0.2% Triton 
X-100 in PBS for 3 min and unspecific staining was blocked by incubation with 1% BSA in 
PBS for 30 min. Primary antibody incubation was done in blocking buffer for 1 h, followed 
by extensive washing and incubation with secondary antibody for 30 min. Secondary 
antibodies used in this study were goat anti–mouse Alexa Fluor 488, goat anti–rabbit Alexa 
Fluor 568, and goat anti–rabbit Alexa Fluor 488 (all from Invitrogen). Hoechst was used to 
stain nuclei and phalloidin Alexa Fluor 415 (Promokine) or phalloidin Texas red (Invitrogen) 
to stain F-actin. Lysotracker Red DND-99 (Molecular Probes) was used to mark acidic/
late endosomes. After washing in 0.1% BSA in PBS, coverslips were mounted in MOWIOL 
supplemented with DABCO and analyzed by confocal microscope Leica SP8 using 63×/1.4 
or 100×/1.4 oil-immersion objective or Nikon A1R using 63 × 1.4 oil-immersion objective. 
Image analysis was done in ImageJ.
Live fluorescence microscopy of FA dynamics
HUVECs were infected with nontargeting control or CUL-3 shRNA. Cells were seeded on 
fibronectin coated eight-well Lab Tek chambers (Thermo Fisher Scientific) and at 72 h after 
infection transfected with pEGFP-C3 vinculin construct (E. Danen, University of Leiden, 
Leiden, Netherlands) using TransIT (Mirus). The next day, cells were imaged for 20 min at 
intervals of 20 s using an Observer Z1 microscope (Zeiss) equipped with 40× oil-immersion 
objective. Still images were uploaded on the FA analysis server (http://faas.bme.unc.edu/), 
and analysis of FA turnover was performed as previously described [65, 66]. In brief, FAs 
were identified based on EGFP-vinculin positivity within thresholded images of single 
cells. To distinguish single cells, masks were created from the overexposed signal of EGFP-
vinculin. Dynamic properties (assembly and disassembly rate) of FAs were obtained by 
the tracking of changes in intensity of the fluorescence from single adhesions through 
subsequent image frames. Four cells per condition were imaged and analyzed.
Microporation of ECs
Microporation of HUVECs was performed using Amaxa 4D nucleofector and P5 Primary-
Cell Nucleofector X-kit (Lonza). A 20-cm2 area of subconfluent HUVECs was trypsinized and 
microporated with 1.5 µg mCherry, mCherry-wtRhoB or mCherry-K162/181R RhoB. The 
cells were immediately seeded either on fibronectin-coated ECIS slides for measurement 
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of the barrier resistance or on 24-well plate containing fibronectin-coated glass slides for 
immunofluorescence imaging.
Real-time PCR analysis
HUVECs were treated with DMSO or MLN4924 (0.3 and 0.6 µM), control siRNA, CUL3 
siRNA, and KCTD10 siRNA for 72 h. Total RNAs were purified from the HUVECs using 
ISOGEN II (Nippon Gene) as described previously [63]. In brief, 1 µg RNA was used for 
first-strand cDNA synthesis using the High Capacity RNA-to-cDNA Master Mix (Applied 
Biosystems). Real-time quantitative PCR was performed (FastStart Universal SYBR Green 
Master ROX; Roche Diagnostics) with the ABI 7300/7500 system (Applied Biosystems). The 
following primers were used for amplification: 5′-GAGGTGGATGGAAAGCAGGTAGAGTTG-3′ 
(RhoA-F), 5′-TTTCACCGGCTCCTGCTTCATCTTGG-3′ for (RhoA-R) for RhoA and 
5′-AGACGTGCCTGCTGATCGTGTTCAG-3′ (RhoB-F) and 5′-CACATTGGGACAGAAGTGCTTCACC-3′ 
(RhoB-R) for RhoB, and 5′-TGCACCACCA ACTGCT TAGC-3′ (GAPDH-F ) and 
5′-GGCATGGACTGTGGTCATGAG-3′ (GAPDH-R) for GAPDH.
Immunoprecipitation
Immunoprecipitation of endogenous RhoB was performed with rabbit αRhoB antibody 
(Santa Cruz) from confluent 60-cm2 dishes. Before lysis, cells were stimulated with either 10 
ng/ml TNF-α (Peprotech) or 300 nm MLN4924 for 4 h or 2.5 µM PR619 for 2 h. Proteasomal 
degradation was inhibited by adding 5 µM MG132 at 2 h before lysis. Upon stimulation, 
cells were washed in PBS containing 1 mM CaCl2 and 0.5 mM MgCl2 and lysed in lysis 
buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, and 1% NP-40), cOmplete Protease 
Inhibitor Cocktail Tablets (Roche), and phosphatase inhibitors (1 mM Na3VO4 and 25 mM 
NaF). Lysates were cleared by centrifugation and incubated with 1 µg RhoB antibody for 2 h 
at 4°C. RhoB containing complexes were pulled out by incubation with Dynabeads protein 
G (Thermo Fisher Scientific) for 1 h at 4°C. Finally, beads were washed four times with lysis 
buffer, and immunoprecipitated proteins were eluted with sample buffer and analyzed with 
SDS-PAGE.
Mutagenesis
Single mutants of RhoB K135R, K162R, and K181R were generated using the site-directed 
mutagenesis. Mutations were introduced into the pmCherryC1-T19N RhoB vector in a PCR 
reaction using site-specific primers (Invitrogen) and high-fidelity Phusion DNA polymerase 
(NEB). Template DNA was digested by DpnI (NEB), and PCR product was transformed into 
competent DH5α Escherichia coli (NEB). Bacterial colonies were screened for presence of 





For HA-tag immunoprecipitation, pmCherryC1-RhoB, pmCherryC1-RhoB-T19N, or 
pmCherryC1-RhoB-G14V (gift of N. Reinhard, Swammerdam Institute for Life Sciences, 
Amsterdam, Netherlands) was cotransfected with NTAP-HA-CUL3 (gift of H. Genau, Goethe 
University Medical School, Frankfurt am Main, Germany). For native coimmunoprecipitation, 
transfected cells were lysed in lysis buffer (150 mM NaCl, 50 mM Tris, pH 7.4, 1 mM EDTA, 
5% glycerol, and 1% IGEPAL) supplemented with protease inhibitor complex (Roche). Lysates 
were cleared by centrifugation and incubated with mouse anti-HA agarose beads (Sigma) for 
3 h at 4°C. Upon incubation, beads were washed four times with the lysis buffer and boiled 
in 50 μl sample buffer, and samples were analyzed by immunoblotting.
In vivo ubiquitination assay
For this assay pcDNA3-HA-K48only-ubiquitin or pcDNA3-HA-K63only ubiquitin (gift 
of K. Husnjak, Goethe University Medical School, Frankfurt am Main, Germany) were 
cotransfected with pmCherryC-1, pmCherryC1-RhoB-T19N, pmCherryC1-RhoB-T19N;K135R, 
pmCherryC1-RhoB-T19N;K162R, or pmCherryC1-RhoB-T19N;K181R into HEK293T cells using 
TransIT (Mirus) according to the manufacturer’s protocol. Before lysis, cells were treated 
with 10 µM MG132 in combination with or without 500 nM MLN4924 for 6 h For analysis 
of ubiquitination of RhoB and mutants thereof, denaturing HA-immunoprecipitation was 
performed at 24 h after transfection as previously described [67].
RhoGTPase and Rac activation assays
For the RhoGTPase activation assay, cells were stimulated with 10 ng/ml TNF-α (Peprotech) 
or 300 nm MLN4924 for 4 h or 2.5 µM PR619 for 2 h and lysed in cold lysis buffer (25 mM 
Tris-HCl, pH 7.2, 150 mM NaCl, 10 mM MgCl2, 1% NP-40, and 5% glycerol) supplemented 
with cOmplete Protease Inhibitor Cocktail Tablets (Roche).
To analyze Rac activity, HUVECs were treated the same as for the RhoGTPase activation 
assay and levels of Rac1-GTP were measured by PAK1-CRIB pull-down assay as previously 
described[68].
Statistical analysis
All graphs in the figures represent means ± SD. Statistical analysis was performed using 
GraphPad Prism software. For comparison of only two groups of samples, the two-tailed 
Student’s t test was applied. One-way ANOVA with Tukey’s post-tests was applied when 
more than two groups were compared (n.s., P ≥ 0.05; *, P = 0.01–0.05; **, P = 0.01–0.001; 
***, P = 0.001–0.0001; ****, P < 0.0001).
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Online supplemental material
Fig. S1 shows the workflow of targeted shRNA screen for EC morphology regulators, the 
table with used constructs, an example of positive hit and additional shRNA clone targeting 
CUL3. Fig. S2 shows FA staining in CUL3 KD cells, VE–cadherin staining, and RhoA protein 
stability analysis upon MLN4924 treatment and RhoB immunoblot upon cycloheximide 
and TNF-α treatment. Fig. S3 shows knockdowns of RhoA, RhoB, and RhoC using siRNA, the 
effect of combined double (RhoA/B, RhoA/C, and RhoB/C) and triple (RhoA/B/C) knockdowns 
on MLN4924-induced endothelial barrier loss, the effect of Y27 and C3 on MLN4924-
induced loss of endothelial barrier, analysis of Rac1 activity upon MLN4924 treatment, and 
quantification of immunoblots from Fig. 4 E. Fig. S4 shows RhoB ubiquitination assay with 
TNF-α stimulation and effects of additional KCTD10 siRNAs on the endothelial barrier. Fig. 
S5 shows ECIS measurement on KCTD10 knockdown cells treated with TNF-α and a model 
for TNF-α’s role in the regulation of RhoB expression. Videos 1 and 2 show FA dynamics in 
control and CUL3 knockdown cells, respectively.
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Figure S1. (A) Workflow of the lentiviral shRNA screen 
for identification of ubiquitin ligases and associated 
proteins involved in regulation of the endothelial actin 
cytoskeleton. (B) Summary table of the shRNA clones 
tested in the screen and phenotype analysis. shRNA 
targeted proteins were grouped into E3 ligases (black), 
substrate recognition receptors (red), ubiquitin prote-
ases (blue), and adaptor proteins directly (green) or 
indirectly (orange) involved in ubiquitination. Based on 
changes in F-actin organization, the different pheno-
types were grouped into (1) pronounced actin stress 
fiber formation, (2) induction of cortical actin bundles, 
(3) a mixed group in which both changes could be observed, and (4) other phenotypes, which include changes in 
actin morphology, that do not fit into the previous phenotype groups. (C) Confocal immunofluorescence images 
of HUVECs infected with lentiviruses carrying nontargeting control shRNA, Smurf1-targeting shRNA, or CYLD-tar-
geting shRNA. Cells were fixed 72 h after infection and stained with VE–cadherin antibody (green) and phalloidin 
(red). Bars, 15 µm. Control panels are identical to control in Fig. 1 A. (D) HUVECs were infected with lentiviruses 
carrying control shRNA or Cullin-3 targeting shRNA (clone 288625). At 72 h after infection, cells were fixed and 
stained with VE–cadherin antibody and phalloidin. Control panels are identical to control in C. Bars, 15 µm.
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Figure S2. (A) Confocal immunofluorescence staining of HUVECs transduced with control or CUL3 shRNA and 
fixed at 72 h after infection. Cells were stained for pPaxillin and vinculin, F-actin, and nuclei. Bars, 10 µm. (B) 
HUVECs were treated with 500 nM MLN4924 for 20 h. Cells were fixed and stained with VE–cadherin antibody 
and DAPI. Bars, 20 µm. (C) HUVECs were pretreated with 500 nM MLN4924 or DMSO control for 48 h followed 
by addition of 25 µg/ml cycloheximide for the indicated time points. Cells were lysed, and 20 µg of total proteins 
was analyzed by immunoblot (IB) with RhoA antibody. Densitometric analysis was performed using ImageJ 
software (n = 3). (D) Immunoblot analysis of RhoB expression in HUVECs treated with 10 ng/ml TNF-α for 4 h 
in combination with increasing concentrations of cycloheximide. Error bars represent SD. *, P = 0.01–0.05; **, 




Figure S3. (A) Immunoblot analysis of 
RhoA, RhoB, and RhoC expression in 
HUVECs transfected with siRNAs. Cells 
were lysed at 72 h after transfection, 
and lysates were analyzed by immu-
noblotting using RhoA, RhoB, or RhoC 
antibody. Erk1/2 immunoblot was 
used as loading control. (B) HUVECs 
were transfected with combinations 
of siRNA targeting RhoA/RhoB, RhoA/
RhoC, RhoB/RhoC, RhoA/RhoB/RhoC, 
or nontargeting control siRNA. 72 h 
after transfection, cells were starved 
for 24 h, followed by the addition of 500 
nM MLN4924, after which resistance of 
endothelial monolayers was measured 
at 4,000 Hz. Resistance was normalized to values measured before the addition of MLN4924. (C) Quantifica-
tion of normalized resistance measured in B at time point 5 h after addition of MLN4924. One-way ANOVA 
statistical analysis with Tukey’s post-tests was performed using GraphPad Prism (n = 7). (D) MLN4924 effect 
on the barrier function of HUVECs pretreated with Y-27632 or C3-transferase. Cells were starved for 1.5 h 
and treated with 10 µM Y-27632 or 1 µg/ml C3-transferase for 30 min, followed by the addition of 500 nM 
MLN4924 and measurement of electrical resistance at 4,000 Hz using ECIS (n = 3–8). (E) CRIB pull-down was 
performed using lysates of HUVECs treated or not with 500 nM MLN4924 or 10 ng/ml human TNF-α for 4 h 
or with 2.5 µM PR619 for 2 h. Input is equal to 2.5% of the lysate used for the pull-down. Vinculin was used 
as loading control (n = 7). Densitometric analysis of the CRIB pull-down immunoblots is shown on the right. 
(F) Densitometric analysis of RhoB and RhoA blots from Fig. 4 E (n = 3). Statistical comparison was calculated 
using an unpaired Student’s t test. Error bars represent SD. n.s., P ≥ 0.05; *, P = 0.01–0.05; **, P = 0.01–0.001.
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Figure S4. (A) HEK293T cells were cotransfected with HA-ubiquitin and mCherry-RhoB or HA-ubiquitin-K63only 
and mCherry-RhoB-T19N. Cells were treated with 10 ng/ml TNF-α for 6 h and 5 μΜ MG132 for last 4 h of treat-
ment. Samples were analyzed by immunoblotting (IB) for RhoB. Vinculin was used as a control. Phospho-p65 
immunoblot shows activation of the NF-κB pathway. (B) RT-PCR analysis of RhoA and RhoB mRNA expression 
in CUL-3 and KCTD10 knockdown HUVECs. mRNA was isolated 72 h after siRNA transfection and analyzed for 
RhoA and RhoB transcripts using RT-PCR (n = 3). (C) HUVECs were transfected with 25 nM control L or control M 
siRNA or three different siRNA all targeting KCTD10. Graph represents quantification of endothelial resistance 
72 h after transfection measured at 4,000 Hz. Measurement was performed in triplicate. Error bars represent 




Figure S5. (A) ECIS measurement (4,000 Hz) of HUVECs transfected with control or KCTD10 siRNA and treated 
with 10 ng/ml TNF-α at 72 h after transfection. Error bars represent SD. (B) Model of the regulation of RhoB ex-
pression in ECs. In unstimulated conditions, Cullin-3–Rbx1–KCTD10 ubiquitinates RhoB, which is subsequently 
degraded in lysosomes and via the proteasomal pathway. TNF-α induces activation of the proinflammatory 
NF-κB pathway and increases transcription of RhoB mRNA followed by protein synthesis. A prerequisite for 
NF-κB activation is degradation of IκBα, which is ubiquitinated by the Cullin-1–β-TRCP complex (Suzuki et al., 
1999), which is blocked by MLN4924.
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Video 1. Focal adhesion dynamics in control shRNA-expressing ECs. Control shRNA-expressing HUVECs 
were transfected with pEGFP-C3 vinculin and imaged every 20 s for 20 min. Frame rate is five frames per 
second. Bar, 10 µm.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839774/bin/JCB_201606055_V1.mp4
Video 2. Focal adhesion dynamics in Cullin-3 knockdown ECs. Cullin-3 shRNA-expressing HUVECs were 
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RhoGTPases regulate cytoskeletal dynamics, migration and cell-cell adhesion in endothelial 
cells. Besides regulation at the level of guanine nucleotide binding, they also undergo post-
translational modifications, for example ubiquitination. RhoGTPases are ubiquitinated by 
Cullin RING ligases which are in turn regulated by neddylation. Previously we showed that 
inhibition of Cullin RING ligase activity by the neddylation inhibitor MLN4924 is detrimental 
for endothelial barrier function, due to accumulation of RhoB and the consequent induction 
of contractility. Here we analyzed the effect of pharmacological activation of Cullin RING 
ligases on endothelial barrier integrity in vitro and in vivo. CSN5i-3 induced endothelial 
barrier disruption and increased macromolecule leakage in vitro and in vivo. Mechanistically, 
CSN5i-3 strongly induced the expression and activation of RhoB and to lesser extent of RhoA 
in endothelial cells, which enhanced cell contraction. Elevated expression of RhoGTPases 
was a consequence of activation of the NF-κB pathway. In line with this notion, CSN5i-3 
treatment decreased IκBα expression and increased NF-κB-mediated ICAM-1 expression 
and consequent adhesion of neutrophils to endothelial cells. This study shows that sustained 
neddylation of Cullin RING-ligases leads to activation the NF-κB pathway in endothelial cells, 
elevated expression of RhoGTPases, Rho/ROCK-dependent activation of MLC and disruption 
of the endothelial barrier.
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INTRODUCTION
Endothelial barrier function controls vascular integrity and is essential for normal physiology. 
Both under resting conditions, and following agonist-mediated stimulation, endothelial 
integrity is regulated at the level of both the actin cytoskeleton and cell-cell contacts [1, 2]. 
Actin dynamics are regulated by members of the family of RhoGTPases. Rac1 and Cdc42 drive 
actin polymerization and formation of membrane protrusions which enhance endothelial 
barrier function, while RhoA induces formation of actin stress fibers and cell contraction 
which disrupts endothelial barrier function [3-5]. Besides being regulated at the level of 
guanine nucleotide binding [6], RhoGTPases undergo post-translational modifications such 
as ubiquitination, which control their activity, localization and expression [7-9].
Protein ubiquitination refers to the covalent attachment of the 76 amino acid ubiquitin 
protein to lysine residues in substrates, and is classically known as part of the degradation 
pathway called the ubiquitin proteasome system (UPS). Besides protein degradation, 
ubiquitination drives internalization and trafficking of proteins, regulating, a.o., inflammatory 
signaling, autophagy and DNA repair [10]. In the first step of ubiquitination, ubiquitin is 
activated by binding to a ubiquitin-activating enzyme (E1). Activated ubiquitin is subsequently 
attached to a ubiquitin-conjugating enzyme (E2) and covalently linked to a lysine residue of 
the substrate protein by a ubiquitin protein ligase (E3) [11]. E3 ligases are divided into two 
classes based on the presence of the Homologous to the E6-AP Carboxyl Terminus (HECT) 
domain or a Really Interesting New Gene (RING) domain [12]. Members of the large group 
of RING-E3 ligases serve as scaffolds that bring substrates and the E2 conjugating enzyme 
together for ubiquitin conjugation. Cullins are RING-ligases that undergo a conformational 
change upon neddylation, the covalent attachment of the ubiquitin-like protein Nedd8. 
This neddylation-induced conformational change of Cullin promotes polyubiquitination 
of the substrate and prevents the binding of the inhibitor CAND1 [13, 14]. This process 
is reversed by de-neddylation, in which Nedd8 is removed by isopeptidase activity of the 
COP9 Signalosome (CSN) [15].
The effect of the COP9 signalosome, and more specifically of CSN5, on the activity of Cullin 
E3 ligases has been investigated both in vivo [16, 17] and in vitro [18, 19]. In addition to 
increased substrate ubiquitination, neddylation of Cullins has been shown to induce auto-
ubiquitination and degradation of the CRL complex. Besides exhibiting deneddylation 
activity, the CSN is associated with the deubiqutinase Ubp12/USP15, hereby increasing 
the stability of Cullins and their associated adaptor proteins [19]. Several years ago, the 




enzyme (NAE) which is currently tested in clinical trials for cancer treatment [20-22]. 
MLN4924 also protects against pulmonary fibrosis by inhibition of inflammation in animals 
and in human cell-lines [23]. Aiming to further explore the therapeutic window of modulators 
of the UPS, a COP9 signalosome inhibitor was developed by Schlierf et al. [24].
This compound, named CSN5i-3, inhibits the activity of CSN5, which forms the catalytic 
core of the COP9 signalosome. As a result, deneddylation of Cullins is inhibited. Whereas 
MLN4924 treatment results in accumulation of the deneddylated, inactive isoform of Cullins, 
CSN5i-3 stabilizes Cullin neddylation and –activity. In functional assays, CSN5i-3 inhibits 
differentiation of cancer cells in vitro and inhibits tumor growth in vivo [24].
Recently, we showed that inhibition of the Cullin-RING E3 ubiquitin ligases in endothelial cells, 
either by MLN4924 or shRNA-mediated knockdown of Cullin-3, increased the expression of 
the RhoGTPase RhoB. This was accompanied by the RhoB-dependent formation of F-actin 
stress fibers, contraction and a loss of endothelial barrier function [9]. Since we found that 
the general inhibition of Cullin neddylation was detrimental for endothelial barrier function 
we set out to investigate the physiological relevance of improved Cullin neddylation on 
endothelial barrier function and in particular on the activity and expression of RhoGTPases. 
Therefore, we investigated the effect of CSN5i-3 on cultured primary Human Umbilical Vein 
Endothelial Cells (HUVECs) in vitro and in zebrafish embryos in vivo.
In HUVECs we observed decreased endothelial barrier function and increased 
macromolecular passage upon application of CSN5i-3. In line with these findings, treatment 
of zebrafish embryos with this compound increased vascular permeability. In subsequent 
analysis, we observed that CSN5i-3 activated the Rho/Rho Kinase (ROCK) signaling pathway 
and induced consequent cell contraction. This was mainly due to increased de novo Rho 
protein synthesis which in turn was caused by the activation of the NFkB pathway in CSN5i-
3 treated endothelial cells. Thus, pharmacological activation of Cullin Ring Ligases induces 
an NFkB-mediated inflammatory response in endothelial cells accompanied by a marked 
loss of junctional integrity.
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RESULTS
Inhibition of the COP9 signalosome disrupts endothelial barrier integrity
CSN5i-3 was designed as an inhibitor of the COP9 signalosome which mediates removal of 
Nedd8 from the Cullin subunit of Cullin-RING ubiquitin ligases, thus inactivating the complex 
[24]. To test the effect of CSN5i-3 on endothelial barrier function, we added the compound 
in different concentrations to confluent primary HUVECs. Electrical cell-substrate impedance 
sensing (ECIS) was used to quantify changes in endothelial barrier function in real time. 
Within 1 hour after addition of CSN5i-3 we observed a small increase in barrier function, after 
which the integrity of the endothelial barrier decreased. This reduction in endothelial barrier 
was dose-dependent (Fig. 1A). 1 μM CSN5i-3 or higher induced a significant attenuation 
of endothelial barrier function at 5 hours after addition (Fig. 1B). In addition to reduced 
resistance of the endothelial barrier, we observed significant barrier disruption by CSN5i-3 
in HRP-leakage experiments after prolonged stimulation (>5 hours) (Fig. 1C). Cytotoxicity of 
CSN5i-3 was reported in cancer cell lines by Schlierf et al. after 72 hours of treatment [24]. 
To investigate if loss of endothelial barrier integrity was caused by increased apoptosis, we 
analyzed caspase-3/7 activity in cells treated with CSN5i-3 for 5 and 24 hours (Supplemental 
Fig. 1). After 5 hours of CSN5i-3 treatment (1 and 4 uM), caspase-3/7 activity was not induced, 
suggesting that initial disruption of endothelial integrity is not caused by apoptosis. However, 
we observed increased caspase-3/7 activity after 24 hours of treatment with CSN5i-3 which 
implicates contribution of apoptosis to the increase of HRP leakage at later timepoints. In 
subsequent experiments we examined the effect of CSN5i-3 on Cullin-1, Cullin-2 and Cullin-3 
neddylation in endothelial cells using immunoblotting (Fig. 1D). We observed a significant 
mobility shift marking the neddylated isoforms for Cullin-1 and Cullin-3, while this shift 
was less pronounced for Cullin-2 (Fig. 1D,E). Moreover, CSN5i-3 induced a decrease in total 
Cullin-2 and Cullin-3 expression, while the levels of Cullin-1 remained unaltered (Fig. 1F). 
From these data we conclude that CSN5i-3 stabilizes Cullin 1–3 neddylation and differentially 
affects their expression. Together, this results in a dose-dependent, significant disruption 
of the endothelial barrier.
CSN5i-3 induces expression and activity of RhoGTPases
Previously, we showed that inhibition of Cullin-3 activity resulted in increased expression 
of RhoB due to a reduction of RhoB-ubiquitination with only a modest effect on RhoA 
[9]. Therefore, we tested the effect of CSN5i-3-mediated Cullin activation on the protein 
expression of RhoA, RhoB and RhoC. Five hours after addition of 1 and 4 μM CSN5i-3, RhoA 
and RhoC protein levels were slightly increased (Fig. 2A,C) with RhoB expression levels 2- and 




Figure 1 - CSN5i-3 disrupts endothelial barrier integrity and differentially affects Cullin-1, -2 and 
-3. (A) Time course of normalized endothelial resistance of HUVEC monolayers during CSN5i-3 treatment in 
different concentrations. (B) Normalized endothelial resistance at timepoint 5 hours after CSN5i-3 treatment 
in different concentrations. *p < 0.05, ***p < 0.001, ****p < 0.0001 compared to control in Dunnet’s post-
hoc test of one-way ANOVA (n = 4). (C) Macromolecule passage (Horseradish peroxidase, HRP) across HUVEC 
monolayers during CSN5i-3 treatment **p < 0.01, ****p < 0.0001 compared to control in Tukey’s post-hoc test 
of two-way repeated measures ANOVA (n = 3 independent experiments). (D) Western blot analysis of Cullin-1, 
Cullin-2 and Cullin-3 after 5 hours of CSN5i-3 treatment (1 μM or 4 μM). ERK1/2 was used as loading control. 
Blot images were cropped for clarity of presentation (full blots are in Supplemental Fig. 3). (E) Quantification of 
neddylated versus unneddylated Cullin-1, Cullin-2 and Cullin-3 after CSN5i-3 treatment. *p < 0.05, ***p < 0.001 
compared to control in Dunnett’s post-hoc test of one-way ANOVA (n = 3 independent experiments). (F) Quan-
tification of total Cullin-1, Cullin-2 and Cullin-3 levels after CSN5i-3 treatment. *p < 0.05, **p < 0.01, ***p < 0.001 
compared to control in Dunnett’s post-hoc test of one-way ANOVA (n = 3).
Previously, we showed that RhoB ubiquitination controls its subcellular localization in 
endothelial cells [9] and we therefore analyzed RhoB localization by immunofluorescent 
staining. Treatment with 1 μM CSN5i-3 induced the upregulated RhoB to localize both to 
intracellular vesicles and the cytoplasm. This was accompanied by stress fiber formation 
and a more discontinuous staining for Vascular Endothelial (VE)-cadherin (Fig. 2D). Higher 
concentration of CSN5i-3 (4 μM) induced similar, but more pronounced effects on RhoB 
expression and endothelial cell morphology (Fig. 2D). To test if the induction of RhoGTPase 
expression and change in cell morphology, induced by CSN5i-3, was accompanied by 
increased activity of RhoGTPases, we performed Rhotekin pulldowns. We found that 
CSN5i-3 strongly increased the activity of RhoB, with limited effects on RhoA and RhoC, 
directly correlating with the differential effects on their expression (Fig. 2E). Together, these 
data indicate that treatment of endothelial cells with CSN5i-3 induces the expression of 
RhoGTPases, primarily RhoB, and the formation of actin stress fibers.
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Figure 2 - CSN5i-3 treatment induces expres-
sion of RhoB in endothelial cells. (A–C) West-
ern blot analysis of RhoA (A), RhoB (B), RhoC (C) 
expression after 5 hours of CSN5i-3 (1 μM or 4 μM) 
treatment. GAPDH was used as loading control. 
Blot images were cropped for clarity of presenta-
tion (full blots are in Supplemental Fig. 4). *p < 0.05, 
**p < 0.01 compared to control in Dunnett’s post-
hoc test of one-way ANOVA (n = 4). (D) Evaluation of 
RhoB (white), F-actin (red) and VE-cadherin (green) 
in control versus CSN5i-3 treated cells counterstained with DAPI (blue). Representative images of n = 3 exper-
iments. Scale bar represents 50 μm in overview images and 20 μm in zoomed images. (E) Rhotekin pulldown 
using lysates of HUVECs treated with CSN5i-3 (1 or 4 μM) for 5 hours followed by Western blot analysis for RhoA, 
RhoB and RhoC. GAPDH was used as loading control. Blot images were cropped for clarity of presentation 




Endothelial barrier disruption by CSN5i-3 is ROCK-mediated
Cell contraction underlies endothelial barrier disruption and is initiated by the activation of 
RhoGTPases and their downstream effector Rho-kinase (ROCK) [25]. We previously showed 
that RhoB is important for endothelial cell contraction [4]. Immunofluorescent staining 
of HUVECs treated with CSN5i-3 showed increased actin stress fiber formation, which is 
likely mediated by Rho/ROCK activation and Myosin Light Chain (MLC) phosphorylation 
[26]. Treatment with the ROCK inhibitor Y27632 of otherwise unstimulated cells, reduced 
stress fiber formation while VE-cadherin staining showed stable, honeycomb-like cell-cell 
contacts (Fig. 3A). Addition of CSN5i-3 promoted stress fiber formation while the VE-cadherin 
showed a more jagged distribution, characteristic for remodeling adherens junctions 
[27]. Pre-treatment of cells with Y27632 clearly abrogated CNS5i-3 –induced stress fiber 
formation and stabilized VE-cadherin-positive junctions (Fig. 3A). In accordance with this 
finding, pre-treatment of HUVECs with Y27632 prevented the barrier disruptive effect of 
CSN5i-3 as shown in ECIS experiments (Fig. 3B,C). Furthermore, CSN5i-3 increased MLC 
phosphorylation as shown by immunoblot analysis, and this was completely abolished by 
pre-treating the cells with Y27632 (Fig. 3D,E). Importantly, pre-treatment with Y27632 did 
not impair CSN5i-3-induced expression of RhoB protein (Fig. 3A,D,F).
In addition to pharmacological inhibition of the Rho/ROCK signaling pathway, we performed 
a siRNA-mediated knockdown of RhoA, RhoB and RhoC to establish the contribution of 
these RhoGTPases to the morphological changes caused by CSN5i-3. Individual depletion 
of RhoA, RhoB or RhoC did not effectively prevent phosphorylation of MLC by CSN5i-3 
(Supplemental Fig. 2). This is likely because these GTPases regulate each other’s expression 
such that loss of one drives increased expression of the other [4], which in turn leads 
to functional compensation [4]. Therefore, we performed a triple knockdown of all three 
GTPases simultaneously and analyzed CSN5i-3-induced MLC phosphorylation. We found 
that only the combined depletion of RhoA, -B and -C effectively abrogated CSN5i-3-induced 
MLC phosphorylation. In conclusion, our data indicate that the barrier disruption caused by 
CSN5i-3 is mediated by activation of RhoGTPase/ROCK signaling leading to increased MLC 
phosphorylation and subsequent cell contraction.
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Figure 3 - CSN5i-3 effect on endothelial barrier can be counteracted by 
inhibition of Rho/ROCK pathway. (A) Evaluation of effect on F-actin (red), 
VE-cadherin (green) and RhoB (white) in control versus CSN5i-3- (1 and 4 μM) 
and Y27632-treated cells counterstained with DAPI (blue). Representative 
images of n = 3 experiments. Scale bar represents 30 μm. (B) Time course 
of normalized endothelial resistance of HUVEC monolayers during CSN5i-3 treatment following pre-incuba-
tion with Y27632. (C) Normalized endothelial resistance after 5 hours of CSN5i-3 treatment with or without 
pre-treatment of Y27632. ***p < 0.001, ****p < 0.0001 in Dunnet’s post-hoc test of two-way ANOVA (n = 3). 
(D–F) Western blot analysis and quantification of pMLC (D,E) and RhoB (D,F) after 5 hours of CSN5i-3 treatment 
(1 μM or 4 μM) with or without pre-treatment with Y27632. GAPDH was used as loading control. Blot images 
were cropped for clarity of presentation (full blots are in Supplemental Fig. 6). **p < 0.01 in Dunnet’s post-hoc 
test of two-way ANOVA (n = 3). (G,H) Western blot analysis and quantification of pMLC after 5 hours of CSN5i-3 
treatment (1 μM and 4 μM) of combined RhoA, RhoB and RhoC knockdown cells. GAPDH was used as loading 
control. Blot images were cropped for clarity of presentation (full blots are in Supplemental Fig. 7). **p < 0.01 




Inhibition of the COP9 signalosome activates NF-κB and enhances ICAM 
expression and leukocyte adhesion
Induction of RhoB mRNA by TNF-α was previously described [9, 28, 29]. Since we found 
that CSN5i-3 induced RhoB mRNA synthesis similar to TNF-α, and because Cullin-RING 
ligases have been implicated in TNF-α mediated NF-κB activation [30], we hypothesized 
that CSN5i-3 increases RhoB mRNA expression via NF-κB. In resting cells, the cytosolic NFκB 
p65 subunit is bound to members of the family of inhibitory IκB proteins. Degradation of 
IκB occurs upon their phosphorylation and subsequent ubiquitination by βTRCp-Cullin-1, 
followed by proteasomal degradation [30]. Degradation of IκB allows the p65-NFκB complex 
to translocate to the nucleus and activate transcription of its target genes, including the 
leukocyte adhesion molecule ICAM-1. Treatment of HUVECs with CSN5i-3 resulted in 
significantly reduced IκBα expression (Fig. 5A,C). Conversely, phosphorylation of the p65 
subunit of NFκB was significantly increased only after prolonged CSN5i-3 (4 μM) treatment 
(Fig. 5A,D). In addition, the expression of ICAM-1 was significantly increased (Fig. 5A,B). To 
confirm the role of the NF-κB pathway in the CSN5i-3-induced upregulation of RhoB, we 
applied the specific IκB phosphorylation inhibitor BAY11-7085 in combination with CSN5i-
3 [31]. Treatment of HUVECs with BAY11-7085 significantly reduced both the TNF-α and 
CSN5i-3-induced increase in RhoB levels (Fig. 5E,G). Also, TNF-α and CSN5i-3-induced ICAM-1 
expression was completely blocked by BAY11-7085 (Fig. 5E,F).
Since CSN5i-3 increased ICAM-1 expression, we tested if this increase is physiologically 
relevant in a leukocyte adhesion assay. We treated HUVEC monolayers with CSN5i-3 or TNF-α 
and analyzed the adhesion of polymorphonuclear neutrophils (PMN) which depend on 
ICAM-1 for strong adhesion. PMN adhesion was dose dependently increased in endothelial 
cells treated with CSN5i-3 as compared to control cells (Fig. 5H,I). TNF treatment increased 
PMN adhesion further, in good agreement with its stronger effect on ICAM-1 upregulation 
(Fig. 5E,F,H). In conclusion, our data indicate that CSN5i-3 induces degradation of IκBα, 
most probably via activation of Cullin-1 RING ligase [30], resulting in induction of the pro-
inflammatory NF-κB pathway. This drives the increased expression of RhoB and ICAM-
1, resulting in a loss of endothelial barrier function and increased leukocyte adhesion, 
respectively.
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Figure 4 - CSN5i-3- induces transcription of RhoB mRNA. (A) HEK293T cells were cotransfected with 
mCherry-RhoB and HA-ubiquitin and treated with CSN5i-3 (1 and 4 μM) or MLN4924 for five hours, with addi-
tion of MG132 for the last four hours. Next, HA-ubiquitin was immunoprecipitated under denaturing conditions. 
Samples were analyzed by western blot for presence of RhoB and ubiquitin using RhoB and HA antibodies, 
respectively. GAPDH was used as loading control. Blot images were cropped for clarity of presentation (full 
blots are in Supplemental Fig. 8). (B,C) RNA expression, determined by qPCR, of RhoA (B) and RhoB (C) from 
HUVECs lysates after 5 hours of treatment with CSN5i-3 (1 and 4 μM) or 10 ng/ml TNF-α *p < 0.05, ***p < 0.001, 
****p < 0.0001 after Dunnet’s post hoc analysis of one-way ANOVA (n = 3). (D–E) Western blot analysis and 
quantification of RhoB expression after CSN5i-3 treatment (1 and 4 μM) for 0, 1, 5, 8 and 16 hours, with or 
without pre-treatment of 0.5 μg/ml cycloheximide. Blot images were cropped for clarity of presentation (full 
blots are in Supplemental Fig. 9). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 after Dunnet’s post hoc 




Figure 5 - CSN5i-3 increases RhoB levels by activation of the NF-κB pathway. (A–D) Western blot analysis 
and quantification of ICAM-1 (B), IκBα (C) and pp65 (D) expression after CSN5i-3 treatment (1 and 4 μM) for 0, 
1, 5, 8 and 16 hours. Vinculin was used as loading control. Blot images were cropped for clarity of presentation 
(full blots are in Supplemental Fig. 10). *p < 0.05, **p < 0.01, ***p < 0.001 after Dunnett’s post-hoc analysis of 
one-way ANOVA (n = 4). (E–G,H) Western blot analysis and quantification (bar graphs) of ICAM-1 (F) and RhoB 
(G) expression after 5 hours of CSN5i-3 (1 μM or 4 μM) or TNF-α (10 ng/mL) in combination with BAY11-7085 
treatment (10 μM). Vinculin was used as loading control. Blot images were cropped for clarity of presentation 
(full blots are in Supplemental Fig. 11). *p < 0.05, **p < 0.01 ***p < 0.001 after Sidak’s post-hoc analysis of 
two-way ANOVA. (n = 3 for ICAM-1, n = 4 for RhoB). (H) Representative pictures of fluorescently labeled PMN 
adherent to a HUVEC monolayer treated with CSN5i-3 or TNF-α. (I) Quantification of PMNs per field of view 
after CSN5i-3 treatment. ***p < 0.001, ****p < 0.0001 after Dunnet post-hoc analysis of one-way ANOVA 
(n = 4 separate experiments with 10 fields of view per experiment).
CSN5i-3 promotes vascular leakage in zebrafish embryos
CSN5i-3 treatment disrupted endothelial barrier integrity in vitro in primary human 
endothelial cells. To confirm this finding in vivo, we examined the effect of CSN5i-3 on zebrafish 
(Danio rerio) vascular integrity. At 24 hours post fertilization (hpf), CSN5i-3 was added to 
the swimming water of Tg(Fli1:GFP)y1 casper zebrafish embryos for 48–72 hours. In a dose-
response experiment, we found that 50 μM CSN5i-3 was required to induce full neddylation 
of zebrafish Cullin-3 (Fig. 6A). Similar to our observation in in vitro experiments, total Cullin-3 
levels were decreased in zebrafish embryos treated with CSN5i-3. As a negative control, 
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zebrafish embryos were treated with 10 μM MLN4924, and as expected, we observed a 
clear shift to the de-neddylated form of Cullin-3 (Fig. 6A). To assess whether CSN5i-3 induces 
vascular leakage in the zebrafish embryos, 70 kDa TMR Dextran was injected directly into the 
bloodstream. We performed live fluorescent imaging of the zebrafish embryos 20 minutes 
after injection of the dextran (Fig. 6B) and quantified the relative dextran extravasation 
(Fig. 6C). We observed a significant increase in dextran leakage from the intersegmental 
vessels in 4 days post fertilization (dpf) zebrafish embryos treated with CSN5i-3 (Fig. 6C). 
In conclusion, our data indicate that CSN5i-3 treatment induces in vivo vascular leakage.
Figure 6 - CSN5i-3 increases vascular leakage in vivo. (A) Zebrafish Tg(Fli1:GFP)y1 casper embryos were 
treated with 1, 10, 20 and 50 μM CSN5i-3, 10 μM MLN4924 or solvent (DMSO 0.5%) for 48 hours from 24 
hpf onward. Embryos were lysed and western blot analysis of Cullin-3 was performed. ERK 1/2 was used as 
loading control. Blot images were cropped for clarity of presentation (full blots are in Supplemental Fig. 12). 
(B) Representative images of vascular leakage in control vs CSN5i-3 treated zebrafish embyros. Zebrafish 
embryos were treated with 50 μM CSN5i-3 or solvent (DMSO 0.5%) from 1 dpf onward for 72 hours. 70 kDa 
TMR-dextran was injected at the intersection of the common cardinal vein, the posterior cardinal vein and 
the primary head sinus to visualize vascular leakage. 70 kDa Dextran is in red, vasculature in green. Scale bar 
represents 50 μm. (C) Quantification of relative extravascular fluorescence from 0.5% DMSO (n = 11) or 50 μM 
CSN5i-3 (n = 9) treated fish. For each embryo, the fluorescence intensity of the dextran was measured in four 
intersegmental vessels and three intervascular areas between the intersegmental vessels. The average of the 
dextran fluorescence in the intervascular areas was normalized to the average dextran fluorescence inside the 
vessels. Obtained values represent the ratio of extravasated dextran compared to dextran inside the vessels. 





Here we show that inhibition of CSN5, the catalytic component of the COP9 signalosome, 
disrupts endothelial barrier function in vitro and in vivo. The prolonged neddylation of Cullin 
RING ligases (CRL), consequent to the inhibition of CSN5, resulted in degradation of IκBα 
and subsequent activation of the NF-κB pathway. This in turn promoted RhoB and, to a 
lesser extent, RhoA mRNA and protein synthesis, which resulted in increased activity of 
RhoGTPases, ROCK-mediated actin stress fiber formation, MLC phosphorylation and cell 
contraction.
Recently, we showed that general inhibition of CRL by MLN4924 enhanced RhoB expression 
and severely disrupted endothelial barrier function through the induction of RhoB-
dependent cell contraction [9]. We identified the Cullin-3-Rbx1-KCTD10 complex as the 
ligase that mediates the poly-ubiquitination and degradation of RhoB [9]. Based on these 
findings, we hypothesized that cullin activation by CSN5i-3 would increase ubiquitination and 
degradation of RhoB, leading to improved endothelial barrier function. In contrast, however, 
prolonged Cullin-3 neddylation induced by CSN5i-3 resulted in decreased expression of 
Cullin-3, increased expression of RhoB and reduced endothelial integrity.
Several studies have shown that in endothelial cells RhoB protein levels are upregulated 
upon TNF-α stimulation of the NF-κB pathway, due to increased mRNA synthesis [9, 28, 29]. 
This TNF-α-induced RhoB localizes to an endosomal compartment, in marked contrast to 
the pool of RhoB which accumulates following CRL inhibition and localizes to the plasma 
membrane9. Therefore, we analyzed localization of RhoB in HUVEC monolayers treated with 
CSN5i-3. To our surprise, we found that prolonged CRL neddylation leads to induction of 
RhoB expression within the endosomal compartment similar to the RhoB localization induced 
by TNF-α stimulation. Therefore we hypothesized that the NF-κB pathway was upregulated 
in endothelial cells treated with CSN5i-3. This assumption was further corroborated by the 
comparable induction of RhoB mRNA expression upon treatment with either CSN5i-3 or TNF-α.
Further analysis confirmed that the NF-κB pathway was indeed activated by CSN5i-3. Originally, 
the CSN5i-3 compound was designed to inhibit the COP9 metalloprotease in order to prolong 
Cullin activation [24]. The transition of Cullins between neddylated and non-neddylated states 
is required in order to exchange the substrate recognition receptors in the CRL complex. 
Schlierf et al. described that prolonged neddylation of Cullin RING ligases by CSN5 inhibition 
can lead to autodegradation of some but not all substrate recognition receptors. Interestingly, 
we found that the expression of Cullin proteins in endothelial cells can be affected by CSN5 
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inhibition as well. The associated deubiquitination activity of the CSN, which is now lost 
by inhibition of the complex using CSN5i-3, may contribute to the decreased stability and 
activity of some CRL complexes [19]. CSN5i-3 treatment reduced levels of Cullin-3, but did not 
significantly affect expression of Cullin-1. This suggests that prolonged CRL activation can have 
opposing effects on expression levels of substrates of different CRLs.
Comparable to our findings, Schweitzer et al. showed that knockdown of CSN2, also a 
component of the COP9 complex, leads to decreased expression of IκBα in HeLa cells, which 
eventually resulted in increased phosphorylated p65 in the nucleus after TNF-α stimulation 
[32]. The essential role of ubiquitination of IκB in the regulation of the NF-κB pathway 
was established previously [30]. Furthermore, the knockdown of CSN5 in endothelial cells 
increased NF-ĸB activity, ICAM-1 expression, and PMN adherence to the EC monolayer 
[18]. In the present study, in accordance with the previous work, we found that CSN5i-3 
treatment decreased expression of IκBα and increased the phosphorylation of p65, resulting 
in increased ICAM-1 expression which promotes adhesion of PMNs.
The CSN5i-3 compound was found to be a promising candidate for potential treatment 
against cancer in vitro and in animal studies [24]. However, in our current study we found 
that prolonged neddylation of CRLs, induced by CSN5i-3, is not beneficial in endothelial cells, 
as it reduced barrier integrity and induced an inflammatory phenotype. The same effect on 
endothelial integrity was found upon general inhibition of CRLs by MLN4924, a compound 
which is already being tested in clinical trials [21-23]. In conclusion, our findings demonstrate 
that both prolonged activation, as well as -inhibition of CRLs can induce unwanted side effects, 
in the case of CSN5i-3 leading to endothelial inflammation and loss of endothelial barrier 
function. More specific inhibitors, targeting a smaller subset of E3 enzymes will be required to 
specifically modulate substrate degradation in cancer- and other cells and at the same time 
preserve the endothelial integrity and prevent adverse effects on the cardiovascular system.
MATERIALS AND METHODS
Antibodies and reagents
The following antibodies were used in this study: αVE-cadherin XP (#2500), αRhoA (#2117), 
αRhoC (#3430), αCullin-3 (#2759), αp44/42 MAPK (ERK1/2) (#9102), αpMLC2 Ser19 (#3671), 
αGAPDH (#2118), αIκBα (#4841) and αpp65 (#93H1) (all from Cell Signaling Technology); 
αRhoB (#sc-8048 and #sc-180), αCullin-1 (#sc-17775), αICAM (#sc-8439) (all from Santa Cruz 





Horseradish peroxidase-conjugated goat anti-rabbit and anti-mouse antibodies (Dako) 
were used as secondary antibodies for western blotting. For immunofluorescent staining 
DAPI (Thermo Fisher scientific), Alexa 488-secondary antibody (anti-rabbit and anti-mouse, 
Invitrogen) and Acti-stain 670 phalloidin (Cytoskeleton) were used.
The following inhibitors and cytokines were used in this study: CSN5i-3 (Novartis), MLN4924 




Primary Human Umbilical Vein Endothelial Cells (HUVECs) were isolated from umbilical cords 
of healthy donors. Umbilical cords were provided by the Amstelland Ziekenhuis, Amstelveen. 
Informed consents were obtained from all donors in accordance with the institutional guidelines 
and the Declaration of Helsinki. The cells were isolated and characterized as described by 
Jaffe et al. [33]. The primary HUVECs were cultured in M199 medium supplemented with: 
penicillin 100 U/mL and streptomycin 100 μg/mL, L-glutamine 2 mMol/L (all from Bio Whittaker/
Lonza), heat-inactivated human serum 10% (Sanquin, Amsterdam, The Netherlands), heat-
inactivated new-born calf serum 10% (Gibco), crude endothelial cell growth factor 150 μg/
mL (locally prepared from bovine brains) and heparin 5 U/mL (Leo pharmaceutical products, 
Weesp, The Netherlands). Cells were cultured at 37 °C and 5% CO2, and medium was refreshed 
every second day. For all experiments, pools of HUVECs of 3 donors in passages 1–2 were used.
Lonza HUVECS
Primary HUVECs were purchased from Lonza (#CC-2519) and cultured on fibronectin-coated 
plates in Endothelial Cell medium (ECM), supplemented with singlequots (Sciencell Research 
Laboratories). Cells were cultured at 37 °C and 5% CO2 and the medium was refreshed every 
second day. Experiments were performed with cells until passage 7.
HEK293T cells
HEK293T cells (ATCC) (#CRL-3216) were grown in Dulbecco’s Modified Eagle Medium 
(Gibco) (#41966-029) supplemented with penicillin 100 U/mL and streptomycin 100 μg/mL, 
L-glutamine 2 mMol/L (all from Bio Whittaker/Lonza), 1 mM sodium pyruvate (Gibco) (#11360-
070) and 10% Fetal Bovine Serum (PAA) (#A15-101).
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siRNA transfection
One day prior to transfection HUVECs were seeded on fibronectin coated 12-well cell 
culture plates. On the day of transfection cells were 70–80% confluent. Transfection was 
performed using Dharmafect I reagent (Dharmacon/Horizon discovery) and 20 nM of one or 
combination several of the following siRNAs: ON-TARGET plus Human RHOA siRNA-SMART 
pool, ON-TARGET plus Human RHOB siRNA-SMART pool or ON-TARGET plus Human RHOC 
siRNA-SMART pool. ON-TARGET plus Non-targeting Control pool was used as a negative 
control. Transfected cells were used for experiments at 72 hours post-transfection.
Protein analysis
The cells were stimulated with compounds for indicated times as stated in individual 
experiments. To analyze protein expression, cells were washed with serum- and growth 
factor- deprived medium and whole-cell lysates were collected in 2x SDS sample buffer 
(SB) (125 mM Tris-HCl, 4% SDS, 20% glycerol, 100 mM DTT, 0.02% Brom Phenol Blue in 
MilliQ). Protein samples were separated using SDS-PAGE and transferred to nitrocellulose 
membranes, followed by incubation with designated primary antibodies. Protein bands 
were visualized with enhanced chemiluminescence (Amersham/GE-healthcare) on the AI600 
machine (Amersham/GE-healthcare).
RhoGTPase activation assay
Confluent endothelial cells seeded on 60 cm2 dishes were treated with 1 or 4 uM CSN5i-
3 for 5 hours. After treatment the cells were washed with ice cold PBS and lysed on ice. 
The lysates were tested for Rho A, -B and -C activity using Rho Activation Assay Biochem 
KitTM (Cytoskeleton) according to the manufacturer’s instructions.
Endothelial barrier function assays
Endothelial barrier function was measured with electrical cell-substrate impedance 
sensing (ECIS) and passage of Horse Radish Peroxidase (HRP). For ECIS measurements, 
cells were seeded on gelatin-coated ECIS plates containing gold intercalated electrodes 
(Applied biophysics). When primary isolated HUVECs were confluent, they were serum-
starved in M199 medium supplemented with 1% human serum albumin (HSA, Sanquin) for 
approximately 90 minutes. Subsequently, compounds were added to the cell medium. For 
Lonza HUVECs, ECIS plates were coated with 5 μg/ml Fibronectin and the compounds were 
directly added to the ECM medium.
Macromolecular permeability of the endothelial barrier was measured by passage of horse 




on top of gelatin-fibronectin coated Thin-CertsTM (Greiner Bio-One) and cultured in ECM 
with a medium change every second day. When a stable barrier was formed the medium 
in the upper compartment was replaced by complete medium containing HRP 5 μg/mL 
and CSN5i-3 or a vehicle control. At several time-points a sample was taken from the lower 
compartment. The HRP concentration was calculated by measuring absorbance after adding 
tetramethylbenzidine (TMB) (Upstate/Millipore) and sulfuric acid to stop the reaction.
Immunofluorescence imaging of cultured endothelial cells
Lonza HUVECs were seeded on 2 cm2 coverslips (Thermo Scientific, Menzel-gläser) 
(#10319303) which were pre-coated with 5 μg/ml fibronectin. Cells were grown until 
confluency with a medium change every second day and upon reaching confluency, 
experiments were performed. Cells were fixed with warm (37 °C) 4% paraformaldehyde 
(Sigma Aldrich) (#158127) in phosphate buffered saline (PBS) (B Braun) (#3623140) and 
incubated at room temperature for 15 minutes. The PFA was washed away with PBS, cells 
were permeabilized with 0,2% triton X-100 in PBS for 3 minutes and blocked for 30 minutes 
with 1% HSA in PBS. Hereafter, coverslips were stained with primary antibodies in 1% HSA/
PBS for 1 hour at room temperature or overnight at 4 °C. After washing with PBS, coverslips 
were incubated with a FITC-labeled secondary antibody (anti-rabbit or anti-mouse 1:100 
in 1% HSA/PBS), Acti-stain 670 phalloidin (Cytoskeleton) (#PHDN1-A) and DAPI (Thermo 
Fisher Scientific) for 1 hour at room temperature. Coverslips were mounted with Mowiol4-
88/DABCO solution (Calbiochem, Sigma Aldrich). Confocal scanning laser microscopy was 
performed on a Nikon A1R confocal microscope (Nikon). Images were analyzed and equally 
adjusted with ImageJ software.
RT-PCR
HUVECs (Lonza) were treated with CSN5i-3 or TNF-α for 5 hours. Total RNA was purified 
from the HUVECs using TRIzol (Thermo Fisher Scientific) and Direct-zol RNA MiniPrep 
kit (Zymo Research) and 500 ng of RNA was used for cDNA synthesis using iScript cDNA 
synthesis kit (Bio-Rad). Quantitative real time PCR was performed (iQ SYBR Green 
Supermix, Bio-Rad) with the CFX384 Real-Time system (Bio-Rad). Following primers were 
used for amplification: TGCACCACCAACTGCTTAGC-3′ (GAPDH-F) and 5′-GGCATGGACT 
GTGGTCATGAG-3′ (GAPDH-R) for GAPDH, 5′-GAGGTGGATGGAA AGCAGGTAGAGTTG-3′ 
(RhoA-F) and 5′-TTTCACCGGCTCCTGCTTCATCTTGG-3′ for (RhoA-R) for RhoA, 5′-AGA 
CGTGCCTGCTGATCGTGTTCAG-3′ (RhoB-F) and 5′-CACATTGGGACAGAAGTGCTTCACC-3′ 
(RhoB-R) for RhoB.
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PMN isolation
Polymorphonuclear neutrophils were isolated from fresh heparinized blood obtained from 
healthy donors. The blood was diluted 1:1 with PBS layered onto Lymphoprep (#07801) (Stem 
cell technologies). By centrifugation, blood components were separated and all the layers 
except the layer containing erythrocytes, neutrophils and eosinophils were removed. After 
erythrocyte lysis in cold lysis buffer (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM Na-EDTA, pH 7.4), 
PMNs were washed twice with PBS and resuspended in HEPES buffer (20 mM HEPES, 132 mM 
NaCl, 6 mM KCl, 1 mM MgSO4, 1.2 mM K2HPO4, 1 mM CaCl2, 0.5% Human Serum Albumin (HSA, 
Sanquin). PMNs were stored at room temperature for a maximum of 3 hours upon isolation.
PMN transendothelial migration
Lonza HUVECs were grown on 2 cm2 fibronectin-coated wells until confluency. Freshly 
isolated PMNs were labelled for 10 minutes at 37 °C with 1 μg/ml calcein AM (#C3099) 
(Thermo Fischer Scientific), washed once with HEPES buffer and incubated for another 
30 minutes at 37 °C. A total of 500,000 PMNs were added per 2 cm2 well on a CSN5i-3 or 
TNF-α treated HUVEC monolayer and placed in the incubator at 37 °C and 5% CO2. After 
25 minutes, non-adherent PMNs were washed away with HEPES buffer and cells were fixed. 
Adherent PMNs were visualized using the green fluorescence filter of a LS720 Microscope 
(Etaluma). Treatments were performed in duplicate and the number of adherent PMNs per 
field of view was counted from five random fields per well using ImageJ.
Zebrafish husbandry, embryo care and compound treatment
Adult Tg(Fli1:GFP)y1casper zebrafish were maintained at 26 °C in aerated 5-L tanks with a 
10/14 hour dark/light cycle [34, 35]. The Tg(fli1:GFP)y1 zebrafish line expresses GFP in the 
endothelial cells of the entire vasculature under the control of the fli1 promoter. Zebrafish 
were raised, staged and maintained according to standard procedures (zfin.org). Zebrafish 
embryos were collected within the first hours post fertilization (hpf) and kept at 28 °C in E3-
medium (5.0 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl·2H2O, 0.33 mM MgCl2·6H2O) supplemented 
with 0.3 mg/L methylene blue. For compound treatment, zebrafish embryos were manually 
dechorionated at 24 hpf and transferred to separate wells. After experiments were 
performed zebrafish embryos were anesthetized in 0.02% (w/v) buffered 3-aminobenzoic 
acid methyl ester (pH 7.0) (Tricaine) (Sigma-Aldrich) (#A5040) and euthanized by hypothermic 
shock. All experiments involving zebrafish embryos were according to local animal welfare 
regulations. VU University medical center animal welfare committee approved the breeding 
procedure of the adult zebrafish. Experimental procedures were performed in zebrafish 
larvae from 1–4 days post-fertilization prior to the stage of free living, which is in accordance 




Dextran leakage assay in Zebrafish embryos
At 24 hpf, CSN5i-3 was added to the water of Tg(fli1:GFP)y1 casper zebrafish embryos to treat 
them for 48–72 hours with the compound. Zebrafish embryos were subsequently injected 
with ~1 nl of a 2 mg/ml solution of 70 kDa TMR dextran (#D1818) (Thermo Fisher Scientific) 
into the vasculature at the intersection of the common cardinal vein, the posterior cardinal 
vein and the primary head sinus using a Pneumatic PicoPump (#SYS-PV820) (World precision 
instruments). During injection and imaging, the zebrafish embryos were anaesthetized in 
0.02% (w/v) buffered 3-aminobenzoic acid methyl ester (pH 7.0) (Tricaine) (#A5040) (Sigma-
Aldrich). For live imaging, zebrafish embryos were mounted in an uncoated 8-well μ-slide 
(#80827) (Ibidi) in 1.5% low melting point agarose dissolved in egg water (60 μg/mL sea salts 
(Sigma-Aldrich; S9883) in MilliQ) with addition of 0.02% (w/v) buffered 3-aminobenzoic acid 
methyl ester (pH 7.0) (Tricaine) (#A5040) (Sigma-Aldrich). Zebrafish embryos were imaged 
after 20 minutes using a Zeiss wide field microscope at 10x magnification.
Preparation of zebrafish embryo lysates for western blot
For western blot analysis of Cullin-3 expression, whole lysate of the zebrafish embryos 
was prepared between 72 hpf and 96 hpf, the same time-frame in which the dextran was 
injected for analysis of leakage. Prior to lysis, zebrafish embryos were anesthetized in 
0.02% (w/v) buffered 3-aminobenzoic acid methyl ester (pH 7.0) (Tricaine) (Sigma-Aldrich) 
(#A5040), collected in an Eppendorf tube and euthanized by hypothermic shock. The water 
was removed and 10 ul 2x SDS sample buffer per fish was added. The lysate was boiled for 
3 minutes at 95 °C and homogenized by sonication.
Caspase-3/7 assay
HUVECs were grown to confluency in a Black Falcon 96-well plate with clear bottom. For the 
analysis of caspase-3/7 activity, medium was replaced by fresh medium containing 0, 1 or 
4 μM CSN5i-3. Cells were treated for 5 hours with 200 nM Staurosporin as a positive control. 
After 5 and 24 hours of treatment with CNS5i-3, caspase-3/7 activity was analyzed using the 
Apo-ONE® Homogeneous Caspase-3/7 Assay kit and following the manufacturer’s protocol.
RhoB ubiquitination assay
HEK293T cells were co-transfected with mCherry-RhoB and HA-Ubiquitin using TransIT-LT1 
(Mirus) (#MIR 2300) and following the manufacturer’s protocol. The next day, cells were 
treated for five hours with 1 or 4 μM CSN5i-3 or 500 nM MLN4924, with addition of 2.5 μM 
MG132 for the last four hours. Next, denaturing HA-immunoprecipitation was performed 
as described previously [36].
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Statistical analysis
Data is represented as mean ± SD. Statistical significance was tested by one-way ANOVA 
or repeated measures ANOVA with Dunnet’s post-hoc test, unless indicated differently. 
P-values were considered statistically significant if p < 0.05. Analysis was performed using 
GraphPad Prism 7 software.
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Supplemental Figure 1 – CSN5i-3 induces apoptosis after 24 hours, but not after 5 hours of treat-
ment. Caspase-3/7 assay of HUVEC monolayers treated with CSN5i-3 (1 or 4 μM) for 5 or 24 hours or 200 nM 
Staurosporin for 5 hours as a positive control. * p<0.05, ** p<0.01, **** p<0.0001 compared to control after 
Dunnet post-hoc analysis of one-way ANOVA.
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Supplemental Figure 2 – single knockdown of RhoA, RhoB or RhoC does not effectively prevent 
MLC phosphorylation by CSN5i-3. A) Western blot analysis of pMLC, RhoA, RhoB, and RhoC expression 
in RhoA, RhoB and RhoC knockdown cells after 5 hr of CSN5i-3 (1 μM or 4 μM) treatment. GAPDH was used 
as loading control. Blot images were cropped for clarity of presentation. B) Quantification of pMLC levels 
compared to control.
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Rho GTPases control both the actin cytoskeleton and adherens junction stability and are 
recognized as essential regulators of endothelial barrier function. They act as molecular 
switches and are primarily regulated by the exchange of GDP and GTP. However, 
posttranslational modifications such as phosphorylation, prenylation, and ubiquitination 
can additionally alter their localization, stability, and activity. F-box proteins are involved 
in the recognition of substrate proteins predestined for ubiquitination and subsequent 
degradation. Given the importance of ubiquitination, we studied the effect of the loss of 62 
members of the F-box protein family on endothelial barrier function in human umbilical vein 
endothelial cells. Endothelial barrier function was quantified by electrical cell impedance 
sensing and macromolecule passage assay. Our RNA interference–based screen identified 
FBXW7 as a key regulator of endothelial barrier function. Mechanistically, loss of FBXW7 
induced the accumulation of the RhoB GTPase in endothelial cells, resulting in their increased 
contractility and permeability. FBXW7 knockdown induced activation of the cholesterol 
biosynthesis pathway and changed the prenylation of RhoB. This effect was reversed by 
farnesyl transferase inhibitors and by the addition of geranylgeranyl pyrophosphate. In 
summary, this study identifies FBXW7 as a novel regulator of endothelial barrier function 
in vitro. Loss of FBXW7 indirectly modulates RhoB activity via alteration of the cholesterol 
biosynthesis pathway and, consequently, of the prenylation status and activity of RhoB, 
resulting in increased contractility and disruption of the endothelial barrier.
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INTRODUCTION
Endothelial cells (ECs) line all blood and lymph vessels throughout the body. They form a 
monolayer of tightly adherent cells that regulates the transmigration of leukocytes and 
transport of plasma proteins from the circulation into the tissues. Proper function of the 
endothelial barrier is crucial, as its dysfunction is a hallmark of chronic inflammatory 
diseases that can result in edema and tissue damage [1]. Adherens junctions (AJs) serve 
as a bridge connecting the actin cytoskeleton of neighboring ECs [2] and are composed 
of multiple proteins, including the transmembrane protein vascular endothelial-cadherin 
(VE-cadherin) and intracellular adaptor proteins such as α- and β-catenin, which link VE-
cadherin to the actin cytoskeleton [3]. Importantly, the dynamics of the cytoskeleton, 
which allow force-generation parallel or perpendicular to cell–cell contacts, can stabilize 
or disrupt AJs [4, 5].
Important regulators of AJs and of the actin cytoskeleton are the Rho GTPases. It is well 
established that Rac1 and Cdc42 promote endothelial barrier stability [6], while RhoA 
activation leads to endothelial barrier disruption [7]. Activity of Rho GTPases is primarily 
regulated by a conformational change that is dependent on GDP or GTP binding [8]. The 
GTP-bound conformation enables interaction with downstream signaling proteins. Rho 
GTPases are activated by guanine-nucleotide exchange factors (GEFs), which promote the 
exchange of GDP for GTP, and by GTPase-activating proteins (GAPs), which stimulate the 
hydrolysis of GTP, leading to GTPase inactivation [9]. Inactive Rho GTPases are protected 
from ubiquitin-dependent degradation by binding to guanine-nucleotide dissociation 
inhibitor in the cytosol [10]. It has become increasingly clear that nucleotide binding and 
the interaction with GEFs and GAPs is one of several mechanisms that regulate Rho GTPase 
activity, as Rho GTPases can also be phosphorylated, prenylated, and ubiquitinated to 
fine-tune their function [11, 12]
Among these posttranslational modifications, prenylation of Rho GTPases is a key 
determinant of their function. Prenylation targets Rho GTPases to the correct subcellular 
location and is important for interactions with regulatory proteins and downstream 
signaling effectors. RhoB is unique among the Rho GTPases, because it can be both 
geranylgeranylated and farnesylated [13]. Farnesyl and geranylgeranyl are isoprenoids that 
are generated through the cholesterol synthesis pathway and covalently attached to the 
CAAX-box at the C-terminus of Rho GTPases through the activity of the enzymes farnesyl 
transferase and geranylgeranyl transferase I, respectively. The geranylgeranylated form 




farnesylated form is active [15]. Accordingly, inhibition of farnesylation of RhoB was shown 
to reduce vascular cell proliferation, increase endothelium-dependent vasodilatation, and 
reduce vasoconstriction of pulmonary arteries in an animal model of hypoxia-induced 
pulmonary hypertension [16].
Besides prenylation, ubiquitination is an important posttranslational modification that 
regulates the protein stability of both RhoA and RhoB [17, 18]. During the ubiquitination 
process, the small protein ubiquitin (76 amino acids) is covalently attached to substrate 
proteins to selectively target them to the proteasome or to lysosomes for degradation. 
Ubiquitination consists of three steps whereby ubiquitin is activated by an E1 ubiquitin 
enzyme, transferred to an ubiquitin-conjugating enzyme E2, and attached to a substrate 
as monoubiquitin or a polyubiquitin by an E3 ligase [19]. The E3 ligases are characterized 
by several defining motifs that allow direct or indirect ubiquitination of substrates [20]. One 
family of E3 ligases, the Cullin RING (Really Interesting New Gene) ligases form large protein 
complexes; the SKP1-Cullin1-FBP ligase is a well-characterized example [21]. In this complex, 
Cullin-1 is the central adaptor protein that interacts via Rbx1 with the E2 ubiquitin ligase 
and with the F-box protein via Skp1. In this E3 ligase complex, the F-box protein acts as a 
specific recognition receptor that dictates the substrates for ubiquitination and subsequent 
degradation. The F-box family contains three groups of proteins, which are named according 
to their structure: the FBWs contain a WD-40 repeat; the FBLs contain a leucine-rich repeat; 
and the FBXs, which do not contain a WD-40 or leucine-rich repeat but often have other 
protein–protein interaction domains. A central question
pertaining to F-box proteins is resolving the function of each individual F-box protein family 
member. The members that have been studied so far are mostly associated with the control 
of proliferation via the degradation of cyclins [21]. Owing to their structural diversity, F-box 
proteins can bind several different substrate proteins and are involved in the pathogenesis 
of various human diseases, including Parkinson’s disease and cancer [22, 23]. Besides 
the function of FBXW7 in angiogenesis and inflammation [24, 25], the role of other F-box 
proteins in endothelium has not been studied in detail.
In the current study, we aimed to determine whether F-box proteins play a role in endothelial 
barrier function. Using primary human umbilical vein endothelial cells (HUVECs) in 
combination with endoribonuclease-prepared small interfering RNA (esiRNA)-mediated 
knockdown of F-box proteins, we found that FBXW7 is involved in regulation of the 
endothelial barrier. We further showed that cells lacking FBXW7 had a contractile phenotype 
that results in reduced barrier function and increased permeability both in resting and 
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thrombin-stimulated cells. This phenotype can be attributed to the increased abundance 
of the contraction-inducing RhoB GTPase. Concomitantly, we found that FBXW7 depletion 
induced activation of the cholesterol synthesis pathway in ECs and thereby impaired both 
the prenylation and degradation of RhoB.
Table 1: F-box proteins included in the screen, with esiRNA targeted F-box proteins grouped into 
three protein families: F-box and -rich repeat (FBXL), F-box only (FBXO), and F-box and WD40 domain 
(FBXW). esiRNAs targeting 19 FBXL, 34 FBXO and 9 FBXW proteins were included in the screen.
FBXL FBXO FBXW
SKP2 CCNF FBXO27 BTRC
FBXL2 FBXO2 FBXO28 FBXW2
FBXL3 FBXO3 FBXO30 FBXW4
FBXL4 FBXO4 FBXO32 FBXW5
FBXL5 FBXO5 FBXO33 FBXW7
FBXL6 FBXO6 FBXO34 FBXW8
FBXL7 FBXO7 FBXO36 FBXW10
FBXL10 FBXO8 FBXO38 AC005838.2











An esiRNA screen of F-box proteins identified both positive and negative regulators of 
endothelial barrier function
To identify new ubiquitination regulators that are important for endothelial barrier function, 
we screened a custom library of esiRNAs (Sigma) targeting 62 F-box proteins in primary 
HUVECs. The targets comprise members of all three different classes of F-box proteins 
(Table 1). Electrical cell–substrate impedance sensing (ECIS) was used to measure endothelial 




was repeated four times with four different pools of HUVECs, each derived from three 
different donors. The endothelial barrier function was measured in real time for 72 h after 
transfection and was then evaluated (Figure 1A). For data analysis, the mean delta increase 
in endothelial barrier resistance of each F-box protein esiRNA was compared with the mean 
delta increase of the control. The only significant hit in this screen after false discovery rate 
(FDR) correction was F-box/WD repeat-containing protein 7 (FBXW7) (p = 0.0079) (Figure 1B, 
depicted in red). Other proteins that showed a significant effect before FDR correction were 
FBXL19, FBXL17, FBXL16, FBXO18, and FBXO28. However, some of the tested F-box proteins 
showed large intraexperimental variation, which could have influenced the interpretation 
of the results. Most of the tested F-box protein esiRNA did not show large effects compared 
with the esiRNA targeting enhanced green fluorescent protein (esiEGFP) control. This 
might be due to redundancy between F-box proteins or their irrelevance for regulation of 
endothelial barrier function. While loss of FBXW7 showed the largest decrease in barrier 
function, depletion of FBXL19 induced the largest increase in barrier function (Figure 1C). 
The effects of FBXW7 and FBXL19 esiRNAs were corroborated by lentivirally expressed short 
hairpin RNA (shRNA) targeting the same proteins (Supplemental Figure 1). These findings 
indicate that a limited subset of F-box proteins is involved in the regulation of the endothelial 
barrier and that FBXW7 is a positive regulator of endothelial barrier function.
FBXW7 knockdown impairs endothelial barrier function
To expand the results from the esiRNA screen, we repeated the experiments with 
independent siRNAs (ON-TARGET plus SMART pools) in different pools of primary HUVECs. 
As control in these experiments, cells were transfected with nontargeting siRNA (siNT). 
First, we confirmed that FBXW7 mRNA was effectively down-regulated in cells that were 
transfected with FBXW7 siRNA. Figure 2A shows that there is ~95% loss of FBXW7 mRNA 
in FBXW7 knockdown cells. siRNA-mediated loss of FBXW7 in ECs resulted in a significantly 
decreased barrier resistance compared with control cells (Figure 2, B and C). Resolving 
the endothelial resistance measurements into separate components reflecting cell–cell 
and cell–matrix interaction [26] showed that loss of FBXW7 did not significantly change 
cell–matrix interaction compared 
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Figure 1 - An esiRNA screen iden-
tifies F-box proteins involved in 
endothelial barrier function. 
(A) Schematic representation of 
the esiRNA screen. Sixty-two esiR-
NAs were transfected into pools of 
HUVECs seeded on 96W10idf ECIS 
arrays (n = 4). Endothelial resistance 
was measured for 72 h following 
transfection. A schematic ECIS graph 
is shown: green, an example of the 
enhancement of the endothelial bar-
rier after knockdown; red, an exam-
ple of disruption of the endothelial 
barrier after knockdown; black, a control EGFP esiRNA. (B) Overview of the mean delta of electrical resistance 
from the start of transfection until the 72 h time point for each esiRNA. White, the EGFP control; green, the 
highest value; red, the lowest value. The gray bar represents the threshold value at ±33% of the EGFP control. 
Data points represent mean ± SEM (n = 4). (C) Effect of loss of FBXL19, EGFP, and FBXW7 on basal endothelial 
barrier function. Data represent normalized average values from the start of transfection (t = 0) until the end 




with control cells (Figure 2, D and E). However, the cell–cell interaction was significantly lower 
in FBXW7 knockdown cells compared with control cells (Figure 2, F and G). Because the 
endothelial resistance measurements showed significant effects on cell–cell interaction, we 
next focused on the morphology of the actin cytoskeleton and AJs in FBXW7 knockdown cells. 
Phalloidin staining showed more intense overall F-actin staining and formation of contractile 
actin rings in FBXW7 knockdown cells (Figure 2H). Furthermore, immunostaining of the 
cell–cell adhesion protein VE-cadherin revealed discontinuous VE-cadherin distribution 
in FBXW7-depleted cells (Figure 2H). These findings were confirmed by use of an shRNA 
targeting FBXW7 (Supplemental Figure 2). Furthermore, we analyzed the colocalization of 
VE-cadherin and F-actin. This analysis showed that colocalization of VE-cadherin and F-actin 
is significantly lower in FBXW7 knockdown cells compared with control cells (Figure 2, I and 
J). Finally, FBXW7 knockdown did not significantly reduce the number of ECs at 72 h post 
transfection (Figure 2K). Together, these findings suggest that decreased barrier function 
in FBXW7 knockdown cells is induced by increased stress fiber formation and loss of stable, 
junctional VE-cadherin distribution.
Loss of FBXW7 delays recovery from thrombin-induced loss of barrier integrity
In the human circulation, the endothelium can become exposed to many vasoactive agents. 
Here, we studied the effect of the proinflammatory protease thrombin on endothelial barrier 
function in control and FBXW7 knockdown cells. The ability of the cells to recover their 
barrier function after thrombin stimulation is another parameter that gives information 
about endothelial junction dynamics. Stimulation with thrombin (1 U/ml) resulted in a rapid 
drop in endothelial barrier resistance (Figure 3A). This drop in resistance was not significantly 
different between control and FBXW7 knockdown cells (Figure 3B). In contrast, the recovery 
after thrombin stimulation at 3 h poststimulation was significantly reduced in FBXW7 
knockdown cells (Figure 3C).
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Figure 2 - FBXW7 knockdown causes 
decreased endothelial barrier function 
by increased contractile ring formation. 
(A) HUVECs were transfected with siNT and 
siFBXW7 and cultured for 72 h. Total RNA 
was isolated, and expression of the indicat-
ed genes was determined by quantitative 
PCR. Each bar and error bar represent the 
mean ± SD (n = 3); ****, p < 0.0001. (B) Effect of the loss of FBXW7 on basal endothelial barrier function. (C) Basal 
endothelial barrier function at t = 72 h. (D) Absolute endothelial resistance attributable to cell–matrix adhesion 
(α) of control and FBXW7 knockdown cells. (E) α at t = 72 h. (F) Absolute endothelial resistance attributable 
to cell–cell adhesion (Rb) of control and FBXW7 knockdown cells. (G) Rb at t = 72 h. (H) Immunofluorescence 
staining of VE-cadherin (green), F-actin (red), and nuclei (blue) in HUVECs for visualization of AJs and actin fibers 
following loss of FBXW7. Scale bars: 50 μm; scale bar in the zoomed images: 10 μm. Representative images of 
three experiments. (I) Immunofluorescence staining of VE-cadherin (green), F-actin (red), and nuclei (blue) in 
HUVECs for visualization of colocalization of AJs and actin fibers following loss of FBXW7. Scale bar: 20 μm. (J) 
Quantification of Mander’s coefficient of colocalization of VE-cadherin with actin from I was performed using 
ImageJ and JACoP plug-in (Bolte and Cordelieres, 2006) (n = 12). (K) Cell number quantification in control and 
FBXW7 knockdown cells at t = 72 h. DAPI-stained nuclei were counted per field of view (n = 12). ECIS data rep-
resent average values (line graphs, representing barrier formation, Rb or α from medium change at 16 h after 
transfection [t = 0] until the end of the experiment) or mean ± SEM (bar graphs) of n = 3 experiments. *, p < 0.05; 
**, p < 0.01, paired t test. Colocalization data represent mean ± SEM of n = 3 experiments. ****, p < 0.0001, 




To test the effect of thrombin on the endothelial barrier in an independent assay, we 
measured macromolecule passage across endothelial monolayers stimulated with thrombin. 
In line with the ECIS results, the FBXW7 knockdown cells displayed increased horseradish 
peroxidase (HRP) leakage compared with control cells under basal conditions (Figure 3D). 
Stimulation with thrombin increased overall permeability of the monolayer, which was 
enhanced in cells lacking FBXW7. The permeability of FBXW7 knockdown cells was higher 
compared with the control cells at all time points, with statistically significant difference at 
1.5 and 2 h after thrombin stimulation (Figure 3D).
To analyze whether the effect on permeability correlated with changes in cell morphology, 
we visualized F-actin and VE-cadherin in control and FBXW7 siRNA transfected cells. At 15 
min after thrombin addition, we observed gaps and stress fiber formation in monolayers 
of both control and FBXW7 knockdown cells. However, the gaps appeared larger and the 
intensity of the F-actin contractile ring was higher in FBXW7 knockdown cells compared 
with control cells (Figure 3, E and I). Both FBXW7 knockdown and control cells displayed 
discontinuous and jagged VE-cadherin staining (Figure 3E) without significant difference 
in overall VE-cadherin levels (Figure 3G). At 3 h after thrombin treatment, we observed 
that control cells, although they still contained stress fibers, did not show interendothelial 
gaps anymore and that VE-cadherin distribution was more continuous and concentrated 
(Figure 3F). In contrast, gaps were still present in the monolayer of FBXW7 knockdown cells 
(Figure 3J). Additionally, at 3 h after thrombin treatment, FBXW7 knockdown cells showed 
less intense and discontinuous VE-cadherin staining compared with the control cells (Figure 
3, F and H). In summary, FBXW7 knockdown cells recover at a slower rate after thrombin 
stimulation, possibly due to increased stress fiber formation and VE-cadherin turnover.
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Figure 3 - The effect of throm-
bin-induced hyperpermeability 
on FBXW7 knockdown cells. (A) 
Thrombin-induced endothelial barrier 
disruption in FBXW7 knockdown cells. 
Arrow indicates addition of thrombin 
(1U/ml). (B) The thrombin response (% 
decrease in normalized resistance) in 
control vs. FBXW7 knockdown cells. Values represent the percentage drop at the lowest point of resistance follow-
ing the addition of thrombin. (C) The percent recovery at 3 h after thrombin relative to the respective start values 
in control vs. FBXW7 knockdown cells. (D) Time-dependent effects of control and FBXW7 knockdown on the 
passage of HRP across control and thrombin-stimulated HUVECs. Data represent average of three experiments. 
(E,F) Immunofluorescence staining of VE-cadherin (green), F-actin (red), and nuclei (blue) in HUVECs for visual-
ization of AJs and actin fibers following loss of FBXW7 and after 15 min (E) and 3 h (F) of thrombin stimulation. 
Arrows indicate gaps. Scale bars: 20 μm. Images are representative of three experiments. (G,H) Quantification of 
VE-cadherin staining intensity at 15 min (G) and 3 h (H) after thrombin stimulation. Integrated density of VE-cad-
herin staining per cell was calculated using ImageJ software. n = 12. (I, J) Quantification of interendothelial gap 
size at 15 min (I) and 3 h (J) after thrombin stimulation. Gap size was measured using ImageJ software. ECIS data 
represent average values or mean ± SEM (bar graphs) of n = 3 experiments. *, p < 0.05, paired t test. D shows 
average values of three experiments performed in triplicate. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 




FBXW7 depletion increases RhoB levels
The increased formation of F-actin stress fibers that we observed in FBXW7 knockdown cells 
could be caused by increased expression and/or activity of Rho GTPases. Previously, RhoA 
was shown to be an important regulator of contraction induced by thrombin stimulation [7]. 
We recently showed that, besides RhoA, RhoB mediates the contraction of ECs [27], and we 
therefore analyzed RhoB protein abundance. We found that FBXW7 knockdown cells showed 
a markedly increased level of RhoB compared with control cells (Figure 4A). In contrast, 
RhoA and to lesser extent RhoC levels were reduced upon FBXW7 depletion (Figure 4A). To 
exclude the possibility that the effects we observed on RhoB levels in FBXW7 knockdown 
cells were unspecific, we performed a rescue experiment. In this experiment, we depleted 
FBXW7 by using lentiviruses encoding an shRNA that targets the 3′UTR of the FBXW7 
mRNA. In accordance with the siRNA experiments, we found that shFBXW7 also increases 
RhoB expression in these experiments (Figure 4B). Ectopic re-expression of FBXW7 from a 
doxocycline-inducible lentiviral vector reduced the expression of RhoB to the levels found in 
control cells. To test whether the increase in RhoB in FBXW7 knockdown cells was the main 
cause of the decreased barrier function, we performed knockdown of FBXW7 in combination 
with loss of RhoA or of RhoB. We found that loss of RhoB significantly increased endothelial 
barrier resistance, while RhoA knockdown did not demonstrate differences compared 
with control cells (Figure 4, C and D). Depletion of FBXW7 decreased endothelial barrier 
significantly compared with control cells, which is in line with the data in Figure 2. Combined 
knockdown of FBXW7 and RhoA induced a decrease in endothelial barrier resistance similar 
to the single FBXW7 knockdown. On the other hand, endothelial resistance measured in cells 
with double knockdown of FBXW7 and RhoB was not significantly different compared with 
control cells (Figure 4, C and D). In additional experiments, we tested whether single siRNA 
sequences targeting FBXW7 similarly enhanced RhoB expression and disrupted endothelial 
barrier function, as we observed with siRNA pool. We found that two out of four tested 
clones indeed increased the levels of RhoB, and this was accompanied by a significant 
loss of endothelial barrier integrity (Supplemental Figure 3, A and B). Because subcellular 
targeting of Rho GTPases is important for their function, we analyzed RhoB localization in 
control and FBXW7 knockdown cells by confocal microscopy. In line with immunoblotting, 
immunostaining for RhoB showed that FBXW7 knockdown cells contained more RhoB 
localized to vesicles compared with control cells (Figure 4E). In summary, our results indicate 
that the decrease of endothelial barrier integrity induced by the loss of FBXW7 expression 
is to a large extent the result of increased levels of RhoB protein.
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Loss of FBXW7 activates the cholesterol synthesis pathway in ECs
In previous studies, FBXW7 was shown to regulate ubiquitination and abundance of RhoA in 
gastric cancer [28]. We recently found that another CRL complex, namely, Cullin-3/KCTD10, 
is responsible for RhoB ubiquitination in ECs [18]. We tested whether ubiquitination of RhoB 
is also regulated by FBXW7. Using an in vivo ubiquitination assay in HEK293T cells, we did 
not observe an increase in RhoB ubiquitination upon coexpression of FBXW7 (Supplemental 
Figure 4A). In accordance with this, we also did not observe reduced ubiquitination of 
endogenous RhoB in FBXW7-depleted ECs (Supplemental Figure 4B).
FBXW7 has previously been demonstrated to control the cholesterol biosynthesis pathway in 
hepatocytes owing to its ability to regulate the level of the sterol-regulatory element binding 
protein (SREBP) transcription factors [29, 30]. To test whether this is also the case in ECs, 
we measured mRNA levels of several proteins that are part of the cholesterol pathway. In 
line with FBXW7 having a similar effect in ECs, its loss leads to increased expression of the 
SREBP-regulated target genes 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR), 
squalene synthase (SQS), squalene epoxidase (SQLE), and the low-density lipoprotein 
receptor (LDLR) (Figure 5, A–D). For two of these genes, we tested whether increased mRNA 
expression also resulted in increased abundance of the encoded protein. We found that, 
mirroring the effects on mRNA levels, the protein abundance of SQLE was increased 2.5-fold 
in FBXW7 knockdown cells compared with control cells. Similarly, LDLR levels were increased 
twofold in FBXW7 knockdown cells compared with control cells (Figure 5E). These data are 
in line with a previous publication, in which FBXW7 knockdown was shown to lead to the 
activation of SREBPs in U2OS and HCT116 epithelial cancer cells [29] and activation of the 
cholesterol synthesis pathway. Together, these findings indicate that FBXW7 knockdown 





Figure 4 - FBXW7 knockdown increased RhoB levels in HUVECs. (A) Western blot of whole-cell lysates 
showing the effect of FBXW7 knockdown on expression of RhoB, RhoA, and RhoC in HUVECs. Representative 
blots from four experiments are shown. GAPDH is included as a loading control. Bar graph represents mean 
± SD of RhoB expression from four individual experiments, all relative to GAPDH and normalized to siNT. (B) 
Western blot of the FBXW7 rescue experiment. Cells were infected with control shRNA lentivirus (sh control) 
or lentivirus carrying shRNA that targets the 3′UTR of FBXW7 mRNA in combination with lentivirus carrying 
empty pTRIPZ doxocycline-inducible vector or pTRIPZ vector containing FBXW7 cDNA. Doxocycline was added 
24 h before cell lysis. GAPDH is shown as loading control. (C) Quantification of the RhoB levels from B. Bar 
graphs represent mean ± SD of RhoB expression from three individual experiments, all relative to GAPDH and 
normalized to sh control + mock condition. (D, E) Effect of loss of RhoA and RhoB in combination with FBXW7 
knockdown on basal endothelial barrier function. (E) Quantification of basal endothelial barrier function at 
t = 72 h. (F) Immunofluorescence staining of RhoB (green), F-actin (red), and nuclei (blue) in control and FBXW7 
knockdown HUVECs. Scale bar: 20 μm. Images are representative of three experiments. ECIS data represent 
average values (line graphs, representing barrier formation from medium change at 16 h after transfection 
[t = 0] until the end of the experiment) or mean ± SEM (bar graphs) of n = 4 experiments. *, p < 0.05, paired t 
test. **, p < 0.01, Dunnett’s post hoc analysis of one-way ANOVA.
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Figure 5 - FBXW7 knockdown induces activation of the cholesterol synthesis pathway. (A–D) HUVECs 
were transfected with siNT and siFBXW7 and cultured for 72 h. Total RNA was isolated, and expression of 
the indicated genes was determined by quantitative PCR. Each bar and error bar represent the mean ± SD 
(n = 3); *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. (E) Western blot of whole-cell lysates showing 
the effect of FBXW7 knockdown on expression of SQLE and LDLR in HUVECs. Representative blots from four 
experiments are shown. Actin is included as a loading control. Numbers represent mean from four individual 
experiments all normalized to siNT.
Stimulation of geranylgeranylation rescues disruption of endothelial barrier in 
FBXW7 knockdown cells
RhoB in ECs is mostly localized in vesicles; however, inhibition of RhoB ubiquitination 
redistributes RhoB predominantly to the plasma membrane [18]. In Figure 4B, we 
demonstrate that, in FBXW7 knockdown cells, the level of RhoB was increased, with the 
protein localizing both to and outside the vesicles. This finding, in combination with the 
up-regulation of the cholesterol pathway, led us to hypothesize that prenylation might play 
a role in redistribution of RhoB upon FBXW7 knockdown. Previously, it was shown that the 
cholesterol synthesis pathway and prenylation of RhoB are crucial for the regulation of RhoB 
levels [31]. RhoB can be either farnesylated by farnesyl transferase or geranylgeranylated 
by geranylgeranyl transferase. Therefore, we treated control and FBXW7 knockdown cells 
for 24 h with a farnesyl transferase inhibitor (FTI), a geranylgeranyl transferase inhibitor 
(GGTI), or a combination of both at 48 h after transfection. In control cells, we observed no 
differences in endothelial resistance following treatment with FTI. Although the addition 
of GGTI alone or in combination with FTI induced an initial drop in electrical resistance, 
there were no statistically significant differences at 24 h after addition (Figure 6, A and B). 




the 24 h during which they were monitored (Figure 6, C and D). When FTI was added to the 
FBXW7 knockdown cells, this drop was largely reversed, while no differences were seen with 
addition of GGTI alone or GGTI in combination with FTI compared with untreated FBXW7 
knockdown cells (Figure 6, C and D).
In subsequent experiments, we analyzed the effects of FTI and GGTI on RhoB protein levels. 
In untreated FBXW7 knockdown cells, we found increased levels of RhoB. Treatment with FTI 
slightly increased RhoB levels in control cells but did not further increase RhoB in FBXW7 
knockdown cells. Addition of GGTI to control cells, as well as combined treatment with 
FTI and GGTI, induced a more robust increase in RhoB protein levels compared with FTI 
treatment (Figure 6E).
Because prenylation is important for the localization of RhoB [13], we analyzed RhoB by 
immunofluorescence after addition of the inhibitors. FBXW7 knockdown cells resulted in 
more RhoB protein, stress fiber formation, and decreased VE-cadherin expression at the 
cell–cell contacts (Figure 6F; see also Figure 2). Treatment with FTI partially reduced stress 
fiber formation and restored the VE-cadherin distribution in FBXW7 knockdown cells (Figure 
6F). Treatment with GGTI and the combined treatment of FTI and GGTI resulted in increased, 
homogeneously distributed RhoB throughout the cell in both control and FBXW7 knockdown 
cells. In the FBXW7 knockdown cells, we observed decreased VE-cadherin intensity 
compared with control cells (Figure 6F). Because addition of FTI protected against the 
barrier-disrupting effect of the loss of FBXW7, possibly by induction of geranylgeranylation 
of RhoB, we hypothesized that addition of geranylgeranyl pyrophosphate (GGPP) might 
also restore the disruptive effect of FBXW7 knockdown. Indeed, addition of GGPP resulted 
in the restoration of barrier function in FBXW7 knockdown cells to control cell levels, while 
addition of farnesyl pyrophosphate (FPP) did not show any significant effects (Figure 6G). 
Together, these data suggest that, due to the increased generation of isoprenoids originating 
from the cholesterol synthesis pathway, which is induced upon FBXW7 knockdown, RhoB is 
increasingly farnesylated, resulting in the accumulation of (active) RhoB in ECs.
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Figure 6 - Endothelial barrier disruption is caused by impaired prenylation of RhoB in FBXW7 knock-
down cells. (A) Effect of FTI (10 μm; red), GGTI (10 μm; green), and FTI + GGTI combination (blue) on normalized 
barrier function of control cells. t = 0 corresponds to 48 h after transfection. (B) Endothelial barrier function 
after 24 h stimulation with FTI + GGTI. (C) Effect of addition of FTI (red), GGTI (green), and FTI + GGTI combi-
nation (blue) on normalized barrier function of FBXW7 (black) knockdown and control (dashed) cells. t = 0 is 
48 h after transfection. (D) Endothelial barrier function after 24 h stimulation with FTI + GGTI. (E) Western 
blot of whole-cell lysates showing the effect of FBXW7 knockdown and stimulation with FTI and GGTI on 
expression of RhoB in HUVECs. Representative blots from two experiments are shown. ERK1/2 is included as 
a loading control. Bar graph represents mean ± SD from two individual experiments all normalized to siNT. 
(F) Immunofluorescence staining of RhoB (green), F-actin (red), VE-cadherin (magenta), and nuclei (blue) in 
control and FBXW7 knockdown HUVECs stimulated with FTI, GGTI, or FTI + GGTI. Scale bar: 25 μm. Images are 
representative of three individual experiments. (G) Effect of GGPP (10 μm) and FPP (10 μm) on barrier function 
of control and FBXW7 knockdown cells. Data represent mean ± SD of n = 2 experiments performed in triplicate. 
In A–D data represent average values (line graphs, representing barrier function from addition of inhibitor 48 
h after transfection [t = 0] until the end of the experiment) or mean ± SEM of n = 3 experiments performed 




RhoB prenylation is impaired in FBXW7 knockdown cells
Changes in protein prenylation can be assessed by analyzing the lipophilic properties of the 
protein using Triton X-114 extraction. This method was recently applied to study prenylation 
of Rab7 in neurons [32]. First, we tested whether distribution of RhoB between detergent-
rich lipophilic and aqueous hydrophilic fractions is changed upon application of GGTI or FTI. 
We found that, in unstimulated cells, RhoB is predominantly detected in the detergent-rich 
lipophilic fraction (Figure 7A). Treatment of ECs with GGTI resulted in a complete shift of 
RhoB toward the aqueous fraction. In contrast, FTI did not change the distribution of RhoB 
between the aqueous and detergent-rich fractions. We then analyzed the distribution of 
RhoB in FBXW7 knockdown cells and found that the fraction of RhoB in the aqueous fraction 
was increased twofold when compared with control cells (Figure 7, B and C). Increased 
RhoB in this fraction in FBXW7 knockdown cells partially mimics geranylgeranyl transferase 
inhibition. In contrast, RhoA and RhoC are detected predominantly in the aqueous fraction 
and their lipophilic properties were not affected by FBXW7 knockdown.
Figure 7 - FBXW7 knockdown mimics impairment in RhoB prenylation induced by GGTI treatment. (A) 
Western blot showing RhoB expression in protein fractions obtained from HUVECs after Triton X-114 extraction 
followed by centrifugation on 6% sucrose cushion solution. The cells were pretreated with dimethyl sulfoxide, 
GGTI, or FTI for 18 h. P, Triton-insoluble pellet; A, aqueous fraction; and D, detergent-rich lipid droplet. GAPDH is 
shown as loading control. (B) Western blot of RhoA, RhoB, and RhoC in samples obtained as in A from HUVECs 
transfected with control or FBXW7 siRNA at 72 h posttransfection. (C) Quantification of RhoB immunoblot 
from B. Bar graph represents mean ± SD of RhoB expression in aqueous and detergent-rich fraction from 
three individual experiments, all relative to GAPDH and normalized to siNT. *, p < 0.05.
In summary, our data suggest a novel model of the regulation of endothelial barrier 
function by FBXW7 (Figure 8). Knockdown of FBXW7 leads to increased activation of the 
cholesterol synthesis pathway, likely a result of SREBP stabilization [29]. In this setting, 
more GGPP and FPP are available for prenylation, and as a consequence, RhoB is both 
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more geranylgeranylated and farnesylated. Because farnesylated RhoB is protected from 
degradation [16], the amount of active RhoB increases, leading to increased stress fiber 
formation and barrier disruption. FTI can counteract this effect by switching the equilibrium 
toward geranylgeranylation of RhoB, which drives inactive RhoB to vesicles. Addition of 
GGPP rescues the siFBXW7-phenotype by promoting geranylgeranylation of RhoB (Figure 8).
Figure 8 - Proposed model of regulation of endothelial barrier function by FBXW7. In quiescent en-
dothelium, SREBP is efficiently degraded via the proteasome because of FBXW7-mediated ubiquitination, so 
there is no or little activation of the cholesterol pathway. RhoB is expressed at low levels; the expressed RhoB is 
modified with a geranylgeranyl group to be inactive and stored in vesicles or with a farnesyl group to be active 
at the cell periphery. Upon loss of FBXW7, SREBP is stabilized, which results in activation of the cholesterol 
pathway by induction of HMCGR. Therefore, more GGPP and FPP is generated to modify RhoB. More RhoB 
will accumulate in the vesicles, but more RhoB will also be active at the cell periphery, inducing stress fiber 
formation and contraction. Addition of FTI will rescue this effect, because this induces geranylgeranylation of 
RhoB, an effect that is mimicked by GGPP. Addition of GGTI will lead to a switch toward farnesylation of RhoB 





We report here the results of an ECIS-based screen of esiRNA-mediated depletion of 62 F-box 
proteins in HUVECs. Our data show that, in this protein family, FBXW7 is a key positive regulator of 
endothelial barrier function. Knockdown of FBXW7 in resting ECs induces stress fiber formation 
and contractile actin ring formation, causing decreased barrier function both in resting and 
thrombin-stimulated cells. Depletion of FBXW7 also leads to up-regulation of RhoB protein 
levels and activation of the cholesterol synthesis pathway. The latter pathway is the source of 
isoprenoids, which are crucial modifiers of RhoB localization, activity, and stability [13, 14]. These 
findings suggest that RhoB prenylation might be affected in FBXW7 knockdown cells, which 
could result in increased activity of RhoB and subsequent disruption of the endothelial barrier.
In parallel, we found that RhoA and RhoC levels were decreased in FBXW7 knockdown cells. 
This might be caused by the regulatory interactions that exist between RhoA, RhoB, and RhoC, 
affecting their respective expression levels [27]. An siRNA-based F-box protein screen was 
previously performed to assess their effect on virus replication [33] and cell proliferation in 
several types of cancers [34, 35]. However, our study is the first to analyze the function of 
F-box proteins in the regulation of the endothelial barrier. In vivo work by Izumi and colleagues 
showed that an endothelial-specific knockout of FBXW7 leads to increased activation of the 
Notch pathway, which results in decreased angiogenesis [24]. In addition, Tsunematsu and 
coworkers reported that FBXW7 knockout mice are not viable due to impaired vascular 
development [36]. FBXW7 was also shown to be involved in regulation of angiogenesis, via 
ubiquitination of KLF2 in ECs [25]. Together, these previous findings already indicate that 
FBXW7 is an important pleiotropic regulator of vascular dynamics.
We recently reported that knockdown of FBXW7 by shRNAs leads to increased stress fiber 
formation [18]. Also, we found that inhibition of ubiquitination greatly increased the level of 
RhoB in ECs. In this situation, RhoB localizes diffusely throughout the cells and at the plasma 
membrane [18]. In the current study, we show that RhoB protein is increased and mainly 
detected in vesicles upon loss of FBXW7. This suggests that, besides ubiquitination of RhoB, 
additional mechanisms might regulate RhoB localization upon depletion of FBXW7 in ECs.
Given the known function of FBXW7 in controlling SREBP ubiquitination [29, 30], we tested 
whether the cholesterol synthesis pathway is affected in FBXW7 knockdown HUVECs [30]. 
Indeed, we found an increase in the SREBP-2–regulated program in siFBXW7-transfected 
ECs. This is in good agreement with data from Sundqvist and coworkers, who showed that 
depletion of FBXW7 stabilized SREBP in the nuclei of HCT116 cells and increased expression 
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of SREBP target genes like LDLR and HMGCR [29]. The same effect was described by Onoyama 
and colleagues, who found that knockdown of FBXW7 leads to liver steatosis and hamartoma 
development, due to hepatic accumulation of lipids [37].
FBXW7 regulates degradation of many target proteins (e.g., SREBP-1 and -2, Myc, Notch-1, and 
cyclin E), and this promiscuity of FBXW7 hinders clear dissection of the molecular mechanism 
behind the endothelial barrier disruption in FBXW7-depleted cells. Nevertheless, by using 
low-proliferating, close to confluent primary human ECs in low passages, we minimalized 
potential effects of FBXW7 loss on cell proliferation. Clear up-regulation of the cholesterol 
synthesis pathway, rescue of the phenotype by enhanced geranylation, and RhoB depletion 
all suggest that the impairment in the FBXW7-prenylated RhoB signaling axis plays a major 
role in disruption of endothelial barrier integrity upon FBXW7 depletion.
FTIs and GGTIs were previously used to study the effects of prenylation on expression and 
localization of RhoB. These studies have shown that FTI induces a shift toward geranylgeranylated 
RhoB, while GGTI leads to a shift toward farnesylated RhoB. As described previously, 
geranylgeranylated RhoB is localized in vesicles [14, 38]. Immunofluorescence staining in this study 
revealed that RhoB is localized in vesicles in FBXW7 knockdown cells, which resembles localization 
of RhoB in control cells treated with FTI. This suggests that there is more geranylgeranylated 
RhoB in FBXW7 knockdown cells when compared with control cells. Interestingly, addition of FTI 
to FBXW7 cells slightly decreased the levels of RhoB, suggesting that there is also farnesylated 
RhoB in FBXW7 knockdown cells and that farnesylation might protect RhoB from degradation. 
In accordance with this, addition of GGTI to the control and FBXW7 knockdown cells caused 
an increase in RhoB protein levels and localization of RhoB outside vesicles. GGTI treatment 
also caused a redistribution of RhoB from the detergent-rich lipophilic cell lysate fraction to 
the aqueous hydrophilic fraction. This was to some degree similar in FBXW7 knockdown cells, 
where RhoB also increased in the aqueous hydrophilic fraction. These findings suggest that 
both farnesylation and geranylgeranylation of RhoB are impaired in FBXW7 knockdown cells.
Knockdown of FBXW7 and/or stimulation with FTI and GGTI resulted in differential effects on 
actin stress fiber formation. The increased stress fiber formation in FBXW7 knockdown cells 
is likely due to increased expression of RhoB, as RhoB promotes stress fiber formation [27]. 
There is evidence that geranylgeranylated RhoB [39], as well as farnesylated RhoB, can induce 
stress fiber formation [16]. Because FTI treatment or supplementation of cell medium with 
GGPP partially rescue the contractile phenotype and loss of endothelial integrity in FBXW7 
knockdown cells, it is conceivable that the major form of RhoB, which induces contraction, 




toward the geranylgeranylated form of RhoB, which is translocated to intracellular vesicles for 
degradation. In contrast, addition of GGTI increases the farnesylated form of RhoB, which is 
less efficiently degraded and may induce contraction.
In conclusion, we found that perturbations in the FBXW7-regulated cholesterol synthesis 
pathway and, consequently, protein prenylation disrupt endothelial integrity. Altered 
prenylation of RhoB upon FBXW7 knockdown appears to be the main cause of this effect. 
This indicates that tight regulation of the expression and activity of RhoB levels is essential 
for the maintenance of endothelial integrity.
MATERIALS AND METHODS
Antibodies, reagents, and siRNAs
The following antibodies were used for immunostaining: α-VE-cadherin XP (#2500; Cell 
Signaling Technologies, Danvers, MA) and a-RhoB (#sc-8048; Santa Cruz Biotechnology, 
Santa Cruz, CA). Alexa Fluor 488 secondary antibody (anti-rabbit and anti-mouse) and Alexa 
Fluor 647 secondary antibody (anti-rabbit) (all Invitrogen) were the secondary antibodies.
The following antibodies were used for protein analysis: ß-actin (Merck), LDLR (Biovision), 
and SQLE (Proteintech). α-p44/42 MAPK (ERK1/2) (#9102), α-RhoA (#2117), α-RhoC (#3430), 
and α-GAPDH (#2118; Cell Signaling Technologies), α-RhoB (#sc-180, #sc-8048; Santa Cruz 
Biotechnology), α-HA (H3663), and α-vinculin (V4139; Sigma-Aldrich), α-Fbxw7 (ab171961; 
Abcam) and mouse α-ubiquitin (FK-2; Boston Biochem). HRP-conjugated goat–anti-rabbit 
antibody and goat–anti-mouse (Dako) were used as secondary antibodies.
For inhibition of geranylgeranylation and farnesylation, GGTI-298 and FTI-277 HCL (both 
Selleck Chemicals) were used. For normalization of prenylation in the FBXW7 knockdown 
cells, GGPP or FPP were applied (Sigma).
The siRNAs used were ON-TARGET plus Nontargeting pool (siNT), ON-TARGET plus Human 
FBXW7 pool (siFBXW7), ON-TARGET plus Human RHOA siRNA pool (siRhoA), ON-TARGET 
plus Human RHOB siRNA pool (siRhoB), and ON-TARGET plus Human FBXW7 siRNA—Set 
of 4 Upgrade (all Dharmacon/GE-Healthcare, Lafayette, CO).
Cell culture
Primary HUVECs were isolated from umbilical cords obtained from the department of 
obstetrics of the Amstelland Ziekenhuis (Amstelveen, The Netherlands). ECs were isolated 
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and cultured as described previously [40]. Informed consent was obtained from all donors 
in accordance with the institutional guidelines and the Declaration of Helsinki. After isolation, 
cells of three different donors were pooled and cultured on 1% gelatin-coated plate in M199 
medium supplemented with 100 U/ml penicillin and 100 μg/ml streptomycin, 2 mmol/l 
l-glutamine, 10% heat-inactivated newborn calf serum (all Lonza, Verviers, Belgium), 10% 
heat-inactivated human serum (Invitrogen), 150 μg/ml crude endothelial growth factor 
(prepared from bovine brains), and 5 U/ml heparin (Leo Pharmaceutical Products, Breda, 
The Netherlands). Cells were cultured at 37°C and 5% CO2 with the medium changed every 
other day. For all experiments, pools of three donors were used in passage 2 or 3.
HEK293T cells (American Type Culture Collection) were cultured in DMEM (Life Technologies) 
supplemented with 100 U/ml penicillin and 100 μg/ml streptomycin, 2 mM l-glutamine 
(all Lonza), 1 mM sodium pyruvate (Life Technologies), and 10% fetal bovine serum (PAA 
Laboratories).
esiRNA screen
A custom MISSION esiRNA library (Sigma-Aldrich) targeting 62 human F-box proteins 
was ordered on a 96-well microtiter plate (Table 1). EGFP and KIF11 esiRNAs were used 
as controls. Subconfluent p1 HUVECs were seeded on 1% gelatin–coated 96 W10idf ECIS 
arrays (Applied Biophysics, Troy, NY) in complete medium, 24 h before transfection. Forward 
transfection of esiRNAs with DharmaFECT 1 was performed according to the manufacturer’s 
instructions using esiRNA at 100 ng final concentration and 0.2% (vol/vol) of DharmaFECT 1 
transfection reagent (Dharmacon/GE-Healthcare) in 100 μl total volume. After 16 h, medium 
was replaced by normal culturing medium to avoid toxicity.
Transfection with siRNA
HUVECs were transfected with DharmaFECT 1, according to the manufacturer’s protocol 
(Dharmacon/GE-Healthcare). Transfection was performed with a final concentration of 25 
nM siRNA and 0.2% (vol/vol) DharmaFECT 1 in 10% NBCSi/M199 per condition. Transfection 
was done on cells that were ~80% confluent in 96-well, 12-well and six-well format. Medium 
was replaced after 16 h of transfection with regular cell culture medium to avoid toxicity.
Endothelial barrier function assays
Endothelial barrier function was measured with ECIS and passage of HRP. For ECIS 
measurements, cells were seeded at 1:1 density on gelatin-coated 96-well ECIS plates or 
eight-well arrays containing gold intercalated electrodes (Applied Biophysics). At 24 h after 




transfection, cells were serum-starved with M199 supplemented with 1% human serum 
albumin (HSA; Sanquin CLP) for 90 min. Subsequently, a thrombin mix was added to the wells 
with a final concentration of 1 U/ml (Sigma-Aldrich). During the growth phase, resistance 
was measured at multiple frequencies to allow calculation for changes in cell–cell adhesion 
(Rb) and cell–matrix interaction (α).
For measurement of HRP passage, ECs were transfected in a six- or 12-well plate for 
24 h before passaging 2:1–1% gelatin–coated 0.33 cm2 polyester ThinCerts cell culture 
inserts (Greiner Bio-one) with a pore size of 3.0 µm. Approximately 72 h after the start of 
transfection, cells were serum-starved with 1% HSA/M199, which was added to the filters 
for 60 min. Before stimulation, medium in the upper compartment was replaced with 1% 
HSA/M199 containing 5 µg/ml HRP (Sigma-Aldrich) and 1 U/ml thrombin or a vehicle control; 
1% HSA/M199 was added to the lower compartment. A sample was taken from the lower 
compartment at different time points. The HRP concentration was calculated by measuring 
absorption after adding tetramethylbenzidine (Upstate/Millipore) and sulfuric acid.
Triton X-114 protein extraction
This experiment was performed with some modifications according to Mohamed et al. 
(2018) [32]. In brief, confluent monolayers of primary HUVECs seeded on 10 cm2 culture 
wells were lysed on ice in Triton X-114–containing lysis buffer (20 mM Tris-HCl, pH 7.5, 150 
mM NaCl, 1% Triton X-114, and protease inhibitor cocktail [Roche]). Cells were scraped, and 
lysates were briefly centrifuged at 13,000 × g. Triton X-114–insoluble pellet (P) was dissolved 
in sample buffer. Supernatant was carefully loaded on 6% cushion solution (20 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 6% sucrose, 0.06% Triton X-114, and protease inhibitor cocktail) 
and incubated for 10 min at 37°C. After 5 min centrifugation at 16,000 × g, fractions were 
separated into aqueous (A) supernatant and detergent-rich lipid-containing droplet (D). All 
fractions were boiled with sample buffer and analyzed by immunoblotting. Before lysis, 
HUVECs were transfected with control or FBXW7 siRNA pools as described before or treated 
with GGTI or FTI for 24 h.
RhoB in vivo ubiquitination assay
HEK293T cells were cotransfected with mCherry-RhoB [18], hemagglutinin (HA)-ubiquitin [18], 
and FBXW7 plasmids (generous gift of C. Nicot, University of Kansas Medical Center) using 
Trans-IT-LT1 (#MIR 2300; Mirus) following the manufacturer’s protocol. The next day, cells 
were treated with 2.5 μm MG132 for the last 4 h, and denaturing HA-immunoprecipitation 
was performed as described previously [18].
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Lentiviral shRNA FBXW7 knockdown and overexpression
For the rescue experiment, we transduced ECs with shRNA targeting the 3′UTR of FBXW7 
(TRCN0000355644; Sigma Mission Library, Sigma-Aldrich). Lentiviral particles were produced 
by transfecting HEK293T cells with the third generation HIV-1 packaging plasmids (Addgene), 
using Trans-IT-LT1 (Mirus) as previously described [18]. For FBXW7 lentiviral overexpression, 
doxocycline-inducible pTripZ-FBXW7 (generous gift of C. Nicot, University of Kansas Medical 
Center) was packed into lentiviral particles using the same protocol. To induce the expression 
of FBXW7, 2 μg/ml doxocycline was added for 24 h to the cell medium.
Immunoprecipitation of RhoB
Immunoprecipitation of endogenous RhoB was performed with rabbit α-RhoB antibody 
(Santa Cruz Biotechnology) from confluent 60 cm2 dishes of primary HUVECs transfected 
with control siRNA or FBXW7 siRNA. Proteasomal degradation was inhibited by adding 5 
µM MG132 at 2 h before lysis. Upon stimulation, cells were washed in phosphate-buffered 
saline (PBS) containing 1 mM CaCl2 and 0.5 mM MgCl2 and lysed in lysis buffer (50 mM Tris, 
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP40, complete protease inhibitor cocktail tablets 
[Roche]) and phosphatase inhibitors (1 mM Na3VO4 and 25 mM NaF). Lysates were cleared 
by centrifugation and incubated with 1 µg RhoB antibody for 2 h at 4°C. RhoB-containing 
complexes were pulled out by incubation with Dynabeads protein G (Thermo scientific) for 
1 h at 4°C. Finally, beads were washed four times with lysis buffer, and immunoprecipitated 
proteins were eluted with sample buffer and analyzed with SDS–PAGE.
Protein analysis
For analysis of protein levels, cells were seeded in 5 or 10 cm2 culture wells and transfected 
as described earlier. At 72 h posttransfection, cells were washed with cold PBS and whole-
cell lysates were collected by scraping the cells in the presence of 2X SDS sample buffer. 
Protein samples were loaded on 12.5% SDS–PAGE gels or NuPAGE Novex 4-12% Bis-Tris 
gels (Invitrogen), electrophoresed, and transferred to nitrocellulose membranes. Protein 
analysis was performed by incubation of the nitrocellulose membranes with the designated 
antibodies. Bands were visualized with enhanced chemiluminescence (Amersham/GE-
Healthcare) on an AI600 machine (Amersham/GE-Healthcare).
Immunofluorescence imaging of cultured ECs
Transfected cells were seeded on 2 cm2 and 12-mm glass coverslips (Menzel), coated with 
1% gelatin and cross-linked with 0.5% glutaraldehyde (Sigma-Aldrich), ~24 h after the start 
of transfection. Cells were grown for 48 h with complete medium to reach the transfection 




to the wells in a final concentration of 1 U/ml. After 15 min or 3 h, cells were fixed with warm 
(37°C) 4% paraformaldehyde (PFA; Sigma-Aldrich) and put on ice for 15 min. The PFA was 
washed away with PBS, and cells were permeabilized with 0.2% Triton X-100 in PBS (Sigma-
Aldrich) and blocked for 30 min with 1% bovine serum albumin (BSA). Then, coverslips 
were stained with primary antibodies against VE-cadherin or RhoB (in 0.1% BSA/PBS) for 
1 h at room temperature. After being washed three times, the cells were incubated with 
a fluorescein isothiocyanate–labeled secondary antibody (anti-rabbit or anti-mouse 1:100 
in 0.1% BSA/PBS) and Acti-stain phalloidin (direct staining, in 0.1% BSA/PBS [Tebu Bio]) 
at room temperature. After being washed, the cells were incubated with 4′,6-diamidino-
2-phenylindole (DAPI; Thermo Fisher Scientific) at room temperature. Coverslips were 
mounted with Mowiol4-88/DABCO solution (Calbiochem, Sigma-Aldrich). Confocal-scanning 
laser microscopy was performed on a Nikon A1R confocal microscope (Nikon). Images were 
analyzed and equally adjusted with ImageJ.
RNA isolation and quantitative PCR
Isolation of total RNA and subsequent real-time quantitative PCR were done as previously 
reported [40]. Sequences of quantitative PCR primers are available on request.
Statistical analysis
For the esiRNA screen, the observed values (n = 4) were compared with the EGFP controls 
by a Student’s t test, after which the p values were corrected for multiple testing by using a 
Benjamini-Hochberg FDR set to <0.05.
For the other experiments, data are represented as mean ± SEM unless indicated otherwise. 
Comparison of two conditions was tested by Student’s t test. Comparison of more than 
two conditions was tested by one-way analysis of variance (ANOVA) or repeated-measures 
ANOVA with Dunnett’s post hoc test. The p values were considered statistically significant 
if p < 0.05. Analysis was performed using GraphPad Prism software.
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FOOTNOTES
This article was published online ahead of print in MBoC in Press (http://www.molbiolcell.
org/cgi/doi/10.1091/mbc.E18-04-0259) on January 2, 2019.
Abbreviations used:
AJ  adherens junction
ANOVA  analysis of variance
BSA  bovine serum albumin
EC  endothelial cell
ECIS  electrical cell–substrate impedance sensing
esiRNA  endoribonuclease-prepared small interfering RNA
esiEGFP  esiRNA targeting enhanced green fluorescent protein
FDR  false discovery rate
FPP  farnesyl pyrophosphate
FTI  farnesyl transferase inhibitor
GAP  GTPase-activating protein
GEF  guanine-nucleotide exchange factors
GGPP  geranylgeranyl pyrophosphate
GGTI  geranylgeranyl transferase inhibitor
HA  hemagglutinin
HRP  horseradish peroxidase
HSA  human serum albumin
HUVEC  human umbilical vein endothelial cell
LDLR  low-density lipoprotein receptor
PBS  phosphate-buffered saline
PFA  paraformaldehyde
shRNA  short hairpin RNA
siNT  nontargeting siRNA
siRNA  small interfering RNA
SQLE  squalene epoxidase
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SUPPLEMENTAL FIGURES
Supplemental Figure 1: shRNA-mediated depletion of GFP, FBXW7 and Fbxl19 affects endothelial barrier 
integrity. 72 hours after infection with lentiviral particles carrying shRNA control, shRNA targeting FBXW7 or 
shRNA targeting FBXL19 cells were seeded on 8-well ECIS arrays and endothelial resistance was measured 
for 15 hours at 4000 Hz. Data represents mean ±sd of n=3-6 measurements. Lentivirus production and the 
constructs used for this experiment have been described in detail in Kovacevic et al. [18].
Supplemental Figure 2: shRNA-mediated knockdown of FBXW7 induces changes of actin cytoskeleton 
morphology in endothelial cells. Primary HUVECs were infected with lentiviral particles carrying either eGFP 
cDNA (control) or shRNAs targeting FBXW7 and stained for F-actin (red) and VE-cadherin (white). Lentivirus 
production and the constructs used for this experiment have been described in detail in Kovacevic et al. [18].
Supplemental Figure 3: A) Western blot of whole cell lysates showing the effect of single siRNA clones 
targeting FBXW7 on RhoB and RhoA expression at 72 hours post-transfection. GAPDH is shown as loading 
control. B) Effect of transfection of single siRNA clones targeting FBXW7 on barrier function. Data represent 
mean ±SD of n=3 experiments performed in triplicate at 72 hours after transfection. * p<0.05, *** p<0.001, 




Supplemental Figure 4: A) Denaturing co-immunoprecipitation of ubiquitin and RhoB. HEK293T cells were 
co-transfected with HA-ubiquitin, mCherry-RhoB and FBXW7. Input is equal to 2.0 % of the lysate used for 
immunoprecipitation. Samples were analyzed by immunoblotting for RhoB using anti-RhoB antibody. GAPDH 
immunoblot was used as a control. B) Western blot showing ubiquitination of endogenous RhoB in HUVECs. 
RhoB was immunoprecipitated from lysates of HUVECs transfected with control or FBXW7 siRNA at 72 hours 
post-transfection. Input is equal to 2.0 % of the lysate used for immunoprecipitation. Ubiquitinated proteins 
were detected using Ubiquitin (FK-2) antibody. Poly-ubiquitinated RhoB is indicated on the right. Vinculin is 
shown as loading control.
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Signaling by the Rho GTPase Rac1 is key to the regulation of cytoskeletal dynamics, cell 
spreading and adhesion. As part of its cycling between the active and inactive state, Rac1 
activation is regulated by binding to the Rho Guanine nucleotide Dissociation Inhibitor (GDI). 
It is widely accepted that the inactive form of Rac1 is bound by Rho GDI, which prevents 
Rac1 activation and Rac1-effector interactions. In addition, GDI-bound Rac1 is protected 
from proteasomal degradation, in line with data showing that Rac1 ubiquitination occurs 
exclusively when Rac1 is activated. We set out to investigate how Rac1 activity, GDI binding 
and ubiquitination are linked. Since WT Rac1 is minimally ubiquitinated, we introduced single 
amino acid mutations in Rac1 which were reported previously to increase Rac1 activity to 
different levels, and compared how the level of Rac1 activity relates to Rac1 ubiquitination 
and GDI binding. Similarly, we introduced lysine-to-arginine mutations in activated Rac1 
to inhibit site-specific ubiquitination, and to establish if ubiquitination of Rac1 affects its 
activity. Morphological effects of the Rac1 mutations were shown in adherent and spreading 
endothelial cells. Our data show that a strong, positive correlation exists between Rac1 
activity and its level of ubiquitination, but also that GDI dissociation does not predispose 
Rac1 to ubiquitination.
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INTRODUCTION
Regulation of the actin cytoskeleton underlies essential aspects of eukaryotic cell 
behavior, including supporting cell structure and enabling directional migration. The main 
orchestrators of cytoskeletal rearrangements are the Rho GTPases, each with distinctive 
regulatory features. Signaling by the small Rho GTPase Rac1 typically induces cell spreading, 
whereas activity of its closely related siblings RhoA and RhoB induces stress fiber formation 
and cell contraction [1, 2]. Rho GTPases cycle between a GDP-bound ‘off’ state and a GTP-
bound ‘on’ state. When GTP-bound, the conformation of Rho GTPases allows for their 
interaction with downstream effectors. The exchange of GDP for GTP, activating the GTPase, 
is catalyzed by Guanine nucleotide Exchange Factors (GEFs). The intrinsic GTPase activity 
of Rho GTPases, driving the hydrolysis of GTP to GDP, is accelerated by so-called GTP-ase 
Activating Proteins (GAPs) [3].
In a resting cell, 90-95% of the Rac1 GTPase is inactive. In this inactive state, Rac1 is bound to 
a Guanine nucleotide Dissociation Inhibitor (GDI) which prevents both its interaction with the 
plasma membrane and its activation by GEFs [4, 5]. Rho GTPases require to be associated 
to a membrane to release the RhoGDI and undergo GEF-mediated activation. Whereas 
most models of the Rac1 activation cycle suggest that active Rac1 is not bound by the GDI, 
several papers have shown an interaction between a constitutively active Rac1 (G12V) and 
the GDI and a lack of GDI binding by the constitutively inactive mutant of Rac1 (T17N) [6-8].
In addition to its regulation by GEFs, GAPs and the GDI, post-translational modification 
(PTMs) of Rac1 has gained increasing interest, providing additional insights in its regulation 
[9]. Rac1, similar to many other small GTPases, is modified by C-terminal lipidation, which 
is involved in both GDI binding as well as Rac1-membrane association. In addition, Rac1 
is subject to post-translational modification by the covalent attachment of ubiquitin or 
ubiquitin-like proteins.
Ubiquitination has, so far, mainly been implicated in the proteasome-mediated degradation 
of the active, but not the inactive, form of Rac1 [10-12]. Several ubiquitin E3 ligases have been 
linked to the regulation of Rac1. Members of the inhibitor of apoptosis protein family (IAPs) 
[12] and the E3 HECT ligase HACE1 ubiquitinate active Rac1 at K147, targeting the protein for 
proteasomal degradation [13, 14]. In contrast, however, the E3 ligase TRAF6 was suggested 




Both the use of Rac1-activating stimuli (e.g., growth factors or bacterial toxins) and of 
‘constitutively active’ mutants have facilitated studies on Rac1 signaling. The constitutively 
active Rac1 Q61L mutant, which is incapable of GTP hydrolysis, has been used widely in 
fundamental studies on the cellular consequences of Rac1 signaling. However, experiments 
with this Rac1 mutant may give an incomplete view, as GTP/GDP cycling is an important 
aspect of Rho GTPase regulation and signaling [16]. Another, commonly used, dominant 
active version of Rac1 has a G12V mutation, in which GTP hydrolysis activity is 6-fold 
decreased as compared to Rac1 WT [16].
In addition to these well-known Rac1 Q61L and G12V mutations, several other ‘activating’ 
mutations of Rac1 have been identified, a.o. in cancer patients. The Rac1 F28L and P29S 
mutations have been extensively analyzed in vitro. These mutations induce rapid GDP 
dissociation and fast GDP-GTP cycling, ultimately increasing the activity of Rac1 [17-19]. 
Tyrosine phosphorylation of Rac1 at Y64 has been linked to its inactivation. Mutation of 
Y64 to a non-phosphorylatable phenylalanine (Y64F) leads to decreased GDI binding, and 
has been proposed to increase Rac1-GTP levels [20]. Similarly, mutation of R66 inhibits the 
binding of GDI to Rac1, theoretically exposing it to activation and/or degradation [21]. The 
oncogenic, activating Rac1 N92I mutation was discovered in the human sarcoma cell line 
HT1080 [22] and the C157Y mutation was discovered in patients with cranial malformations 
and has, as yet, unclear effects on Rac1 activity [22, 23]. All these single amino acid mutations 
affect Rac1 activity by different, but in some cases poorly defined, means. Analysis of these 
Rac1 mutants may provide new insights in Rac1 regulation and signaling.
In this study, we analyzed two sets of Rac1 mutants: (i) a series of Rac1 mutants encoding 
different activating mutations, and (ii) a set of lysine-to-arginine (K-R) mutants in activated 
Rac1 to prevent its ubiquitination. We expressed these mutant proteins and the appropriate 
controls in human endothelial cells (ECs) and analyzed (i) their localization, activity, and 
ubiquitination, and (ii) effects of the mutations on GDI binding and induction of endothelial 
cell spreading. Our data reveal a strong correlation between the level of Rac1 activity and 
(i) its level of ubiquitination and (ii) its morphological effects in endothelial cells. RhoGDI 
binding, however, does not correlate with ubiquitination of or downstream signaling by 
activated Rac1 mutants. These data show that the activity of Rac1, rather than its interaction 
with RhoGDI, determines its signaling capacity and susceptibility to ubiquitination.
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RESULTS
Rac1 activity is regulated by the ubiquitin-proteasome system.
Our group previously showed that inhibition of the family of Cullin E3 ubiquitin ligases, 
either by using the small molecule inhibitor MLN4924 or by Cullin-3 knockdown, dramatically 
impairs the integrity of endothelial monolayers. We identified Cullin-3 as the specific 
ubiquitin E3 ligase for the GTPase RhoB and showed that decreased levels of Cullin-3 
activity induced a rapid increase in RhoB protein level and activity with consequent, F-actin 
mediated contraction and disruption of the endothelial monolayer [25]. In contrast to 
RhoB, Rac1 activity is linked to strengthening of the endothelial barrier [26, 27]. Since active 
Rac1 is prone to ubiquitination, we tested whether the application of general inhibitors of 
the ubiquitin-proteasome system (UPS) would influence Rac1 activity in endothelial cells. 
We treated stable HUVEC monolayers with MG132 (proteasome inhibitor), MLN7243 (E1 
ubiquitin activating enzyme inhibitor), PR619 (Deubiquitinating (DUB) enzyme inhibitor) or 
a combination of PR169 and MG132 and measured Rac1 activity by CRIB pulldown (Figure 
1A and 1B). Total levels of Rac1 were unchanged, but we observed a clear increase in Rac1 
activity induced by MLN7243, and a decrease in Rac1 activity induced by PR619. Inhibition of 
proteasomal degradation by MG132 slightly elevated Rac1 activity levels, but simultaneous 
treatment of PR619 and MG132 was similar to PR619 treatment only. These data show 
that short-term inhibition of the cellular machinery that controls (de-)ubiquitination has 
differential effects on Rac1 activity in ECs, without significantly affecting Rac1 levels. This 
suggest that, in addition to GEF- and GAP-mediated regulation of Rac1 activity, direct or 
indirect modification by ubiquitin plays an important role in the induction and/or stability 
of the GTP-bound, active form.
Rac1 activity levels correlate positively with Rac1 ubiquitination
After analyzing the effect of inhibitors of the UPS system on Rac1 activity, we set out to 
investigate whether differential Rac1 activity levels could be regulating its ubiquitination. 
We introduced single amino acid mutations in mCherry-Rac1 that were previously identified 
in, a.o., cancer patients, and were found to increase Rac1 activity (Figure 2A,B). We next 
compared their activity by performing CRIB pulldown assays after expression in HEK293T 
cells (Figure 2C). As supported by published literature, we found different levels of mCherry-
Rac1 activation in the different mutants when compared to WT mCherry-Rac1. Rac1 G12V 
and Q61L, included as positive controls, showed an average 9.0- and 11.2-fold increase in 
Rac1 activity compared to Rac1 WT, respectively, followed by Rac1 N92I with an 8.5-fold 
increase in activity. Rac1 C157Y showed a 5.7-fold increase, followed by Rac1 F28L with a 4.6-




by others [20, 21], we did not find an increase in activity for Rac1 Y64F and R66A. The Y64F 
mutation even decreased Rac1 activity to 0.8 compared to WT, close to the 0.7-fold change 
by the constitutive inactive mutant T17N. The increase in activity of Rac1 R66A was 1.1-fold 
compared to WT.
Figure 1 - Rac1 activity is regulated by the ubiquitin-proteasome system. A) Representative western 
blot analysis of Rac1-GTP by CRIB pulldown (PD). HUVECs were treated for 2 hrs with the indicated inhibitors 
and pulldown of endogenous active Rac1 was performed as described in materials and methods. B) Quantifi-
cation of Rac1 activity by densitometric analysis of western blot after CRIB pulldown (n=4). * p<0.05 compared 
to control in Holm-Sidak’s post-hoc test of one-way ANOVA.
We next performed a ubiquitination assay for the same Rac1 mutants (Figure 2D) and found 
that, as shown before [28], Rac1 Q61L ubiquitination is significantly increased (2.2-fold) 
compared to Rac1 WT. In addition, we observed a significant 1.4-fold increased ubiquitination 
of Rac1 G12V and N92I compared to WT. Rac1 R66A was less ubiquitinated than WT, namely 
0.8-fold, comparable to T17N. Total ubiquitination of Rac1 F28L, P29S, Y64F and C157Y was 
not significantly changed (1.0-. 1.3-, 1.1-, and 0.9- fold compared to WT, respectively) but 
correlation analysis of activity versus ubiquitination of all Rac1 activating mutants showed a 
significant, positive correlation, meaning that increased activity is correlated with increased 
ubiquitination (R2 = 0.2894, p=0.0003) (Figure 2E).
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Figure 2 - Relationship between activity and ubiquitination of Rac1 in vivo. A) Predicted effects of 
the introduced Rac1 mutations on Rac1 cycling and activity. B) Amino acid sequence of Rac1 with indicated 
G1-G5, switch-1 and -2 and insert regions and highlighted amino acids mutated to activate (green) or inacti-
vate (orange) Rac1. C) Representative Western blot and quantification of CRIB pulldown of mCherry-Rac1 and 
mutants after overexpression in HEK293T. * p<0.05, ** p<0.01, *** p<0.005 and **** p<0.001 in Holm-Sidak’s 
post-hoc test of one-way ANOVA. D) Representative Western blot and quantification of in vivo ubiquitination 
assay of mCherry-Rac1 and the indicated mutants after expression in HEK293T. ** p<0.01 and **** p<0.001 
in Holm-Sidak’s post-hoc test of one-way ANOVA. E) Correlation graph with linear regression of the ubiquiti-




Rac1 activating mutants differentially bind RhoGDI
It is widely accepted that Rac1-GDP binds to the GDI, whereas Rac1-GTP is not GDI bound, 
and can therefore associate with the plasma membrane and downstream effectors [5]. We 
investigated GDI binding of the mCherry-Rac1 activating mutants by performing a mCherry 
co-IP with endogenous GDI protein in HEK293T cells (Figure 3A,B). We found that the Rac1 
mutants T17N, Q61L and R66A did not, or very little, bind the GDI, which is in accordance 
with previous research [6]. Rac1 N92I and C157Y bound the GDI to a similar extent as Rac1 
WT, and the GDI-binding capacity of Rac1 G12V, F28L, P29S and Y64F was approximately 
50% reduced compared to Rac1 WT (Figure 3A,B).
Figure 3 - In vivo GDI binding properties of Rac1 activating mutants. A and B) Representative Western 
blot (A) and quantification (B) of mCherry-Rac1 Co-IP with endogenous RhoGDI. MCherry-Rac1 was expressed 
in HEK293T cells, after which CO-IP for mCherry was performed as described in materials and methods. *p< 
0.05, ** p< 0.01 and **** p<0.001 in compared to WT in Holm-Sidak’s post-hoc test of one-way ANOVA (n=3).
All activating mutants except for F28L and R66A induce an active Rac1 
phenotype in endothelial cells
Rac1 activity induces cell spreading and membrane ruffling, consequent to its induction 
of cortical actin polymerization. After testing the activity, ubiquitination and GDI binding 
of the Rac1 mutants in HEK293T cells, we investigated the morphological effects of these 
proteins upon expression in HUVECs seeded at low density to allow analysis of individual 
cell size and shape (Figure 4A). Between the mutants, we did not observe a significant 
difference in cell size, in part since the spread of the data is considerable (Figure 4B). As 
expected, the mutations G12V and Q61L induced clear lamellipodia formation in HUVECs 
and the concomitant cell morphology is markedly circular. The N92I mutation induced a 
phenotype similar to G12V and Q61L, as deduced from the quantification of cell shape 
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solidity as description for cell deformability (Figure 4C)[29] . Interestingly, the P29S mutation 
showed a clear active Rac1 phenotype compared to Rac1 WT whereas the increase in solidity 
of Rac1 F28L was only moderate, although these mutations induced a similar increase in 
Rac1 activity, based on binding to the CRIB peptide (Figure 2C). Additionally, Rac1 Y64F 
activity was not increased in the CRIB pulldown compared to Rac1 WT but this mutant, be 
it only moderately, increased HUVEC shape solidity. Rac1 C157Y mutation also increases the 
solidity of the cell shape compared to Rac1 WT. As expected, the morphology of HUVECs 
expressing Rac1 T17N and Rac1 R66A was similar to cells expressing Rac1 WT. A correlation 
plot of the Rac1 activity measured by CRIB pulldown versus the HUVEC solidity shows a 
significantly positive correlation (R2= 0.7235, p = 0.0018), indicating that the measurement 
of Rac1 activity by CRIB pulldown is a valid indication for its biologically relevant activity.
Ubiquitination of proteins generally occurs on lysine residues that are exposed on the 
surface of the protein and thus accessible to the ubiquitin ligase [30]. Following our analysis 
of the correlation between Rac1 activity levels and Rac1 ubiquitination, we investigated 
whether the individual mutation of a selection of surface-exposed lysine residues in 
constitutively active Rac1 Q61L would alter its expression or activity. We introduced lysine 
(K) to arginine (R) point mutations in myc-Rac1 Q61L based on published literature and on 
the tertiary structure of Rac1 (Figure 5A and 5B). The K to R mutation ensures that ubiquitin 
attachment is prevented while retaining a positive charge at that specific location in the 
protein to minimize the effect of the mutation on the tertiary structure of Rac1. As shown 
in Figures 2-4, Rac1 Q61L does not bind the GDI, is most active and is most ubiquitinated, 
which is why we choose this mutant as background for the K to R mutations.
Mutation of lysine 16 of Rac1 impairs both ubiquitination and activity of 
constitutively active Rac1.
We observed a significant increase in total ubiquitination of the myc-tagged Rac1 Q61L 
compared to WT as was shown previously [28] (Figure 5C). This increase was absent when 
lysines 16 or 147 in Rac1 Q61L were mutated (0.4- and 0.6- fold compared to Rac1 Q61L). 
Conversely, we found that the introduction of the K133R and K166R mutation increased 
total Rac1 Q61L ubiquitination levels 1.6- and 1.9-fold, respectively. The total ubiquitination 
of Rac1 Q61L/K183R and Rac1 Q61L/K184R was unchanged.
The activity of Rac1 Q61L/K16R and Q61L/K166R was significantly decreased compared 
to Rac1 Q61L (0.15- and 0.45-fold, respectively) while the activity of Rac1 Q61L/K184R was 
increased (1.2-fold) (Figure 5D) as measured by CRIB pulldown from transfected HEK293T 




The lack of Rac1 Q61L/K147R ubiquitination is in line with published literature, while the loss 
of ubiquitination of Rac1 Q61L/ K16R was less expected. Rac1 K16, but not K147, has been 
proposed to be subject to TRAF6-mediated ubiquitination. However, in our studies, Rac1 
Q61L/K147R is not ubiquitinated, even with the K16 residue intact. Based on these and the 
CRIB pulldown data, we conclude that the lack of K16 ubiquitination is primarily due to a 
loss of its GTP-binding capacity.
Figure 4 - Rac1 G12V, Q61L and N92I mutants induce comparable morphology change in HUVECs. 
A) Immunofluorescent analysis of mCherry (red) and F-actin (gray) of HUVECs with transient overexpression 
of mCherry-Rac1 and mutants. Scale bar represents 50 µm. B) Quantification of cell size defined by surface 
area covered. C) Quantification of cell shape solidity of > 20 cells per sample. **p<0.01 and **** p<0.001 
compared to WT in Holm-Sidak’s post-hoc test of one-way ANOVA. D) Correlation graph with linear regression 
of the solidity versus activity levels of mCherry-Rac1 activating mutants.
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Figure 5 - Single K-to-R mutations alter Rac1 ubiquiti-
nation and activity. A) Amino acid sequence of Rac1 with 
indicated G1-G5 regions, switch-1 and -2 and insert regions 
and (highlighted) lysine residues that were mutated to arginine. 
B) Tertiary structure of GTP-bound Rac1 with arrows pointing 
to the mutated lysines. Rac1 structure was obtained from the 
Rac1/PRK1 complex crystal structure 2RMK from RCSB protein 
data bank (rcsb.org) C) Representative Western blot and quanti-
fication of the ubiquitination assay. Myc-Rac1 and HA-Ubiquitin 
were expressed in HEK293T, after which denaturing HA immu-
noprecipitation was performed, followed by Western blot of the immunoprecipitates for myc-Rac1. * p<0.05 
and ** p<0.01 after Holm-Sidak’s post-hoc analysis of one-way ANOVA (n=3). D) Representative Western blot 
and quantification of CRIB pulldown from overexpressed myc-Rac1 in HEK293T cells. ** p<0.01 and **** 
p<0.001 after Holm-Sidak’s analysis of one-way ANOVA (n=4). E) Representative Western blot of co-IP showing 




Based on the decrease in Rac1 activity of myc-Rac1 Q61L/K16R and Q61L/K166R, we 
questioned whether these mutants would bind to RhoGDI. As previously shown by others, 
Rac1 Q61L does not interact with the GDI, whereas the wild type Rac1 protein does (Figure 
5E) [7]. Interestingly, the Q61L/K16R Rac1 mutant shows a modest recovery of GDI binding 
compared to Rac1 Q61L, but we found no change in GDI binding for Rac1 Q61L/K166R. This 
indicates that GDI binding does not correlate with a change in Rac1 activity of these K to R 
mutants.
Figure 6 - Morphological effects of myc-Rac1 K-R mutants in HUVECs. A) Immunofluorescent analysis 
of myc (green) and F-actin (gray) of HUVECs with transient overexpression of myc-Rac1 and mutants. Scale 
bar represents 50 µm. B) Quantification of cell size defined by surface area covered. C) Quantification of cell 
shape solidity of > 5 cells per sample. **** p<0.001 compared to WT in Holm-Sidak’s post-hoc test of one-
way ANOVA. D) Correlation graph with linear regression of the solidity versus activity levels of mCherry-Rac1 
activating mutants.
To investigate morphological effects of the myc-Rac1 Q61L K to R mutants, we expressed the 
proteins in HUVECs (Figure 6A). Upon transient expression, myc-Rac1 Q61L clearly induces 
the expected phenotype including membrane ruffling and circumferential cell spreading, 
represented by the solidity parameter. The decrease in Rac1 activity in Rac1 Q61L/K16R, 
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as compared to Rac1 Q61L (Figure 5D), was clearly reflected in the HUVEC phenotype. The 
decrease in activity of Rac1 Q61L/K166R had limited effects on HUVEC solidity, which was 
not statistically significant. No change in overall cell size was observed for any of the Rac1 
Q61L K-R mutants (Figure 6B).
The solidity of ECs expressing Rac1 Q61L/K16R was significantly decreased compared to Rac1 
Q61L (Figure 6C), while for all other mutants, there was no significant change in endothelial 
cell shape. We found a significant, positive correlation (R2 = 0.8146, p = 0.0021) between the 
activity of the myc-Rac1 Q61L K-R mutants as measured by CRIB pulldown, and the solidity 
of HUVECs expressing the same mutants (Figure 6D). Together, these data show that, in 
addition to ubiquitination pattern, a selection of K-R mutations affect both Rac1 activity 
and its consequent morphological effects in HUVECs.
DISCUSSION AND CONCLUSION
We have generated comparative data on the relationship between Rac1 GDI binding, 
-activity and -ubiquitination using manipulation with inhibitors of the UPS, introducing either 
activating Rac1 mutations, or K to R mutations in constitutively active Rac1 Q61L.
Firstly, we show that short-term manipulation of the UPS (2 hours) can change the activity 
of Rac1 in endothelial cells. Inhibition of DUBs decreased GTP-Rac1 levels, whereas the 
inhibition of the E1 ubiquitin ligase increased GTP-bound Rac1, both without changing total 
Rac1 levels. Although these effects were obtained with general inhibitors that do not target 
Rac1 specifically, these data indicate that ubiquitination, either directly or indirectly, plays 
an important role in the activation and inactivation cycle of Rac1.
Using several, be it confirmed or putative, activating Rac1 mutations G12V, F28L, P29S, 
Q61L, Y64F, R66A, N92I and C157Y, we directly compared the effect of different Rac1 activity 
levels on its ubiquitination and output. Hereby we were able to show a positive correlation 
between the level of Rac1 activity and its ubiquitination, and that this depends on the 
intrinsic Rac1 GTP binding only, rather than its binding to RhoGDI.
The Rac1 F28L and P29S mutants were extensively described previously, and these mutants 
induce a moderate increase in Rac1 activity. The mutations are located in the Switch 1 region 
of Rac1 and induce a fast-cycling phenotype, meaning that both GTP association and GDP 
dissociation are accelerated [18, 19, 31-33]. Rac1 F28L and Rac1 P29S were included in our 




by the G12V and Q61L mutations. In our assays, moderate Rac1 activity indeed leads to a 
moderate increase in Rac1 ubiquitination.
Remarkably, the Rac1 N92I mutation increased Rac1 activity and ubiquitination to a similar 
extent as the extensively studied Rac1 Q61L and G12V. The Rac1 N91I mutant still retains full 
GTPase activity whereas the intrinsic GTPase activity of Rac1 Q61L and Rac1 G12V is impaired 
(0% and 5% GTP hydrolysis over 10 minutes compared to 30% in Rac1 WT) [16]. It was 
suggested that the N92I mutation alters Rac1 activity through interaction with the P-loop 
(residues 9-16) [22], although this mechanistic explanation still needs to be confirmed.
Rac1 C157Y was, just as Rac1 F28L, P29S and N92I, described as a fast-cycling mutant with 
modest increase in activity. This mutant however displays increased GTP dissociation in 
addition to GTP association and GDP dissociation, whereas GTP dissociation of Rac1 F28L, 
P29S and N92I is equal to Rac1 WT [22]. The C157Y mutation of Rac1 was also found in an 
individual with a developmental disorder and neurological disability. Although no activity 
differences were observed for this mutant in in vitro experiments in fibroblasts by Reijnders 
et al., the research from Kawazu et al. did show increased activity of the Rac1 C157Y mutant 
in HEK293T cells [22, 23]. In accordance with this latter study, our data show an increase 
in activity of Rac1 C157Y compared to Rac1 WT, albeit that its level of ubiquitination was 
not detectably increased, likely because the ubiquitination assay is less sensitive than the 
CRIB pulldown.
It has been generally accepted that only inactive Rac1 bound to the GDI, which was why 
activation and degradation of Rac1 seemed to go seamlessly hand in hand, but a vast 
body of research has shown that the GDI regulates Rac1 activation in an active rather 
than passive manner [4, 5, 7, 34-38]. Based on the notion that loss of GDI binding induces 
activation and degradation of Rac1, we expected that Rac1 R66A, a mutant defective for GDI 
binding, would be either more active, or in any case more ubiquitinated and that we would 
see a decrease in total protein levels for this Rac1 mutant [21]. However, ubiquitination of 
Rac1 R66A is slightly decreased and there was no increase in Rac1 activity, although GDI 
binding was sufficiently inhibited (Figure 2C). The Rac1 Y64F mutant was previously shown 
to decrease the Rac1-GDI interaction and increase Rac1 activity [20, 38], and although we 
could confirm the decrease in GDI binding, we detected no change in activity between Rac1 
WT and Rac1 Y64F. Rac1 F28L and P29S both showed an approximate 50% decrease of 
GDI binding, but the GDI binding itself did not correlate with the activity or ubiquitination 
levels of these Rac1 mutants. Interestingly, the active N92I Rac1 mutant bound equally well 
to the GDI as WT Rac1, whereas the G12V mutation decreased GDI binding, and Rac1 Q61L 
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showed no interaction with the GDI at all. The fact that Rac1 N92I binds equally well to the 
GDI as Rac1 WT makes this an interesting mutation to use in fundamental studies on the 
role of GDI binding and activation in Rac1 signaling. In conclusion, our data show that lack 
of GDI binding is not sufficient to induce activation of Rac1, that Rac1 activation does not 
exclude GDI binding and that GDI binding does not protect active Rac1 from ubiquitination.
Single lysine mutations have been used in many studies to identify site-specificity of 
ubiquitination by ubiquitin ligases [13, 15, 39], but we set out to also investigate the effect 
of these mutations on Rac1 ubiquitination and activity. Analysis of single lysine mutations 
in myc-Rac1 Q61L showed several opposing effects. The K16R mutation, as was described 
before [28], inhibits Rac1 activity even when the Q61L mutation is present and also fails 
to induce ruffling and the stereotypical circular cell shape that is associated with Rac1 
activity in HUVECs. From the structure model of Rac1 from the RCSB protein data bank 
(Supplemental Figure 1), it can be seen that Rac1 K16, which is located in the P loop of Rac1, 
interacts with the second phosphate of GDP or GTP. This was also shown for Ras GTPases 
[40]. Mutation of K16, potentially leading to a mutant that is deficient in nucleotide binding 
may functionally resemble the T17N or T35S mutations, which interact with the Mg2+ ion 
required for GTP binding (Supplemental Figure 1). Since the C18Y mutation of Rac1, which 
is located in the P-loop, was also found to function as a dominant negative mutant of Rac1 
[23], it is plausible that the K16R mutation, and other P-loop mutations for that matter, does 
not influence ubiquitination directly, but does so indirectly, by interfering with Rac1 activity. 
This supposition is also in line with our data that the Rac1 Q61L/K147R mutant (in which K16 
is intact) does not show ubiquitination while being active. This indicates that K147, in line 
with earlier findings[28, 41, 42], is strictly required for the ubiquitination of activated Rac1.
Compared to Rac1 Q61L, both Rac1 Q61L/K133R and Q61L/K166R displayed increased 
ubiquitination, although there was no change in activity for Rac1 Q61L/K133R and the activity 
of Rac1 Q61L/K166R was even decreased. We also did not observe clear changes in the 
activity of WT Rac1 with the same mutations (Supplemental Figure 2) although the K133R 
mutation slightly decreased basal WT Rac1 activity. K133 is located in the insert region, but 
the side chains of both K133 and K166 are not involved in intramolecular interactions within 
Rac1, so mutation of these lysines may influence interactions with other proteins directly. 
Rac1 K166R was less degraded in MEFs and less ubiquitinated in vitro compared to Rac1 WT 
[39], but the effect of this mutation may be different in Rac1 Q61L/K166R versus Rac1 WT/
K166R since we do not observe an increase in Rac1 Q61L/K166R protein levels. Rac1 Q61L/
K166R was also still able to induce membrane ruffling in HUVECs, whereas this property was 




Both Rac1 Q61L/K183R and K184R were not differentially ubiquitinated, although an 
approximate 50% increase in activity was observed for Rac1 Q61L/K184R. This increase in 
activity is remarkable given that it occurs in an already constitutively active Rac1 protein. 
Since lysine 183 and 184 are targeted for SUMOylation [42], the loss of SUMOylation at this 
location may explain the increase in activity [43]. Since no definitive 3D structure of the 
C-terminus of Rac1 is available, it is difficult to determine which structural changes may be 
induced by the K183R and K184R mutations.
Taken together, this study compared a large number of (active) Rac1 mutants to further 
chart the relationship between Rac1-GDI binding, -activity and -ubiquitination. Although 
we cannot formally exclude that the pool of ubiquitinated Rac1 is distinct from the pool we 
found associated with the GDI, our data strongly suggest that the ubiquitination of Rac1 is 
closely linked to its level of activity and that GDI binding by activated Rac1 versions does not 
protect from increased ubiquitination. Further studies are required to define the localization 
of Rac1 ubiquitination and -degradation and to establish its role as an alternative Rac1-
inactivating mechanism, next to GAP- stimulated GTP hydrolysis.
MATERIALS AND METHODS
Antibodies and reagents
Antibodies used in this study were anti-Myc-tag (#2278), anti-GAPDH (#2118), anti-RhoGDI 
(#2564), all from Cell Signaling, anti-mCherry (#NBP2-25157, Novus Bio) and anti-HA-tag 
(#H3663, Sigma)
For immunofluorescent staining, DAPI (Thermo Fisher scientific), Alexa 488-secondary 
antibody (anti-rabbit, Invitrogen) and Acti-stain 670 phalloidin (Cytoskeleton) were used.
The inhibitors PR619 (#S7130) and MLN7243 (#S8341) were used at 2.5 µM concentration. 
MG132 (#S2619) was used at 5 µM concentration. All were from Selleck Chemicals.
Cell culture
HUVECs
Primary HUVECs were purchased from Lonza (#CC-2519) and cultured on fibronectin-
coated plates in Endothelial Cell medium (ECM) (ScienCell Research Laboratories). Cells were 
cultured at 37 °C and 5% CO2 and the medium was refreshed every second day. Experiments 
were performed with cells until passage 5.
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HEK293T cells
HEK293T cells (ATCC) (#CRL-3216) were grown in Dulbecco’s Modified Eagle Medium 
(Gibco) (#41966-029) supplemented with penicillin 100 U/mL and streptomycin 100 μg/mL, 
L-glutamine 2 mMol/L (all from Bio Whittaker/Lonza), 1 mM sodium pyruvate (Gibco) (#11360-
070) and 10% Fetal Bovine Serum (PAA) (#A15-101).
Mutagenesis
Single mutants of mCherry-Rac1 were generated using the site-directed mutagenesis. 
Mutations were introduced into the pmCherryC1-Rac1 vector in a PCR reaction using site-
specific primers (Invitrogen) and high-fidelity Phusion DNA polymerase (NEB). Template 
DNA was digested by DpnI (NEB), and PCR product was transformed into competent DH5α 




Plasmid overexpression in HEK293T cells was done using TransIT-LT1 (MirusBio) according 
to the manufacturer’s protocol.
HUVEC
Ectopic expression in HUVECs was done using the 4D-NucleofectorTM system (Lonza). 
Per plasmid, 10 cm2 subconfluent HUVECs were electroporated with 2 µg of DNA with 
transfection protocol CA-167.
Western blot
Cells were washed PBS supplemented with 1mM CaCl2 and 0.5 mM MgCl2 and lysed in 2x 
SDS sample buffer (125 mM Tris-HCl pH 6.8, 4% SDS, 20% glycerol, 100 mM DTT, 0.02% 
Bromophenol Blue in MilliQ). Proteins were separated by SDS-PAGE and transferred to 
nitrocellulose membranes, followed by incubation with designated primary antibodies in 5% 
BSA in TBS-T. Protein bands were visualized with enhanced chemiluminescence (Amersham/
GE-healthcare) on the AI600 machine (Amersham/GE-healthcare).
Immunofluorescence staining and confocal imaging
HUVECs were seeded on fibronectin-coated (5 μg/ml) 2 cm2 coverslips (Thermo Scientific, 
Menzel-gläser) (#10319303). Warm (37 °C) 4% paraformaldehyde (Sigma Aldrich) (#158127) 
in phosphate buffered saline (PBS) (B Braun) (#3623140) was added onto the cells and 




permeabilized with 0,2% triton X-100 in PBS for 3 minutes and blocked for 30 minutes with 
1% HSA in PBS. Coverslips were stained with primary antibodies in 1% HSA/PBS for 1 hour 
at room temperature or overnight at 4 °C. After washing with PBS, coverslips were incubated 
with a FITC-labeled secondary antibody (anti-rabbit or anti-mouse 1:100 in 1% HSA/PBS), 
Acti-stain 670 phalloidin (Cytoskeleton) (#PHDN1-A) and DAPI (Thermo Fisher Scientific) for 
1 hour at room temperature. Coverslips were mounted on Mowiol4-88/DABCO solution 
(Calbiochem, Sigma Aldrich). Confocal scanning laser microscopy was performed on a Nikon 
A1R confocal microscope (Nikon). Images were analyzed and equally adjusted with ImageJ 
software.
CRIB pulldown
To analyze Rac activity, a 6-cm dish (21 cm2) of HUVECs or 10 cm2 of HEK293T were washed 
once with PBS++ and lysed in 500 µl of cold Lysis buffer (150 mM NaCl, 50 mM Tris pH 7.6, 1% 
Triton-X 100, 20 mM MgCl2) with 30 ug CRIB peptide. Cell debris was spun down at 14.000 
rpm for 5 minutes, after which 10% of lysate was mixed with 3x SB (187.5 mM Tris-HCl pH 
6.8, 6% SDS, 30% glycerol, 150 mM DTT, 0.03% Bromophenol Blue in MilliQ) (input) and the 
remaining lysate was incubated with Streptavidin beads for 30 minutes rotating at 4 °C. Next, 
the beads were washed 5 times in lysis buffer with freshly added 10mM MgCl 2, all buffer 
was aspirated and the beads were lysed in 30-50 µl 2x SB (pulldown). Rac1 in the input and 
pulldown samples was analyzed by Western Blot.
In vivo Rac1 ubiquitination assay
pcDNA3-HA-Ubiquitin was co-transfected with pmCherryC1-Rac1 or pcDNA-2x myc-Rac1 
mutants into HEK293T cells using TransIT (Mirus) according to the manufacturer’s protocol. 
Before lysis, cells were treated with 5 µM MG132 for 4 hrs. For analysis of ubiquitination 
of Rac1, denaturing HA-immunoprecipitation was performed at 24 h after transfection as 
previously described [24].
Co-IP of myc- and mCherry-tagged Rac1
Myc- or mCherry-tagged Rac1 was transiently expressed in HEK293T cells. After 16 hours, 
Co-IP was performed using the Myc-TRAP or RFP-TRAP kit (Chromotek) according to the 
manufacturer’s protocol.
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Supplemental Figure 1 - Snapshots from Rac1 structure from https://www.rcsb.org/3d-view/3TH5 
depicting interactions between of K16 and T17 with the GTP molecule. K16 forms a direct bond with 
one of the phosphates of the GTP molecule, Whereas T17 and T35 interact with the Mg2+ ion.
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Supplemental Figure 2 - K-R mutations do not significantly change activity of mCherry-Rac1 WT. 
mCherry-Rac1 and mutants thereof were ectopically expressed in HEK293T cells and CRIB pulldown was 








The research described in this thesis focuses on novel mechanisms that regulate the 
integrity of the vascular endothelial barrier. The most important functions of this barrier 
are (i) preventing passive vascular leakage to protect against tissue dysfunction and (ii) 
regulating the transport of nutrients and solutes, as well as inflammatory cells across the 
vessel wall. Many stimuli can influence endothelial barrier integrity, including disturbed 
flow, receptor agonists and local or systemic inflammation. These stimuli induce various 
signaling events to control endothelial barrier function. Mechanistically, members of the 
family of Rho GTPases act at the center of such endothelial cell signaling networks, through 
their regulation of the organization and dynamics of the F-actin cytoskeleton. In this thesis, 
we explored the regulation of Rho GTPases by post-translational modifications (PTM) in 
endothelial cells in the context of vascular leakage. To investigate the activation and PTMs 
of the relevant GTPases, we used a variety of inhibitors, protein-specific siRNA-mediated 
knockdowns, and single amino acid mutations in ectopically expressed proteins.
In chapter 2, we reviewed the current knowledge on the role of ubiquitination in the 
regulation of endothelial junctional integrity. There are many isolated findings regarding 
this topic, in part also related to parallel studies in epithelial cells, which currently precludes 
drawing a comprehensive picture. However, from this literature overview it became clear that 
ubiquitination of junctional proteins, as well as of a subset of Rho GTPases, clearly plays a 
role in controlling junctional integrity. Yet, mechanistic knowledge of the signaling function 
of ubiquitination, as compared to its role in protein stability, is still quite limited.
In the other chapters in this thesis, we presented novel molecular insights regarding 
regulation of endothelial junctional integrity by ubiquitination, focusing on the Rho GTPases 
RhoB and Rac1. We identified novel aspects of RhoB regulation through PTMs in endothelial 
barrier function and studied the relationship between ubiquitination, activity and GDI 
binding of Rac1. We here summarize and briefly discuss these findings.
RhoB regulation in endothelial cells by PTMs
The main body of work in this thesis focuses on regulation of the Rho GTPase RhoB, which 
shares 85% amino acid sequence identity with its siblings RhoA and RhoC [1]. However, 
as compared to the canonical mode of regulation, based on GEF/GAP-driven GDP/GTP 
cycling and RhoGDI-mediated sequestration of RhoA/C, RhoB is regulated differently. Firstly, 
differences in the C-terminal amino acid sequence of RhoB, as compared to those of RhoA 
and RhoC, allow for differential prenylation [2]. Although it has not been studied for all 
Rho GTPases, it has been shown that the prenylation of the Rho GTPases RhoA and Rac1 
is limited to geranylgeranylation. These lipid modifications are required for association to 
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endosomes or the plasma membrane and have additionally been shown to be important 
for interaction of Rho GTPases with GDIs and GAPs [3]. Prenylation of RhoB includes both 
geranylgeranylation and farnesylation, the exact function of which is still under debate. 
Secondly, RhoB does not bind to RhoGDI1 or to RhoGDI3, which are ubiquitously- or 
hematopoietically expressed, respectively. RhoGDI binding typically protects Rho GTPases 
from ubiquitination and degradation [4]. Therefore, whereas RhoA and RhoC activation 
and inactivation are regulated by RhoGDI, the majority of RhoB protein which is present 
in the cell is rapidly activated after synthesis and available for interaction with effector 
proteins. Consequentially, RhoB is degraded quickly, and has a half-life of only 30 minutes. 
An additional effect of the lack of RhoB-RhoGDI binding is that prenylated RhoB cannot 
reside in the cytosol as a soluble protein, but is consistently associated with a vesicular or 
plasma membrane [5].
We have defined the regulation of endothelial barrier function by RhoB regulation through 
its 1) ubiquitination, 2) prenylation and 3) transcription. More importantly, we identified 
some of the relevant proteins that regulate RhoB through these pathways. A summary of 
our findings on RhoB regulation is shown in Figure 1.
The Cullin-3-Rbx1-KCTD10 complex regulates RhoB ubiquitination and lysosomal 
degradation
In resting endothelial cells, RhoB levels are kept low to prevent cell contraction. The RhoB 
gene and mRNA are continuously transcribed and translated, but in healthy conditions, 
RhoB protein is also continuously degraded, as has been shown through the fast increase 
in RhoB levels upon inhibition of protein degradation [6].
In chapter 3 we show that, in endothelial cells, the Cullin-3-Rbx1-KCTD10 complex is 
responsible for RhoB ubiquitination and degradation to maintain a stable endothelial barrier. 
We used MLN4924 to inhibit Cullin neddylation, a modification necessary for the activity of 
Cullin E3 ubiquitin ligases [7]. By inhibiting Cullin activity or by knocking down either Cullin-
3, Rbx1 or KCTD10, RhoB degradation is halted and protein levels of RhoB increase, leading 
to EC contraction. Regarding K48- versus K63-linked ubiquitination of RhoB, we found that 
MLN4924 treatment induced an accumulation of K63-linked poly-ubiquitinated RhoB. K63-
linked ubiquitination of proteins has been linked to lysosomal degradation [8], and it was 
shown before that RhoB is degraded through the endo-lysosomal pathway, directed through 
its C-terminal sequence [9]. We therefore concluded that the Cullin-3-Rbx1-KCTD10 complex 




Figure 1 - Model of RhoB regulation in endothelial cells by transcription, prenylation and ubiq-
uitination. Upon synthesis and prenylation, RhoB will be rapidly activated, allowing signaling at the plasma 
membrane. A major signaling pathway leads to the induction of myosin-based contraction of actin stress fibers. 
Superimposed on this canonical mode of GTPase regulation are several novel mechanisms that control RhoB. 
(1). The Cullin-3-Rbx1-KCTD10 complex is responsible for the K63-linked poly-ubiquitination and consequen-
tial lysosomal degradation of active RhoB. Alternatively, RhoB can be degraded by the proteasome following 
K48-linked poly-ubiquitination. (2). The Cullin-1 – βTrCP complex degrades IkB, which allows for the initiation 
of RhoB transcription through the transcription factor NFkB. NFkB is activated by inflammatory stimulation 
of endothelial cells such as with TNF-α. (3) The prenylation of RhoB is indirectly regulated by the E3 ubiquitin 
ligase substrate adapter FBXW7. Farnesylated RhoB is the major contributor to RhoB-mediated cell contraction, 
whereas geranylgeranylation of RhoB is important for its targeting to lysosomes.
The Cullin neddylation inhibitor MLN4924 is also known under the name Pevonedistat. 
Pevonedistat is a cytostatic drug, and most research on this compound has been done in 
cancer cells, where it inhibits migration and proliferation [10]. However, MLN4924 targets 
multiple Cullin-based E3 ligases, underscoring the need for more specific approaches and 
targeting strategies. As an example, Shi et al. show that MLN4924-treatment of endothelial 
cells decreases angiogenesis, which aids in the perturbation of tumor growth [11] but may 
affect physiological angiogenesis as well. A study from Xu et al. identified that in liver cancer 
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cells the Cullin-2-Rbx1 complex is responsible for RhoB degradation [12]. In our experiments 
in endothelial cells however, RhoB levels remained unchanged upon Cullin-2 knockdown, 
indicating cell type-specific activity of this Cullin E3 ligase. So, in this example, specific 
targeting of Cullin-2 may be a good treatment opportunity to target liver tumor cells without 
affecting the (micro)vasculature, and many similar examples can be exploited in the future.
A recent paper from 2021 shows that RhoB is ubiquitinated in hepatocellular carcinoma cells 
by TNFAIP1 [13]. Although the effect was not as strong as for KCTD10 knockdown, we found 
an increase in RhoB levels upon TNFAIP1 knockdown as well, indicating that this adaptor 
protein functions similarly in the hepatocellular carcinoma cells and in ECs. The same holds 
true for KCTD10, which regulates ubiquitination and degradation of RhoB in both ECs and 
in HER2-positive breast cancer cells [14]. To be able to target RhoB in cancerous cells only 
without affecting the endothelium, an adaptor protein with differential expression or activity 
in terms of RhoB regulation still needs to be identified.
Activation of Cullin-1 and consequential activation of the NF-κB pathway 
outweighs Cullin-3-mediated RhoB degradation
Following up on our findings on the increase in RhoB through inhibition of Cullin E3 ligase 
neddylation by MLN4924, we used the small molecule CSN5i-3 to induce the opposite 
effect. These results are presented in chapter 4. CSN5i-3 inhibits the enzyme CSN5, which 
deneddylates proteins. The net effect of CSN5i-3 is therefore the activation of Cullin E3 
ligases [15]. We quickly found that, although CSN5i-3 was expected to induce an opposite 
effect as compared to MLN4924, a similar decrease in endothelial barrier integrity was 
induced. Previous research suggested that constitutive activation of Cullin E3 ligases could 
(i) induce auto-degradation, and (ii) keep the ligase associated to only one adaptor protein. 
However, these results differ between cell types[15, 16]. We found that in endothelial cells, 
both Cullin-1 and Cullin-3 activity were indeed elevated by treatment with CSN5i-3, whereas 
Cullin-2 activity was unaltered. However, we observed significant degradation of Cullin-3 
protein, whereas Cullin-1 levels remained equal. The Cullin-1-βTrCP complex is responsible 
for degradation of IκB, which inhibits translocation of the NF-κB transcription factor complex 
to the nucleus, induced by pro-inflammatory stimuli [17, 18]. TNF-α stimulation of endothelial 
cells and activation of the NF-κB pathway, besides upregulation of many inflammatory 
proteins including ICAM-1, induces RhoB transcription (chapter 3 and [6]). In our study 
using the Cullin deneddylation inhibitor CSN5i-3, increased RhoB transcription through the 




Since the half-life of RhoB is short, dysregulation of its degradation or transcription rate 
can be detected rapidly. The accumulated RhoB induced by treatment with CSN5i-3 showed 
vesicular localization, analogous to the observation made earlier on RhoB localization upon 
TNF-α stimulation (chapter 3). We observed that RhoB that is localized in endosomes or 
lysosomes (after TNF-α stimulation) induces less cell contraction compared to RhoB that 
is localized at the plasma membrane (after MLN4924 treatment). This finding suggests 
differential signaling by RhoB at the plasma – or endosomal membranes. The minimally 
characterized RhoGDI3, which, as opposed to RhoGDI1 and RhoGDI2, does not reside in 
the cytosol but is associated to the Golgi apparatus, was found to specifically bind RhoB and 
RhoG [4-6]. Possibly, RhoGDI3 maintains RhoB in an inactive state at endosomal or Golgi-
associated membranes, whereas RhoB signals freely at the plasma membrane.
Our findings in chapter 4 elucidate the balance in activity that exists between the Cullin RING 
ligases. For RhoB specifically, these data show how its transcription versus degradation rates 
are key to RhoB downstream signaling.
FBXW7 alters prenylation of RhoB by interfering with the cholesterol  
synthesis pathway
Our study described in chapter 5 underscores the significance of the different RhoB 
pools. In this work, we could show that the Cullin-1-FBXW7 complex regulates RhoB, but 
not by ubiquitination as we first hypothesized, but by indirectly altering RhoB prenylation. 
Prenylation of Rho GTPases is crucial for their membrane targeting and, for most GTPases 
but not RhoB, for interaction with RhoGDI [3, 19]. As mentioned previously, RhoB can be 
both farnesylated and geranylgeranylated, whereas the prenylation of other Rho GTPases is 
limited to geranylgeranylation [2]. In the normal situation, FBXW7 targets the transcription 
factor SREBP for ubiquitination and degradation. Transcription of one of the target genes of 
SREBP, namely HMCGR, drives the conversion of HMG-CoA into mevalonate, one of the first 
steps in the cholesterol synthesis pathway [20]. This would induce both geranylgeranylation 
and farnesylation of RhoB, and one might postulate that the balance between the two 
remains equal. We observed an increase in total RhoB protein, in addition to increased RhoB 
prenylation. Interestingly, Stamatakis et al. showed that prenylation of RhoB is necessary for 
its degradation, meaning that increased RhoB prenylation would only favor its degradation 
[21]. However, no distinction was made in their research between geranylgeranylation and 
farnesylation, which is where the discrepancy in our results may lie.
We have shown that RhoB geranylgeranylation is important for localization of RhoB to 
membranes since treatment with GGTI (geranylgeranyl transferase inhibitor) caused a shift 
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of RhoB from the membrane-bound pool to the cytoplasm. On the other hand, inhibition 
of RhoB farnesylation with FTI (farnesyl transferase inhibitor) showed no effect on RhoB 
membrane- versus cytoplasm localization. FTI treatment of NIH 3T3 cells (fibroblasts) was 
shown to reduce RhoB farnesylation and increase RhoB geranylgeranylation [22]. Especially 
the pool of farnesylated RhoB appears to be responsible for actomyosin-based contraction 
in these cells [23]. Based on these data and our data in chapter 5, we suggest that, while 
both the geranylgeranylated and farnesylated forms of RhoB are increased in endothelial 
cells upon knockdown of FBXW7, it is the farnesylated RhoB that is not degraded, induces 
EC contraction and disrupts the endothelial barrier.
GDI binding is not everything: loss of GDI binding in activating mutants of Rac1 
does not correlate with levels of activity or ubiquitination
In contrast to RhoB, Rac1 protein levels are usually stable, partially due to its interaction with 
RhoGDI. In addition, previous research has shown that primarily the active form of Rac1 is 
susceptible to ubiquitination and proteasomal degradation [24, 25]. We investigated whether 
Rac1-GDI binding is affected by Rac1 activity or Rac1 ubiquitination, and vice versa, in chapter 6.
To induce a range of Rac1 activity levels in cells, we introduced single amino acid mutations 
that were previously found to increase Rac1 activity. The Rac1 G12V and Q61L mutations 
are widely known and used as constitutively active Rac1 proteins, and we additionally 
generated the Rac1 mutants F28L, P29S, Y64F, R66A, N92I and C157Y. The F28L, P29S and 
N92I mutations were identified in cancer patients and the increase in Rac1 activity by these 
mutations is attributed to rapid GDP/GTP cycling [26-28]. The mutations Y64F and R66A were 
described to disrupt Rac1-RhoGDI binding, and one can hypothesize that this exposes Rac1 to 
both GEFs and ubiquitin ligases, to induce Rac1 activation or ubiquitination, respectively [4]. 
Visvikis et al. showed convincingly that constitutively active Rac1 Q61L is more ubiquitinated 
than WT Rac1 [25], and we were now also able to show, using a range of differently 
activated Rac1 proteins, that Rac1 activity and ubiquitination are positively correlated.
Upon transition of the Rho GTPase between their RhoGDI-bound and the plasma membrane 
associated state, GEFs induce the GDP to GTP exchange and conformational changes of the 
Rho GTPase [4]. The constitutively active Rac1 Q61L would therefore, due to its permanently 
GTP-bound conformation, not be associated to RhoGDI. Using our Rac1 mutants with 
activating mutations, we expected to see less GDI binding with increased activity. Rac1 Q61L, 
and also the dominant negative Rac1 T17N for that matter, indeed did not bind to RhoGDI 
[29], but for the other Rac1 activating mutations we observed no correlation between 




depend on the Rac1 activity level may explain why there was no correlation between loss 
of RhoGDI binding and Rac1 ubiquitination in our experiments. Thus, we only found a clear 
relationship between Rac1 activity and its ubquitination.
Our lab previously demonstrated that mono-ubiquitination of active Rac1 may control its 
internalization and degradation [30]. To study potential regulation of Rac1 activity and 
GDI binding by ubiquitination, we generated K (lysine) to R (arginine) mutations in the 
constitutively active Rac1 Q61L, to inhibit ubiquitination at specific sites. K147 is the major 
ubiquitination site of Rac1, and targets Rac1 for degradation [25]. Additional lysines that 
were mutated to arginine (K16, K135, K166, K183 and K184) were selected based on prior 
description in literature and on the 3D structure of Rac1. Most lysine side chains at these 
locations are directed outward of the Rac1 molecule, and we therefore postulated that 
mutation of these lysines would minimally affect Rac1 tertiary structure, while potentially 
affecting specific, ubiquitin-mediated, interactions with Rac1 regulators. Interestingly, the 
K16R mutation completely abolished the activity of Rac1 Q61L. It was previously suggested 
that TRAF6 ubiquitinates Rac1 at this position, inducing Rac1 activity and formation and 
activation of the NADPH complex [31]. However, upon detailed analysis of the Rac1 structure, 
we found that K16 is part of the nucleotide-binding pocket and directly interacts with GTP. 
We therefore propose that mutation of K16 to R is enough to disrupt GTP binding, leading to 
a complete loss of Rac1 activity. Although no striking differences were observed in activity 
of the other K-R mutations in Rac1 Q61L, we found a modest positive correlation between 
Rac1 activity and ubiquitination levels in this set of Rac1 mutants as well. Figure 2 shows 
a brief, graphical summary of our conclusions on the relationship between Rac1 activity, 
ubiquitination and GDI binding.
Figure 2 - Model of the correlation between Rac1-GDI binding, -activity and -ubiquitination. GDI-me-
diated regulation of Rac1 activation and ubiquitination has not been effectively shown in our experiments. 
An increase in Rac1 activity strongly correlates with Rac1 ubiquitination, but whether Rac1 ubiquitination can 




We have added – to our best knowledge – new experimental evidence on the regulation of 
Rho GTPase signaling by PTMs in endothelial cells. However, we are aware of possible study 
limitations. We have used endothelial cells isolated from umbilical veins (human umbilical 
cord endothelial cells; HUVEC) to study endothelial barrier function and EC morphology. 
HUVECs are the most easily obtainable type of endothelial cells, but EC characteristics are 
heterogenous throughout the body, and – as far as they can be maintained in culture – can 
influence the outcome of experiments when done in ECs of different origin. Direct translation 
of findings in HUVECs to, e.g., pulmonary endothelial cells could be incorrect and different 
results may be found when experiments are repeated in this endothelial cell lineage.
Barrier function was measured by Endothelial Cell-substrate Impedance Sensing (ECIS) 
and by Horseradish Peroxide (HRP) passage (chapters 3, 4 and 5). EC morphology was 
analyzed using immunofluorescence staining and imaging. These were all two-dimensional 
assays, while endothelial cells in blood vessels exist in a three-dimensional structure. With 
the development of ‘vessel on a chip’ technology, vascular leakage assays measuring the 
extravasation of e.g. fluorescently labelled dextrans may give more translational insights. 
We have successfully demonstrated vascular leakage in zebrafish embryos in chapter 4, and 
this approach may be insightful for translational purposes in further studies.
Finally, some remarks can be made on our experimental set-up. To investigate normal Rho 
GTPase signaling in endothelial barrier function, we needed to trigger the ‘normal’ signaling 
system in ECs or remove components of it. For some experiments, we ectopically expressed 
fluorescently tagged protein to follow its processing in the cells. To investigate the function 
of a protein, we knock it down and try to draw conclusions from the phenotype caused 
by loss of function of this specific protein. While these approaches might not seem most 
physiologically relevant at the first glance, the molecular cell biology research which was 
applied throughout this thesis will aid in understanding the physiological regulation of Rho 
GTPase signaling in endothelial cells. Our findings can give direction to experimental design 
in a more elaborate, translational set-up, e.g., 3D cultures harboring multiple cell types, or 
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The inside of our blood vessels is lined with a single layer of endothelial cells, known as 
the endothelium. The endothelium forms a barrier with a strict degree of permeability 
for nutrients, waste products and cells from the blood to the tissues. The endothelial 
cells are also important for forming new blood vessels, wound healing and regulating 
local inflammatory responses. Abnormal functioning of the endothelial cells is therefore 
the basis of cardiovascular diseases such as atherosclerosis, vascular leakage and tissue 
oedema. In this thesis, molecular mechanisms underlying endothelium dysfunction have 
been investigated.
Rho GTPases are important for the regulation of vascular permeability
Endothelial cells form and maintain their barrier through cell-cell connections – also called 
junctions. These junctions span across the cell walls of neighboring cells, and are connected 
to the cytoskeleton within the cell. Like the skeleton of the human body, the cytoskeleton 
gives structure to the body of the cell. However, the endothelial cell does not move by muscle 
contraction, but by adaptation of its cytoskeleton. Important regulators of this cytoskeleton 
are proteins called the Rho GTPases, of which 22 are known. The most researched Rho 
GTPases are RhoA, RhoB, Rac1, and Cdc42. RhoA and RhoB cause the cells to contract, 
creating holes in the endothelial barrier that lead to vascular leakage. Rac1 and Cdc42 do 
the opposite: they cause the endothelial cells to expand and promote the formation of cell-
cell connections. Rho GTPases can switch between an active and inactive form, allowing 
endothelial cells to adapt their cytoskeleton as needed. However, there are more aspects 
to the regulation of Rho GTPases, which we have investigated in this thesis.
Post-translational modifications: newly discovered ways of Rho GTPase regulation
In this thesis, we mainly focus on the regulation of Rho GTPases by two post-translational 
modifications called ubiquitination and prenylation. A post-translational modification is a 
change made to a protein after it has been transcribed from the DNA.
Ubiquitination is the attachment of a ubiquitin molecule to a protein. This is done by three 
groups of enzymes called the E1, E2 and E3 ligases, in sequential order. There are also 
hundreds of different adapters that form a unique connection between the E3 ligase and 
the target: the protein that has to be ubiquitinated. Ubiquitination of a protein usually 
leads to recognition by the proteasome, which then breaks down the protein. However, 
the ubiquitin molecule can form several types of chains, so ubiquitination can also signal 
enzymatic degradation in small vesicles called lysosomes, or a change in the function of the 
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ubiquitinated protein. In chapter 2 we summarized the current knowledge on regulation 
of the endothelial barrier by ubiquitination. From this literature review it became clear that 
ubiquitination of junctional proteins, as well as of a part of the Rho GTPases, clearly plays 
a role in organizing the endothelial barrier. However, the knowledge about Rho GTPase 
ubiquitination in endothelial cells is still rather limited, and we have further investigated this.
In chapter 3 we describe the role of RhoB ubiquitination in the the endothelial barrier. To 
maintain the endothelial barrier, the amount of RhoB is kept low to prevent contraction 
of the cells. The RhoB gene is continuously transcribed and translated into protein, but 
under healthy conditions the RhoB protein is also continuously broken down. By specifically 
removing the E3 ligases Cullin-1, Cullin-2 and Cullin-3 and some adapter proteins from the 
endothelial cells, we found that the Cullin-3-Rbx1-KCTD10 complex is most important for 
RhoB ubiquitination. We could also distinguish that this ubiquitination leads to degradation 
of RhoB in lysosomes, and not by the proteasome.
Having discovered that Cullin-3 activity is important for RhoB degradation, we tried to 
activate Cullin E3 ligases with the substance CSN5i-3 (chapter 4). We expected that this 
would lead to increased RhoB degradation and an enhanced endothelial barrier. However, 
it soon became apparent that the activation of all Cullin E3 ligases led to an imbalance 
in the endothelium. Although we expected activation of the Cullin-3 complex to promote 
RhoB degradation, in this case RhoB gene transcription was induced by increased Cullin-1 
activity. Cullin-1 is important for the conversion of an external pro-inflammatory signal to an 
adequate response in endothelial cells. This leads to an increase in, among other things, the 
molecules necessary for the binding of leukocytes to the endothelial cells, which is essential 
to be able to resolve inflammation in the tissue. There was more RhoB transcription than 
degradation in the endothelial cells treated with CSN5i-3, leading to a high RhoB protein 
level and contraction of the endothelial cells. We concluded that the chemical activation of 
all Cullin E3 ligases is not a good strategy for reducing endothelial cell contraction.
The role of another group of E3 ligase adaptors, called the F-box proteins, in the regulation 
of the endothelial barrier was still unknown. In our study described in chapter 5, we 
investigated the function of the F-box proteins in the endothelium by deactivating them 
and subsequently measuring the integrity of the barrier. We found that loss of the F-box 
protein FBXW7 decreased the endothelial barrier. However, this was not due to a change in 
ubiquitination, but in RhoB prenylation. Prenylation is the attachment of a fatty side chain 
to a protein and comes in two forms: geranylgeranylation (GG) and farnesylation (F). In 




both a GG and an F fat chain. By removing FBXW7 from endothelial cells, both GG-RhoB and 
F-RhoB increased and the total RhoB protein level was increased, leading to contraction of 
the endothelial cells. Moreover, by specifically inhibiting the GG and F additions, we found 
that especially F-RhoB is responsible for the contraction of the endothelium.
The Rac1 protein level in cells is higher than that of RhoB, but 90-95% of Rac1 is inactive. 
One of the reasons for this difference in degradation is the binding of Rac1 to the protein 
RhoGDI, which is not the case for RhoB. RhoGDI binds to inactive Rho GTPases to prevent 
their degradation and regulate activation. With a great body of knowledge from the literature 
to support us, we investigated the relationship between Rac1-GDI binding, activity and 
ubiquitination in chapter 6. These three components of Rac1 regulation had not been 
linked in this way before. We introduced mutations in Rac1, each known to cause different 
activity, ubiquitination or GDI binding of Rac1. This allowed us to show that Rac1 activity 
and ubiquitination are positively correlated to each other. However, we did not see loss of 
RhoGDI binding with increased Rac1 activity as we expected, which puts the regulation of 
Rac1 by RhoGDI in a new light.
In summary, we were able to establish the link between post-translational regulation of 
Rho GTPases, specifically RhoB and Rac1, and the regulation of the endothelial barrier. 
To investigate normal Rho GTPase signaling in endothelial barrier function, we had to 
activate the endothelial cells, or inhibit or ablate specific proteins. For some experiments, 
we expressed fluorescently synthesized Rho GTPases to better track them in the cells. The 
molecular cell biology research we performed in this thesis will help to understand the 
physiological regulation of Rho GTPase signaling in endothelial cells. We hope that these 





De binnenkant van onze bloedvaten is bekleed met een enkele laag endotheelcellen, ook 
wel het endotheel genoemd. Het endotheel vormt een barrière met een strikte mate van 
vasculaire permeabiliteit (doorlaatbaarheid) voor voedingsstoffen, afvalstoffen en cellen 
vanuit het bloed naar de weefsels. Ook zijn de endotheelcellen belangrijk voor het vormen 
van nieuwe bloedvaten, wondgenezing en het reguleren van lokale ontstekingsreacties. 
Afwijkend functioneren van de endotheelcellen ligt daarom aan de basis van hart- en 
vaatziekten zoals atherosclerose, vasculaire lekkage en weefseloedeem. In dit proefschrift 
zijn moleculaire mechanismen onderzocht die ten grondslag kunnen liggen aan de disfunctie 
van het endotheel.
Rho GTPases zijn belangrijk voor de regulering van vasculaire permeabiliteit
Endotheelcellen vormen en behouden hun barrière door cel-cel verbindingen – ook wel 
juncties genoemd. Deze juncties spannen over de celwanden van naburige cellen heen, 
en zijn binnenin de cel verbonden met het cytoskelet. Net als het skelet van het menselijk 
lichaam, geeft het cytoskelet structuur aan het lichaam van de cel. De endotheelcel beweegt 
echter niet door het samentrekken van spieren, maar door aanpassing van zijn cytoskelet. 
Belangrijke regulatoren van dit cytoskelet zijn eiwitten genaamd de Rho GTPases, waarvan 
er 22 bekend zijn. De meest onderzochte Rho GTPases zijn RhoA, RhoB, Rac1 en Cdc42. 
RhoA en RhoB zorgen ervoor dat de cellen samentrekken, waardoor er gaten ontstaan in de 
endotheel barrière die leiden tot vaatlekkage. Rac1 en Cdc42 doen het tegenovergestelde: 
zij zorgen voor het uitspreiden van de endotheelcellen en bevorderen de vorming van de 
cel-cel verbindingen. Rho GTPases kunnen wisselen tussen een actieve en inactieve vorm, 
waardoor endotheelcellen hun cytoskelet naar behoeven kunnen aanpassen. Er zijn echter 
meer aspecten aan de regulatie van Rho GTPases, waar we in dit proefschrift onderzoek 
naar gedaan hebben.
Post-translationele modificaties: nieuw ontdekte vormen van Rho GTPase regulatie
In dit proefschrift richten we ons vooral op de regulatie van Rho GTPases door twee post-
translationele modificaties genaamd ubiquitinatie en prenylatie. Een post-translationele 
modificatie is een verandering die wordt aangebracht aan een eiwit nadat het afgeschreven 
is van het DNA.
Onder ubiquitinatie verstaan we de aanhechting van een ubiquitine molecuul aan een eiwit. 
Dit gebeurt door drie groepen enzymen genaamd de E1, E2 en E3 ligases, in opeenvolgende 




tussen de E3 ligase en het doelwit: het eiwit dat geubiquitineerd moet worden. Ubiquitinatie 
van een eiwit leidt meestal tot herkenning door het proteasoom, wat het eiwit vervolgens 
afbreekt. Het ubiquitine molecuul kan echter verschillende soorten ketens vormen, 
waarrdoor ubiquitinatie ook een signaal kan zijn voor enzymatische afbraak in kleine blaasjes 
genaamd lysosomen, of voor een verandering in de functie van het geubiquitineerde eiwit. 
In hoofdstuk 2 hebben we de huidige kennis over regulatie van de endotheel barrière door 
ubiquitinatie samengevat. Uit dit literatuuroverzicht werd duidelijk dat ubiquitinatie van 
junctionele eiwitten, evenals van een deel van de Rho GTPases, duidelijk een rol speelt bij 
het organiseren van de endotheel barrière. Toch is de kennis over Rho GTPase ubiquitinatie 
in endotheelcellen nog vrij beperkt, en hebben wij dit verder onderzocht.
In hoofdstuk 3 beschrijven we rol van RhoB-ubiquitinatie in de endotheel barrière. Voor 
het behoud van de endotheel barrière wordt de hoeveelheid RhoB laag gehouden om 
samentrekking van de cellen te voorkomen. Het RhoB-gen wordt continu afgeschreven 
en vertaald naar eiwit, maar onder gezonde omstandigheden wordt het RhoB-eiwit ook 
continu afgebroken. Door specifiek de E3 ligases Cullin-1, Cullin-2 en Cullin-3 en enkele 
adaptor-eiwitten uit de endotheelcellen te verwijderen, ontdekten we dat het Cullin-3-Rbx1-
KCTD10-complex het meest belangrijk is voor de ubiquitinatie van RhoB. Ook konden we 
onderscheiden dat deze ubiquitinatie leidt tot afbraak van RhoB in lysosomen, en niet door 
het proteasoom.
Nu we ontdekt hadden dat Cullin-3 activiteit belangrijk is voor de afbraak voor RhoB, 
probeerden wij Cullin E3 ligases te activeren met de stof CSN5i-3 (hoofdstuk 4). Wij 
verwachtten dat dit zou leiden tot meer RhoB afbraak en een versterkte endotheel barrière. 
Al snel bleek echter dat de activatie van alle Cullin E3 ligases tot een disbalans in het 
endotheel leidde. Hoewel we verwachtten dat activatie van het Cullin-3 complex de RhoB 
afbraak zou bevorderen, werd in dit geval de gentranscriptie van RhoB geïnduceerd door 
verhoogde activiteit van Cullin-1. Cullin-1 is belangrijk voor de omvorming van een extern 
pro-inflammatoir signaal tot een adequate reactie in endotheelcellen. Dit leidt tot verhoging 
van, onder andere, de moleculen die nodig zijn voor de binding van leukocyten aan de 
endotheelcellen, wat essentieel is om een ontsteking in het weefsel te kunnen oplossen. Er 
was meer RhoB transcriptie dan afbraak in de endotheelcellen die behandeld waren met 
CSN5i-3, wat leidde tot een hoog RhoB eiwitniveau en contractie van de endotheelcellen. 
We konden hieruit concluderen dat de chemische activatie van alle Cullin E3 ligases geen 
goede strategie is voor het verlagen van endotheelcel contractie.
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Van een andere groep E3 ligase adaptoren, genaamd de F-box eiwitten, was de rol in de 
regulatie van de endotheel barrière nog onbekend. In onze studie beschreven in hoofdstuk 
5, onderzochten we de functie van de F-box eiwitten in het endotheel door deze uit te 
schakelen en vervolgens de integriteit van de barrière te meten. We bevonden dat het verlies 
van het F-box eiwit FBXW7 de endotheel barrière verlaagde. Dit was echter niet het gevolg 
van een verandering in ubiquitinatie, maar in RhoB prenylatie. Prenylatie is de aanhechting 
van een vettige zijketen aan een eiwit en bestaat in twee vormen: geranylgeranylatie (GG) 
en farnesylatie (F). Bij RhoA, RhoC en Rac1 kan alleen een GG-vetketen aangehecht worden, 
maar RhoB kan gemodificeerd worden door zowel een GG- als een F- vetketen. Door 
FBXW7 weg te nemen uit endotheelcellen, nam zowel GG-RhoB als F-RhoB toe en werd het 
totale RhoB eiwitniveau verhoogd, wat leidde tot samentrekking van de endotheelcellen. 
Bovendien ontdekten we, door de GG- en F- toevoegingen specifiek te remmen, dat vooral 
F-RhoB verantwoordelijk is voor de contractie van het endotheel.
Het Rac1 eiwitniveau in cellen is hoger dan dat van RhoB, maar 90-95% van Rac1 is 
inactief. Eén van de redenen voor dit verschil in afbraak is de binding van Rac1 aan het 
eiwit RhoGDI, wat voor RhoB niet het geval is. RhoGDI bindt aan inactieve Rho GTPases 
om hun afbraak te voorkomen en activatie te reguleren. Met veel kennis uit de literatuur 
om ons te ondersteunen, hebben we in hoofdstuk 6 onderzocht hoe Rac1-GDI-binding, 
-activiteit en -ubiquitinatie tot elkaar in verhouding staan. Deze drie componenten van 
Rac1 regulatie waren nog niet eerder op deze manier met elkaar in verband gebracht. We 
brachten mutaties aan in Rac1 waarvan bekend was dat die elk voor verschillende activiteit, 
ubiquitinering of GDI binding van Rac1 zorgden. Hiermee konden we aantonen dat Rac1-
activiteit en ubiquitinatie positief aan elkaar gecorreleerd zijn. We zagen echter geen verlies 
van RhoGDI binding bij verhoogde Rac1 activiteit zoals we verwacht hadden, wat de regulatie 
van Rac1 door RhoGDI in een nieuw daglicht zet.
Samenvattend hebben we de link kunnen leggen tussen post-translationele regulering 
van Rho GTPases, specifiek RhoB en Rac1, en de regulatie van de endotheel barrière. Om 
de normale Rho GTPase-signalering in de endotheliale barrièrefunctie te onderzoeken, 
moesten we de endotheelcellen activeren, of specifieke eiwitten remmen of wegnemen. 
Voor sommige experimenten brachten we fluorescent gemaakte Rho GTPases tot expressie 
om deze in de cellen beter te kunnen volgen. Het moleculaire celbiologische onderzoek 
dat we in dit proefschrift hebben gedaan, zal helpen bij het begrijpen van de fysiologische 
regulatie van Rho GTPase-signalering in endotheelcellen. Wij hopen dat deze inzichten zullen 





Jisca Majolée (baptismal names: Johanna Hendrika) was born on May 12th, 1994, in Gouda. 
After 4 years, she moved to Leusden. She obtained her Gymnasium diploma at the Johan 
van Oldenbarnevelt in Amersfoort in 2011 and went on to do her bachelor education in 
Biomedical Sciences at the Vrije Universiteit in Amsterdam. In 2013, she went to Lund in 
Sweden to complete her bachelor minor. Her bachelor internship was at the department 
of Experimental Cardiology at the AMC under supervision of dr. P. Barnett, investigating 
epigenetic regulation using TALEN-activated DNA transcription. This sparked interest in 
molecular biology, and she continued her master’s education at the VU in 2015, following the 
Immunology track with additional courses on molecular biology. Her first master’s internship 
was under supervision of dr. I. Kovačević at the department of Molecular Cell Biology at 
Sanquin, focusing on the role of ubiquitin E3 ligases and F-box proteins in endothelial cells. 
She completed her second internship with drs. Y. Leestemaker on regulation of proteasomal 
activity, starting in the department of Cell Biology II at the NKI and later at the LUMC, where 
the lab moved to during the internship. In October 2016, she started her PhD research under 
supervision of dr. I. Kovačević and prof.dr. P.L. Hordijk at the department of Physiology at 
the VUmc. Since February 2021, Jisca has continued her scientific career as postdoc at the 
Hubrecht institute in Utrecht with prof.dr. J. den Hertog. Throughout her studies up till now, 





Majolée, J., Podieh, F., Hordijk, P. L.*, Kovačević, I*. (2021). The interplay of Rac1 activity, 
ubiquitination and GDI binding and its consequences for endothelial cell spreading. Revision 
pending
Manz, X.D., Szulcek, R., Pan, X., Symersky, P., Dickhoff, C., Majolée, J., Kremer, V., Michielon, 
E., Jordanova, K., Radonic, T., Bijnsdorp, I. V., Piersma, S. R., Pham, T.V., Jimenez, C., de 
Man, F., Boon, R., Voorberg, J., Hordijk, P.L., Aman, J.*, Bogaard, H. J.*. (2021). Epigenetic 
modification and enhanced NFkB2 binding to the Von WIllerbrand Factor promotor drive in 
situ thrombosis in chronic thromboembolism pulmonary hypertension. Submitted
Bogunovic, N., Meekel, J. P., Majolée, J., Hekhuis, M., Pyszkowski, J., Jockenhövel, S., Kruse, 
M., Riesebos, E., Micha, D., Blankensteijn, J. D., MD, Hordijk, P. L., Ghazanfari. S.*, Yeung, K. K.*. 
(2021). Patient-Specific 3D Model of Smooth Muscle Cell and Extracellular Matrix Dysfunction 
for the Study of Aortic Aneurysms. Journal of Endovascular Therapy, 15266028211009272.
Mossadeghzadeh, N.*, Jasemi, N. S. K.*, Majolée, J., Zhang, S. C., Hordijk, P. L., Dvorsky, R., 
Ahmadian, M.R. (2021). Novel molecular and functional insights into the regulation of the 
RAC1-membrane interaction by GDI1: An electrostatic force mechanism. Submitted
van der Wijk, A. E., Georgakopoulou, T., Majolée, J., van Bezu, J. S., van der Stoel, M. M., van 
Het Hof, B. J., de Vries H. E., Huveneers, S., Hordijk, P.L., Bakker, E. N. T. P., van Bavel, E. (2020). 
Microembolus clearance through angiophagy is an auxiliary mechanism preserving tissue 
perfusion in the rat brain. Acta neuropathologica communications, 8(1), 1-14.
Majolée, J., Kovačević, I., Hordijk, P. L. (2019). Ubiquitin-based modifications in endothelial 
cell–cell contact and inflammation. Journal of Cell Science, 132(17), jcs227728.
Majolée, J.*, Pronk, M. C.*, Jim, K. K., van Bezu, J. S., van Der Sar, A. M., Hordijk, P. L., Kovačević, 
I. (2019). CSN5 inhibition triggers inflammatory signaling and Rho/ROCK-dependent loss of 
endothelial integrity. Scientific reports, 9(1), 1-12.
Dekker, N. A., van Leeuwen, A. L., van Strien, W. W., Majolée, J., Szulcek, R., Vonk, A. B., 
Hordijk, P.L., Boer, C., van den Brom, C. E. (2019). Microcirculatory perfusion disturbances 
following cardiac surgery with cardiopulmonary bypass are associated with in vitro 




Pronk, M. C., Majolée, J., Loregger, A., van Bezu, J. S., Zelcer, N., Hordijk, P. L., Kovačević, 
I. (2019). FBXW7 regulates endothelial barrier function by suppression of the cholesterol 
synthesis pathway and prenylation of RhoB. Molecular biology of the cell, 30(5), 607-621.
Kovačević, I.*, Sakaue, T.*, Majoleé, J., Pronk, M. C., Maekawa, M., Geerts, D., Fernandez-
Borja, M., Higashiyama, S., Hordijk, P. L. (2018). The Cullin-3–Rbx1–KCTD10 complex controls 
endothelial barrier function via K63 ubiquitination of RhoB. J Cell Biol, 217(3), 1015-1032.
Schaefer, A., Van Duijn, T. J., Majolee, J., Burridge, K., Hordijk, P. L. (2017). Endothelial CD2AP 
binds the receptor ICAM-1 to control mechanosignaling, leukocyte adhesion, and the route 
of leukocyte diapedesis in vitro. The Journal of Immunology, 198(12), 4823-4836.




In de ruime vier, bijna vijf jaar die ik heb gedaan over het behalen van mijn PhD, heb ik 
wel geleerd dat het meer is dan wat wetenschappelijke studies voltooien. De mensen om 
me heen hebben mijn promotietraject veel meer vormgegeven dan ik vooraf had kunnen 
denken, en die wil ik natuurlijk graag bedanken.
Geachte professor Hordijk, beste Peter. Misschien weet je nog hoe terughoudend ik was 
toen ik voor het eerst in je groep kwam, toen nog als masterstudent, maar ook nog aan het 
begin van mijn PhD. De eerste paar maanden moest je nog lachen als ik weer de moed bij 
elkaar had geraapt om je kamer binnen te stappen en wat te vragen, waar ik ook zeker om 
mee kon lachen. Dat is door de jaren heen zeker wel veranderd. Ook al had je een erg drukke 
agenda, ik kon altijd even bij je binnenlopen met een vraag of we planden snel een meeting 
tussendoor. Al zit je nu al jaren in het Rho GTPase-onderzoek, je bent er altijd nog erg 
enthousiast over en dat werkt erg aanstekelijk! Je hebt me vaak de feedback en bevestiging 
gegeven die ik nodig had om me verder te ontwikkelen. Ik kijk met heel veel plezier terug op 
mijn PhD bij jou, en ben trots op hoe ik het gebouw nu verlaten heb. Bedankt voor de kansen 
die je me hebt geboden en de groei die ik onder jouw begeleiding heb mogen doormaken.
Dear dr. Kovacevic, dear Igor. Although you are my copromotor, we have worked a lot together 
in the lab. I inherited a bit of impatience from you throughout the years – I remember 
some occasions where you already analysed my western blot picture before I could even 
walk down from the machine. Well, impatience is not the right word, it should be called 
enthusiasm, which you have definitely transferred to me. I enjoyed all the discussions, mostly 
about work but sometimes also just about life in general. You have set a good example on 
work-life balance, working hard but also taking time to relax and socialize. I was very sad to 
see you leave to Germany, but we still finished a paper together in the end. Thank you for 
your help and the good times, and I am sure we will keep in touch throughout the years to 
come.
Ik wil graag alle stafleden van de afdeling fysiologie bedanken: Jolanda, Victor, Pieter, Ed, 
Coen, Diederik, Reinier, Bianca en Renée, dank jullie wel voor jullie input, al was het soms 
maar even om me met beide benen op de grond te zetten met de vraag “en waarom is dit 
nu fysiologisch relevant?”. Jolanda, al spraken we elkaar eigenlijk zelden, ik was erg blij in 
jouw afdeling te mogen werken. Ook al was mijn onderzoek niet zo direct translationeel, alle 




I would like to thank my reading committee: prof.dr. M. G. Vervloet, prof.dr. A.W. Griffioen, 
prof.dr. J. van Buul, prof.dr. E. Lutgens, prof.dr. C. L. Williams and dr. J. van Gils for assessing 
my thesis and taking place as opponent in my defense.
Natalija, still sometimes wonder how we ever became friends, since we are maybe the exact 
opposite in a lot of things. We share a passion for research though, and we share some 
overthinking qualities. We could challenge each other and had a lot of good conversations 
over an AH or Science Café cappuccino or the crappy machine coffee. During corona-times 
we could keep each other occupied by challenging each other with some dance moves or 
crazy tricks, which kept us sane through the boredom. Although we might be each other’s 
opposites, we became very good friends, and for that I am very thankful.
Xue, wat hebben wij een gezellige jaren mogen beleven. Dat we uiteindelijk in een andere 
afdeling zaten na de ‘scheiding’ maakte niets uit, we bleven lekker naast elkaar zitten. We 
hebben een hele hoop gedeeld, lab-spullen, protocollen, en het belangrijkste: chocola en 
koekjes. We hebben ook meerdere succesvolle fysiologie-kerstfeestjes georganiseerd, 
en heel af en toe kwam ik bij longziekten opdagen. Bedankt voor alle koffiepauzes, zeur 
momentjes (ik heb een heeeeel zwaaar leven) en tussendoor ook wetenschappelijke 
discussies en hulp bij experimenten!
Liza, wij startten onze PhD op exact dezelfde dag en onze bureaus zaten ook nog eens 
naast elkaar. Ik vond het harstikke leuk jou wegwijs te maken op het lab en in de wereld van 
cellulaire biologie, waarin ik al een voorsprongetje had door eerdere stages. Al hoor ik soms 
nog steeds wel de “Jiscaaa... Mag ik wat vragen?” nagalmen. Na zo’n anderhalf jaar ging je 
meer klinische studies doen en kwam je nog wel af en toe gezellig in het lab werken, maar 
ook meer aan ‘de overkant’. Wel bleven we elkaar op de hoogte houden, en zo leerde ik een 
hele hoop over hoe alles eraan toe gaat in klinische studies en in het ziekenhuis, dus heb jij 
mij ook meer wegwijs gemaakt dan je misschien zou denken.
Fabienne, it has been great to work together with you for the last year of my PhD. I think I 
have transferred almost all my knowledge to you in that year, and I’m happy I can still help 
out from time to time. You quickly started giving the research it your own twist and I’m sure 
you will write a very nice thesis. It was very nice to share projects and thoughts with you, 
and I’m happy we now also still enjoy dinners and drinks together.
Manon, de laatste anderhalf jaar van je PhD hebben wij samengewerkt en in die laatste 
eindsprint heb je nog veel data verzameld, waarvan een deel ook in mijn boekje zit. Ook al 
197
Acknowledgements
had je niet zo’n vliegende start, je bleef positief en hoe dichter ik bij het einde van mijn PhD 
kwam, hoe meer ik dat kan bewonderen.
Jan, we waren het misschien niet altijd met elkaar eens maar ik heb fijn met je samengewerkt. 
Als ik wilde weten of iemand ooit iets al gedaan had, had je dat eigenlijk zo teruggevonden 
in je papieren of digitale labjournaal – organisatie die ik ooit hoop te bereiken. Bedankt voor 
al je hulp, ik wens je nog een paar zo probleemloos mogelijke jaren toe op het lab!
Joana and Marc, I only worked alongside you in the group of Peter for a short time. You 
were there for my introduction to PhD life and we had some nice parties and good laughs!
Karlijn en Milou, ook al begonnen jullie echt in de ‘corona-tijd’, we hebben er het beste van 
gemaakt, zowel op het lab als erbuiten. Bedankt voor de gezellige lunches en drankjes, even 
stoom afblazen of gewoon heel hard lachen – en dat zetten we hopelijk nog wel even voort!
Phat, de altijd gezellige eerst schuin-tegenover en daarna recht-tegenover buurman. 
Gelukkig was jij er om het vrouwen-gehalte nog een beetje naar beneden te halen, en de 
moraal omhoog met af en toe wat slechte grapjes.
And all other (full or partly) physiology members, almost too many to count throughout the 
years and I’m sure I am forgetting people: Edgar, Yeszamin, Kennedy, Ricardo, Sylvia, Stefan, 
Leon, Maike, Larissa, Martijn, Max, Zeineb, Sun, Aida, Robert, Rowan, Eva, Pan, Diewertje, 
Veerle, Laura, Noelia, Rio, Tatjana, Anke, Philippa, Vanessa, Charissa, Anoek, Nicole, Michiel, 
Jeroen, Ruud, Aimée, thanks for sharing the fun and not-so-fun times in research, and many 
Friday-afternoon borrels at Mahler which sometimes turned into dinner at the Zuidas.
Ook vond ik het erg leuk samen te werken met onderzoekers buiten de afdeling fysiologie. 
Anne-Eva, met plezier heb ik bijgedragen aan je experimenten met de microspheres op 
endotheelcellen. Kin ki en Astrid, bedankt voor het wegwijs maken in de wereld van zebravis-
onderzoek, ik vond het erg leuk om te leren en ben blij dat ik de experimenten aan mijn 
paper heb kunnen toevoegen.
Natalia, Karin, Iris. Al vele jaren zwemmen we samen, en nu konden we ook af en toe lief 
en leed delen over onze PhDs. De onderwerpen zijn best verschillend, maar de struggles 
zijn natuurlijk hetzelfde. Ook mijn andere zwemmaatjes, bedankt voor de zware maar ook 





En natuurlijk ook mijn familieleden. Mijn ouders en broertje, schoonouders, opa’s en oma’s 
en de rest van de familie, dank jullie wel voor de steun en vertrouwen door de jaren van 
studeren en promoveren heen.
Last but not least, lieve Finn, met elke stap stond jij naast, achter of voor me, waar ik je dan 
ook maar nodig had. Ook al wilde ik mijn experimenten soms niet eens uitleggen, je hoorde 





Regulation of Rho GTPases by 
post-translational modification 
in endothelial barrier function
Jisca Majolée
Regulation of Rho G
TPases by post-translational m
odifi
cation in endothelial barrier function
Jisca M
ajolée
